2019

• AP Douglas, M Atarod, HM Prince. FDG-PET/CT findings, the vital clue to rare diagnosis of Herpes Simplex Virus lymphadenitis simulating Richter transformation. Pathology 2019 Jan;51(1):102-104. doi: 10.1016/j.pathol.2018.08.016. [IF: 3.068]
• van der Weyden C, McCormack C, Lade S, Johnstone RW, Prince HM. Rare T-Cell Subtypes. Cancer Treat Res. 2019;176:195-224. doi: 10.1007/978-3-319-99716-2_10. [IF: 3.360]
• G Hapgood, JM Stone, D Zanino, A George, P Marlton, HM Prince, C-H Hui, I Prosser, I Lewis, K Bradstock, JF Seymour on behalf of the Australasian Leukaemia and Lymphoma Group. A phase II study of a modified Hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. Leuk Lymph 2018 60:4, 904-911, DOI: 1080/10428194.2018.1516873 [IF: 2.644]
• Rademaker M, Rubel D, Agnew K, Andrews M, Armour K,Baker C, Foley P, Gebauer K, Michelle Goh M, Monisha Gupta M, Marshman G, Prince HM, Sullivan J. Psoriasis and cancer. An Australian/New Zealand narrative. Aust J Dermatol 2019; 60: 12-18 Article DOI: 10.1111/ajd.12889 [IF:1.304]
• C van der Weyden, M Dickinson, J Whisstock, HM Prince. Brentuximab vedotin in T-cell lymphoma. Expert Rev Hematol 2019; 12: 5-19 [IF: IF:1.937]
• Blombery P, HM Prince. Molecular drivers of breast implant-associated anaplastic large cell lymphoma. Plas Rec Surg 2019; 143: 59S-64S [IF: IF:3.843]
• N Wong Doo, V White, K Martin, J Bassett, HM Prince, SJ Harrison, M Jefford, I Winship, JL Millar, RL Milne, JF Seymour, GG Giles. The use of optimal treatment for DLBCL is improving in all age groups and is a key factor in overall survival, but non-clinical factors influence treatment. Cancers 2019, 11: 928; doi:10.3390/cancers11070928 [IF: IF:5.326]
• J Scarisbrick, P Quaglino, HM Prince, E Papadavid, E Hodak, S Whittaker,M Bagot, O Servitje, E Berti,P Ortiz-Romero,V Nikolaou, C Tomasina, I Amitay, F Child, C Ram-Wolff, S Alberti-Violetti, V  Gargallo, R Stadler, R Stranzenbach, A Patsatsi, T Koletsa, C Jonak, R Knobler, S Porkert, C Mitteldorf, T Estrach, C Muniesa, M Ms, J Csomor, A Szepesi, A Cozzio, E Guenova, R Dummer, N Pimpinelli, V Grandi, M Beylot-Barry, A Pham-Ledard, M Wobser, E Geissinger,U Wehkamp, M Weichenthal, G Dunnill, R Cowan, E Parry, J Harris, R Wachsmuth, D Turner, A Bates, E Healy, F Trautinger, J Eder, J Yoo, B Vydianath, R Amel-Kashipaz, L Marinos, A Oikonomidi, A Stratigos, M-D Vignon-Pennamen, M Battistella, F Climent,  E Georgiou,R Senetta, PL Zinzani, L Vakeva, A Ranki, A-M Buschots, E Hauben, A Bervoets, JS Woei-A-Jin,R Matin, G Collins, S Weatherhead, J Frew, M Bayne, G Dunnill, P Beatson,  A Arumainathan, K Benstead, R Twigger, K Rieger, R Brown,E Hong, J Sanchez, D Miyashiro, A Oleg, S McCann, C Querfeld, D Klemke, P Enz, R Pujol, L Cerroni, W Kempf, F Evison, M Vermeer, Y Kim, R Willemze. The PROCLIPI International Registry of Early-Stage Mycosis Fungoides Identifies Substantial Diagnostic Delay in Most Patients. Brit J Dermatol 2019; 181: 350-357 [IF: IF:6.129]
• HM Prince, C Querfeld. Intergrating novel systemic therapies for the treatment of Mycosis fungoides and Sezary syndrome. Best Prace Res Clin Hematol 2018; 31; 322-335 [IF:2.687]
• M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, X Leleu, F Schjesvold, P Moreau, MA Dimopoulos, JS-Y Huang, J Minarik, M Cavo, HM Prince, S Macé, KP Corzo, F Campana, S Le-Guennec, F Dubin, KC Anderson on behalf of the ICARIA-MM study group. Isatuximab plus pomalidomide and low dose dexamethasone versus pomalidomide and low dose dexamethasone in relapsed and refractory multiple myeloma: a randomized, multicenter, open-label, phase 3 study.  Lancet 2020; 394: 2096-2107 [IF: 102]
• Photiou L, Prince HM, McCormack C, van der Weyden. Systemic treatment options for advanced stage mycosis fungoides and Sezary Syndrome.  Current Oncology Reports 2018 (In Press) [IF:2.608]
• MA Dimopoulos, J San-Miguel, A Belch, D White, L Benboubker, G Cook, M Leiba, J Morton, PJ Ho, K Kim, N Takezako, P Moreau, JL Kaufman, HJ Sutherland, M Lalancette, H Magen, S Iida, JS Kim, HM Prince, T Cochrane, A Oriol, NJ Bahlis, A Chari, L O’Rourke, K Wu, JM Schecter,T Casneuf, C Chiu, D Soong, AK Sasser, NZ Khokhar, H Avet-Loiseau, SZ Usmani. Daratumumab Plus Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Analysis of POLLUX. Hematologica 2018 (In Press) [IF: 9.090]
• Magnusson M, Cooter R, Locke M, Prince HM, Hopper I, Elder E and Deva AK. SPECIAL UPDATE: The epidemiology of Breast Implant Associated Large Cell Lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breast implants Plastic and Reconstructive Surgery 2019; 137: 1659-1669 (In Press) [IF: IF:2.993]
• A Wirth, HM Prince, D Roos, J Gibson, P O’Brien, J Reynolds, D Zannino, B Khodr, J Stone, M Hertzberg. A prospective, multicentre study of involved field radiotherapy with autologous stem cell transplantation for patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Int J Rad Oncol Biol Phys 2018 (In Press) [IF: IF:5.554]
• JJ Scarisbrick, P Quaglino, HM Prince, YH Kim, R Willemze.^. Ethnicity in Mycosis Fungoides: White patients present at an older age and with more advanced disease. Brit J Dermatol 2018 (In Press) [IF: IF:6.129]
• N Horvath, A Spencer,M Kenealy,D Joshua,PJ Campbell,JJ Lee,J Hou,L Qiu,A, A Kalff, T Khong, A Londhe, S Siggins, M van Kooten Losio, M Eisbacher, HM Prince. Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidationaftersubcutaneous bortezomib-basedinduction and ASCT in patients with previously untreated multiple myeloma: the VCAT study. Leuk Lymph 2019 (In Press) [IF: IF:2.644]
• GP Gregory, M Dickinson, CK Yannakou, J Wong, P Blombery, G Corboy, L Kats, TME Crozier, HM Prince, SS Opat, J Shortt. Rapid and durable complete remission of refractory angioimmunoblastic T-cell lymphoma with azacytidine treatment in the absence of TET2 mutation or concurrent myelodysplasia HemaSphere 2019 (In Press)
• K Molloy, E Guenova, R Cowan, AM Busschots, S Woei-A-Jin, C Jonak, E Papadavid, M Beylot-Barry, E Berti, T Estrach, R Matin, O Akilov, L Vakeva, HM Prince, A Bates, M Bayne, R Wachsmuch, U Wehkamp, M Marschalko, O Servitje, D Turner, S Weatherhead, M Wobser, JA Sanches, P McKay, D Klemke,C Peng, A Howles, J Yoo, F Evison, J Scarisbrick. Quality of life in patients with mycosis fungoides and Sézary syndrome is significantly worse in female patients with worse symptom and emotional burden but without functional disability. Brit J Dermatol 2019 (In Press) [IF: IF:6.129]
• J Brooker, J Julian, J Millar, HM Prince, M Kenealy, K Herbert, A Graham, R Smith, D Kissane, K Taylor, M Frydenberg, I Porter, J Fletcher, I Haines, S Burney. A feasibility and acceptability study of an adaptation of the Mindful Self-Compassion program for adult cancer patients. Palliative and Supportive Care. 2019 (In Press) [IF: IF:1.494]
• N Whyler, J Teng, D Brewster, R Chin, I Cox, HM Prince, D Sheffield, E Teh_, V Sarode. Diagnosis of West Nile Virus encephalitis in a returned traveller. Med J Aust 2019 (In Press) [IF: IF:5.332]
• BA Campbell, MS Hofman, HM Prince. A novel application of [¹⁸F]fluorothymidine (FLT)-positron emission tomography (PET) in clinical practice: to quantify regional marrow function in a patient with treatment-induced cytopenias, and a guide to marrow sparing radiotherapy. Clin Nuclear Med (In Press) [IF: IF:6.498]
• C Gao, C McCormack, C van der Weyden, MS Goh, BA Campbell, R Twigger, O Buelens, SJ Harrison, C Khoo, S Lade, HM Prince. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary Syndrome. Blood (In Press) [IF: 562]
• T Papps, C McCormack, O Buelens, C Van der Weyden, R Twigger, BA Campbell, M Dickinson, HM Prince. A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome. Brit J Dermatol (In Press) [IF: 6.714]
• W Zhang, HM Prince, K Reardon. Statin-induced anti-HMGCR antibody related immune mediated necrotising myositis achieving complete remission with rituximab: case series and literature review. Brit Med J (In Press) [IF: 27.604]
• Bhurani M , Admojo L, Van Der Weyden C, Twigger R, Bazargan A, Quach H, Zimet A, Coyle L , Lindsay J, Radeski D, Hawkes EA, Kennedy G, Irving I, Gutta N, Trotman J, Yeung J, Dunlop L, Hua M, Giri P, Yuen S, Panicker S, Moreton S, Khoo L, Scott A, Kipp D,McQuillan A, McCormack C, Dickinson  M, Prince HM. Pralatrexate in relapsed and/or refractory T-cell lymphoma.  Leuk Lymph (In Press) [IF: 2.674]
• BA Campbell, G Ryan, C McCormack, E Tangas, M Bressel, R Twigger, O Buelens, C Van Weyden, HM Prince. Lack of durable remission with conventional-dose total skin electron therapy for the management of Sezary syndrome and multiply-relapsed mycosis fungoides. Cancers (In Press) [IF: 162]
• AK Deva, A Loch-Wilkinson, HM Prince, J French, K Shaw, K Vickery, KJ Beath, MR Magnusson, R Cooter. Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia: A Longitudinal Study of Implant and Other Related Risk Factors. Aes Surg J (In Press) [IF: 3.480]
• MG Maqbool, CS Tam, I Morison, D Simpson, P Mollee, H Schneider, H Chan, S Juneja, Y Harvey, L Nath, P Hissaria, HM Prince, H Wordsworth, D Talaulikar. A practical guide to laboratory investigations at diagnosis and follow up in Waldenström Macroglobulinaemia. Pathology (In Press) [IF: 3.163]

2018

1. NA Gherardin, L Loh, L Admojo, AJ Davenport, K Richardson, A Rogers, PK Darcy, MR Jenkins, JA Trapani, HM Prince, SJ Harrison, H Quach, DP Fairlie, K Kedzierska, J McClusky, AP Uldrich, PJ Neeson, DS Ritchie, DI Godfrey. Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed myeloma. Sci Rep 2018; 8(1):4159. doi: 10.1038/s41598-018-22130-1[IF:4.847]
2. H Quach, S Benson, H Haysom, A-M Wilkes, N Zacher, M Cole-Sinclair, HM Prince, P Mollee, A Spencer, PJ Ho, SJ Harrison, C Lee, B Augustson, J Daly. Considerations for pretransfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. Int Med J 2018; 48(2):210-220 [IF:1.526]
3. C van der Weyden, C McCormack, S Lade, RW Johnstone, HM Prince. Book Chapter: Rare T-cell Subtypes:  In T cell and NK cell lymphomas. Springer publishing. Ed C Querfeld. 2018
4. Davenport AJ, Cross RS, Watson KA, Liao Y, Shi W, Prince HM, Beavis PA, Trapani JA, Kershaw MH, Ritchie DS, Darcy PK, Neeson PJ, Jenkins MR. Proc Nat Acad Sci2018; 115(9):E2068-E2076[IF:9.661]
5. HM Prince,A Gautam, YH Kim.Brentuximab vedotin: targeting CD30 as standard in CTCL (Editorial) Oncotarget 2018; 9: 11887-11888 [IF:5.168]
6. Rastogi P, Deva A, Prince HM. Breast implant associated anaplastic large cell lymphoma. Current Hematol Malig Reports 2018 doi: 10.1007/s11899-018-0478-2. [IF:2.388]
7. PKK Wong, H Bagga, C Barrett, G Chong, P Hanrahan, T Kodali, M Marabani, HM Prince, J Riordan, P Swarbrick, R White, L Young.   A practical approach to the use of conventional synthetic, biologic and targeted synthetic disease modifying anti-rheumatic drugs for the treatment of inflammatory arthritis in patients with a history of malignancy. Curr Rheumatol Rep 2018  Sep 1;20(10):64. doi: 10.1007/s11926-018-0774-9.  [IF:3.850]
8. LC Fox, CK Yannakou, G Ryland, S Lade, M Dickinson,BA Campbell, HM Prince. Molecular mechanisms of disease progression during ibrutinib therapy in primary cutaneous diffuse large B cell lymphoma – leg type In J Mol Sci 2018 Jun 13;19(6). pii: E1758. doi: 10.3390/ijms19061758 [IF:3.226]
9. GL Ryland, K Jones, M Chin, J Markham, Y Kankanige, M Caruso, J Guinto, M Dickinson, HM Prince, K Yong, P Blombery. Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing. J Clin Path 2018 Oct;71(10):895-899. doi: 10.1136/jclinpath-2018-205195. Epub 2018 May 14 [IF:2.687]
10. P Blombery, G Ryland, J Markham, J Guinto, M Wall, D Cameron, M McBean, K Jones, E Thompson, T Papenfuss, HM Prince, M Dickinson, D Westerman. Detection of clinically relevant early genomic lesions in B-cell malignancies from circulating tumour DNA using a single hybridisation-based next generation sequencing assay Brit J Haematol 2018 (In Press) [IF:5.670]
11. Photiou L, Prince HM, McCormack C, van der Weyden.  Systemic treatment options for advanced stage mycosis fungoides and Sezary Syndrome.  Current Oncology Reports2018(In Press) [IF:2.608]
12. HM Prince. Pralatrexate (Folotyn^®) for relapsed or refractory peripheral T-cell lymphoma. Haematology Research Review 2018(In Press)[IF:5.168]
13. Rademaker M, Rubel D, Agnew K, Andrews M, Armour K,Baker C, Foley P, Gebauer K, Michelle Goh M, Monisha Gupta M, Marshman G, Prince HM, Sullivan J. Psoriasis and cancer. An Australian/New Zealand narrative. Aust J Dermatol  2018 Article DOI: 10.1111/ajd.12889 (In Press)  [IF:1.304]
14. C van der Weyden, M Bagot, P Neeson, HM Prince. IPH4102 a monoclonal antibody directed against the immune receptor molecule KIR3DL2 for  cutaneous T cell lymphoma. Exp Opin Invest Drugs 2018(In Press)
15. HM Prince, C Querfeld. Intergrating novel systemic  therapies for the treatment of Mycosis fungoides and Sezary syndrome. Best Prace Res Clin Hematol 2018 (In Press)  [IF:2.687]
16. Germline TIM-3 mutations characterize sub-cutaneous panniculitis-like T-cell lymphomas with hemophagocytic lymphohistiocytic syndrome. T Gayden, FE Sepulveda, D-A Khuong-Quang, J Pratt, E Valera, A Garrigue, S Kelso, F Sicheri, LG Mikael, N Hamel, A Bajic, R Dali, S Deshmukh, D Dervovic, D Schramek, F Guerin, M Taipal, H Nikbakht, J Majewski,D Moshous, J Charlebois, S Abish, C Bole-Feysot, P Nitschke, B Bader-Meunier, D Mitchell, C Thieblemont, M Battistella, S Gravel, V-H Nguyen, R Conyers, J-S Diana, C McCormack, HM Prince, M Besnard, S Blanche, PG Ekert, S Fraitag, WD Foulkes, A Fischer, B Neven, D Michonneau, G de Saint Basile, Nada Jabado. Nature Genetics 2018 (In Press)  [IF:31.154]
17. AP Douglas,  M Atarod, HM Prince. FDG-PET/CT findings, the vital clue to rare diagnosis of Herpes Simplex Virus lymphadenitis simulating Richter transformation. Pathol 2018 (In Press)  [IF: 3.068]
18. MA Dimopoulos, J San-Miguel, A Belch, D White, L Benboubker, G Cook, M Leiba, J Morton, PJ Ho, K Kim, N Takezako, P Moreau, JL Kaufman, HJ Sutherland, M Lalancette, H Magen, S Iida, JS Kim, HM Prince, T Cochrane, A Oriol, NJ Bahlis, A Chari, L O’Rourke, K Wu, JM Schecter,T Casneuf, C Chiu, D Soong, AK Sasser, NZ Khokhar, H Avet-Loiseau, SZ Usmani. Daratumumab Plus Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Analysis of POLLUX. Hematologica 2018 (In Press)  [IF: 9.090]
19. G Hapgood, JM Stone, D Zanino, A George, P Marlton, HM Prince, C-H Hui, I Prosser, I Lewis, K Bradstock, JF Seymour on behalf of the Australasian Leukaemia and Lymphoma Group. A phase II study of a modified Hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. Leuk Lymph 2018 (In Press)  [IF: 2.644]
20. P Blombery, E Thompson, G Ryland, R Joyce, DJ Byrne, C Khoo, S Lade, M Hertzberg, G Hapgood, P Marlton, A Deva, G Lindeman, S Fox, D Westerman, HM Prince. Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma. Oncotarget 2018 (In Press) [IF: 5.168]
21. Magnusson M, Cooter R, Locke M, Prince HM, Hopper I, Elder E and Deva AK. SPECIAL UPDATE: The epidemiology of Breast Implant Associated Large Cell Lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breast implants Plastic and Reconstructive Surgery 2018; 137: 1659-1669 (In Press) [IF: IF:2.993]
22. J Scarisbrick, P Quaglino, HM Prince, E Papadavid, E Hodak, S Whittaker,M Bagot, O Servitje, E Berti,P Ortiz-Romero,V Nikolaou, C Tomasina, I Amitay, F Child, C Ram-Wolff, S Alberti-Violetti, V  Gargallo, R Stadler, R Stranzenbach, A Patsatsi, T Koletsa, C Jonak, R Knobler, S Porkert, C Mitteldorf, T Estrach, C Muniesa, M Ms, J Csomor, A Szepesi, A Cozzio, E Guenova,  R Dummer, N Pimpinelli, V Grandi, M Beylot-Barry, A Pham-Ledard, M Wobser, E Geissinger,U Wehkamp, M Weichenthal, G Dunnill, R Cowan, E Parry, J Harris, R Wachsmuth, D Turner, A Bates, E Healy, F Trautinger, J Eder, J Yoo, B Vydianath, R Amel-Kashipaz, L Marinos, A Oikonomidi, A Stratigos, M-D Vignon-Pennamen, M Battistella, F Climent,  E Georgiou,R Senetta, PL Zinzani, L Vakeva, A Ranki, A-M Buschots, E Hauben, A Bervoets, JS Woei-A-Jin,R Matin, G Collins, S Weatherhead, J Frew, M Bayne, G Dunnill, P Beatson,  A Arumainathan, K Benstead, R Twigger, K Rieger, R Brown,E Hong, J Sanchez, D Miyashiro, A Oleg, S McCann, C Querfeld, D Klemke, P Enz, R Pujol, L Cerroni, W Kempf, F Evison, M Vermeer, Y Kim, R Willemze. The International PROCLIPI Study of Early Stage Mycosis Fungoides; Identification of Substantial Delays in Diagnosis of Most Patients. Brit J Dermatol 2018 (In Press) [IF: IF:6.129]
23. C van der Weyden, M Dickinson, J Whisstock, HM Prince. Brentuximab vedotin in T-cell lymphoma. Expert Rev Hematol 2018 (In Press) [IF: IF:1.937]
24. Blombery P, HM Prince. Genetic Determinants of BIA-ALCL. Plas Rec Surg 2018 (In Press) [IF: IF:3.843]

• P Varma, J Falconer, A Aga, HM Prince, S Pianko. Rituximab-Induced Crohn’s Disease. Scand J Gastroenterol 2017; 52: 606-608 [IF:2.199]
• D Talaulikar, CS Tam, D Joshua, J Ho, J Szer, H Quach, A Spencer, S Harrison, P Mollee, AW Roberts, N Horvath, C Lee, A Zannettino, R Brown, B Augustson, W Jaksic, J Gibson, A Kalff, A Johnston, J Trotman, A Kalro, G Grigoriadis, C Ward, HM Prince. Treatment of Patients with Waldenström Macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Int Med J 2017; 47: 35-49 [IF:1.526]
• Chan, KL; Van Der Weyden, C; Koo, C; Lade, S; Blombery, P; Westerman, D; Khot, A; Melo, B; Johnstone, R; Prince, HM; Dickinson, M. Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement. Leuk Lymphoma 2017; 58: 996-998 [IF:2.755]
• Chan KL, Lokan J, Tam CS, Lew TE, Prince HM. Central nervous system immune reconstitution inflammatory syndrome after ibrutinib therapy for Richter transformation. Leuk Lymphoma 2017; 58:207-210 [IF:2.755]
• CY Slaney, B von Scheidt, AJ Davenport, PA Beavis, JA Westwood, S Mardiana, DC Tscharke, HM Prince, JA Trapani, RW Johnstone, MJ Smyth, MW Teng, SA Rosenberg, NP Restifo, P Neeson, PK Darcy, MH Kershaw. Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting. Clin Canc Res (In Press) [IF:8.738]
• D Oberoi, V White, J Seymour, HM Prince, S Harrison, M Jefford, I Winship, D Hill, D Bolton, A Kay, J Millar, N Wong Doo, G Giles.  The course of anxiety, depression and unmet needs in survivors of Diffuse Large B Cell Lymphoma and Multiple Myeloma in the early survivorship period. J Canc Survivorship 2017 (In Press) [IF:3.478]
• Shustov A, Coiffier B, Horwitz S, Sokol L, Pro B, Wolfson J,Balser B,Frye Eisch R,Popplewell L,Prince HM,Allen SL, Piekarz R,Bates S. Romidepsin Is Effective and Well Tolerated in Older Patients With Peripheral T-Cell Lymphoma: Analysis of 2 Phase II Trials Leuk Lymphoma 2016; 58: 2335-2341 [IF:2.755]
• White V, Marco DJT, Bolton D, Davis ID, Jefford M^, Hill D, Prince HM, Millar J, Winship M, Coory M, Giles GG. Trends in the surgical management of Stage 1 Renal Cell Carcinoma: findings from a population-based study Brit J Urol Int 2017 (Epub ahead of Print) [IF:4.387]
• Newland K, Prince HM. Denileukin Diftitox for the treatment of cutaneous T cell lymphoma. Expert Opinion on Orphan Drugs. 2016 (In Press) [IF: 3.525]
• Van der Weyden C, Bates S, Dickinson M, Prince HM. Romidepsin for treating cutaneous T-cell lymphoma. Expert Opinion on Orphan Drugs. 2016 (In Press) [IF: 3.525]
• F Foss, B Pro, HM Prince, L Sokol,M Greenwood,D Caballero, S Horwitz, B Coiffier. Responses to Romidepsin by Line of Therapy in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. (PTCL) Cancer Med 2016 (In Press) [IF:3.420]
• H Quach, L Fernyhough, R Henderson, G Corbett, B Baker, P Browett, H Blacklock, C Forsyth, C Underhill, P Cannell, J Trotman, A Neylon, S Harrison, E Link, A Swern, L Cowan, MA Dimopoulos, HM Prince.^.Lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: Final analysis of the phase II RevLite study. B J Hematol 2016 (In Press) [IF:5.812]
• HM Prince, YH Kim, SM Horwitz, R Dummer, J Scarisbrick, P Quaglino, PL Zinzani, P Wolter, JA Sanches, PL Ortiz-Romero, OE Akilov, L Geskin, J Trotman, K Taylor, S Dalle, M Weichenthal, J Walewski, D Fisher, B Dréno, R Stadler, T Feldman, TM Kuzel, Y Wang, MC Palanca-Wessels, E Zagadailov, WL Trepicchio,W Zhang, H-M Lin,Y Liu, D Huebner,M Little, S Whittaker, M Duvic on behalf of the ALCANZA study group^. Brentuximab vedotin or Physician’s Choice in CD30-positive Cutaneous T-Cell Lymphoma. Lancet (On line http://dx.doi.org/10.1016/S0140-6736(17)31266-7 [IF:45.217]
• Seymour JF, Blombery P, Prince HM. Primary Breast Lymphoma – population level insights into an infrequent, but increasingly recognized, subtype of lymphoma. (Editorial) J Nat Canc Inst 2017 (In Press) [IF:11.370]
• TA Rasmussen, J McMahon, JJ Chang, F Wightman, J Symons, M Roche, A Solomon, A Dantanarayana, A Okoye, B Hirner, S Palmer, WS Lee, S Kent, C Van Der Weyden, HM Prince, PU Cameron, SR Lewin. Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary’s syndrome AIDS 2017 (In Press) [IF:4.407]
• A Loch-Wilkinson, KJ Beath, RJW Knight, WLF Wessels, M Magnusson, T Papadopoulos, T Connell, J Lofts, M Locke, I Hopper, R Cooter, K Vickery, PA Joshi, HM Prince, AK Deva. Breast implant associated Anaplastic Large Cell Lymphoma in Australia and New Zealand – higher surface area textured implants are associated with increased risk Plas Rec Surg 2017 (In Press) [IF:3.087]
• Mota TM, Rasmussen TA, Rhodes A, Tennakoon S, Dantanarayana A, Wightman F, Hagenauer M, Roney J, Spelman T, Purcell DF, McMahon J, Hoy JF, Prince HM, Elliott JH, Lewin SR. No adverse safety or virological changes two years following vorinostat in HIV-infected individuals on antiretroviral therapy. AIDS 2017 (In Press) [IF:4.407]
• OL Lee, N Horvath, C Lee, D Joshua, J Ho, J Szer, H Quach, A Spencer, S Harrison, P Mollee, AW Roberts, D Talaulikar, R Brown, B Augustson, S Ling, W Jaksic, J Gibson, A Kalff, A Johnston, A Kalro, C Ward, HM Prince, Andrew Zannettino. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Int Med J 2017 (In Press) [IF:1.526]

• N Wong Doo, E Makalic, E Joo, CM Vajdic, DF Schmidt, M Wong, C-H Jung, G Severi, DJ Park, J Chung, L Baglietto, HM Prince, JF Seymour, C Tam, JL Hopper, DR English, RL Milne, SJ Harrison, MC Southey, GG Giles. Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B cell neoplasms. Epigenomics 2016; 8: 55-66 [IF: IF:4.649]
• F Foss, S Horwitz, B Pro, HM Prince, L Sokol, B Balser, J Wolfson, B Coiffier. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol 2016: 9 (1) 22. doi: 10.1186/s13045-016-0243-8. [IF: IF:4.81]
• DV Oberoi; V White; M Jefford; D Bolton; I Davis; D Hill; I Winship; M Prince; J Millar; S Harrison; A Kay; G Giles. Caregivers’ information needs and their ‘experiences of care’ during treatment are associated with elevated anxiety and depression: A cross sectional study of the caregivers of renal cancer survivors. Support Care Canc 2016; 24: 4177-86 [IF:2.364]
• Van der Weyden C, Prince HM. High-dose thiotepa-based conditioning regimens for relapsed lymphoma involving the central nervous system: from ‘orphan drug’ to a standard-of-care? Leuk Lymphoma 2016; 57: 1-3 [IF:2.397]
• Whittaker S, Hoppe R, Prince HM. How I treat Mycosis Fungoides and Sezary Syndrome. Blood 2016; 127: 3142-3153 [IF: IF:10.452]
• CF Hughes, K Newland, C McCormack, HM Prince. Mycosis Fungoides and Sézary Syndrome: Current challenges in assessment, management and prognostic markers. Australas J Dermatol 2016; 57: 182-191 [IF:0.982]
• KL Chan, S Lade, HM Prince, SJ Harrison. Update and new approaches in the treatment of Castleman disease. J Blood Med 2016; 7:145-15
• Prince HM, Johnstone RJ. Commentary on: Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Aesth Surg J 2016; 36: 782-783 [IF: IF:1.841]
• H Hu, K Aljohani, A Almatroudi, K Vickery, B Van Natta, ME Kadin, G Brody, M Clemens, CY Cheah, S Lade, P Joshi, HM Prince, A Deva. Bacterial biofilm infection detected in breast implant associated anaplastic large cell lymphoma. Plastic and Reconstructive Surgery 2016; 137: 1659-1669 [IF: IF:2.993]
• TE Lew, C Cheah, DA Carney, HM Prince, M Wolf, A Bazargan, EH Januszewicz, R Filshie, D Westerman, JF Seymour, CS Tam. Dose reduced fludarabine, cyclophosphamide and rituximab (FCR) is well tolerated in older patients with chronic lymphocytic leukaemia (CLL) and has preserved therapeutic efficacy. Leuk Lymphoma 2016; 57: 1044-1053 [IF:2.397]
• Cooke RE, Gherardin NA, Harrison SJ, Quach H, Godfrey DI, Prince HM, Neeson P, Koldej R, Ritchie DS. Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human myeloma J Transl Med 14:259: DOI 10.1186/s12967-016-0994-6 [IF:3.694]
• Newland K, Prince HM. Denileukin Diftitox for the treatment of cutaneous T cell lymphoma. Expert Opinion on Orphan Drugs. 2016 (In Press) [IF: 3.525]
• Van der Weyden C, Bates S, Dickinson M, Prince HM. Romidepsin for treating cutaneous T-cell lymphoma. Expert Opinion on Orphan Drugs. 2016 (In Press) [IF: 3.525]
• Chan KL, Lokan J, Tam CS, Lew TE, Prince HM. Central nervous system immune reconstitution inflammatory syndrome after ibrutinib therapy for Richter transformation. Leuk Lymphoma 2016 (Epub ahead of Print) [IF:2.397]
• CSM Yong, LB John, C Devaud, HM Prince, RW Johnstone, JA Trapani, PK Darcy, M Kershaw. A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer. Oncotarget 2016 (In Press) [IF: IF:6.359]
• A Newbold, KJ Falkenberg, HM Prince, RW Johnstone. How do tumor cells respond to HDAC inhibition? FEBS J 2016 (In Press) [IF:4.001]
• Blombery P, Thompson E, Jones K, Mir Arnau G, Lade S, Markham JF, Li J, Deva A, Johnstone RW, Khot A, Prince HM, Westerman D. Whole exome sequencing reveals activating JAK1 and STAT3mutations in breast-implant associated anaplastic large cell lymphoma. Haematologica 2016; 101(9): e387-90 [IF:5.814]
• B Pro, SM Horwitz, HM Prince, FM Foss, L Sokol, M Greenwood, D Caballero, F Morschhauser, M Wilhelm, L Pinter-Brown, S Iyer, AR Shustov, J Wolfson, BE Balser, B Coiffier. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematological Oncology 2016 (Epub ahead of Print) [IF:3.084]
• Chan, KL; Van Der Weyden, C; Koo, C; Lade, S; Blombery, P; Westerman, D; Khot, A; Melo, B; Johnstone, R; Prince, HM; Dickinson, M. Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement. Leuk Lymphoma 2016 (Epub ahead of Print) [IF:2.397]
• F Foss, B Pro, HM Prince, L Sokol,M Greenwood,D Caballero, S Horwitz, B Coiffier. Responses to Romidepsin by Line of Therapy in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. (PTCL) Cancer Med 2016 (In Press) [IF:3.420]
• CS Tam, D Talaulikar, D Joshua, J Ho, J Szer, H Quach, A Spencer, S Harrison, P Mollee, AW Roberts, N Horvath, C Lee, A Zannettino, R Brown, B Augustson, W Jaksic, J Gibson, A Kalff, A Johnston, J Trotman, A Kalro, G Grigoriadis, C Ward, HM Prince. Treatment of Patients with Waldenström Macroglobulinaemia: Position Statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Int Med J 2016 (In Press) [IF:1.526]

• CF Hughes, A Khot, C McCormack, S Lade, DA Westerman, R Twigger, O Buelens, K Newland, C Tam, M Dickinson, G Ryan, D Ritchie, C Wood, HM Prince. The lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 2015; 125:71-81 [IF:9.775]
• H Quach, D Joshua, J Ho, J Szer, A Spencer, SJ Harrison, P Mollee, AW Roberts, N Horvath, D Talulikar, B To, A Zannettino, R Brown, L Catley, B Augustson, W Jaksic, J Gibson, HM Prince. Treatment of Patients with Multiple Myeloma who are Eligible for Stem Cell Transplantation: Position statement of the Myeloma Foundation Australia Medical and Scientific Advisory Group. Int Med J 2015; 45; 94-105 [IF:1.699]
• Newland K, Prince HM. Denileukin Diftitox for the treatment of cutaneous T cell lymphoma. Expert Opinion on Orphan Drugs. 2014 (In Press) [IF: 3.525]
• Trubiano JA, George A, Teh BW, Barnett J, Siwan M, Prince HM, Slavin MA.A Different Kind of ‘allogeneic transplant’: Successful Faecal Microbiota Transplantation for Recurrent and Refractory Clostridium difficile Infection in a Patient with Recurrent Aggressive B-cell Lymphoma. Leuk Lymphoma 2014 (In Press) [IF:2.397]
• Newland, CJ McCormack, HM Prince, S Lade. Cutaneous CD30 positive lymphoproliferative disorders with coexistent epithelial neoplasms: Report of two cases. Aust J Dermatol 2014 (In Press) [IF:0.965]
• Cheah CY, Hofman MS, Seymour JF, Ritchie DS, Dickinson M, Wirth A, Prince HM, Wolf M, Januszcewicz EH, Carney DA, Herbert KE, Harrison SJ, Burbury K, Tam CS. The utility and limitations of PET-CT in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. Leuk Lymphoma 2014 (In Press) [IF:2.397]
• N Weber, P Mollee, B Augustson, R Brown, L Catley, J Gibson, S Harrison, J Ho, N Horvath, W Jaksic, D Joshua, H Quach, A Roberts, A Spencer, J Szer, D Talaulikar, B To, A Zannettino, HM Prince. Management of Systemic Light Chain (AL) Amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Int Med Journal 2014 (In Press) [IF:1.699]
• H Quach, D Joshua, J Ho, J Szer, A Spencer, SJ Harrison, P Mollee, AW Roberts, N Horvath, D Talulikar, B To, A Zannettino, R Brown, L Catley, B Augustson, W Jaksic, J Gibson, HM Prince. Treatment of Patients with Multiple Myeloma who are Not Eligible for Stem Cell Transplantation: Position statement of the Myeloma Foundation Australian Medical and Scientific Advisory Group (MSAG). Int Med J. 2014 (In Press) [IF:1.699]
• Horwitz, B. Coiffier, F. Foss, HM. Prince, L Sokol, M Greenwood, D Caballero, F Morschhauser, L Pinter-Brown, SP Iyer, A Shustov, J Nichols, J. Balser, B Balser, B Pro. Utility of ¹⁸Fluoro-Deoxyglucose Positron Emission Tomography for Prognosis and Response Assessments in a Phase 2 Study of Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. Ann Oncol(In Press) [IF:6.578]
• J. Harrison, H. Quach, E. Link, H. Feng, J. Dean, M. Copeman, H. Van De Velde, A. Schwarer, B. Baker, A. Spencer, J. Catalano, P. Campbell, B. Augustson, K. Romeril, HM Prince. Bortezomib and dexamethasone from cycle 1 improves response and time to progression for patients with relapsed Myeloma. Am J Hematol (In Press) [IF:3.477]
• Bates S et al. Romidepsin in Peripheral and Cutaneous T-Cell Lymphoma: Mechanistic Implications from Clinical and Correlative Data Brit J Haematol (In Press) [IF:xxxxx]

• N Wong Doo, T Joyce, PA Thompson, HM Prince, JF Seymour, D Ritchie, K Stokes, K Burbury, M Wolf, S Peinert, SJ Harrison. Bortezomib with high dose melphalan conditioning for autologous transplantation is safe and effective in patients with heavily pre-treated and high risk multiple myeloma. Leuk Lymphoma 2013: 54;: 1465-72 [IF:2.397]
• M Duvic, R Dummer, JC Becker, N Poulalhon, PO Romero, MG Bernengo, C Lebbé, C Assaf, M Squier, D Williams, M Marshood, F Tai, HM Prince. Panobinostat Activity in Both Bexarotene-Exposed and -Naïve Patients With Refractory Cutaneous T-Cell Lymphoma: Results of a Phase II Trial. Eur J Cancer 2013; 48: 386-394 [IF: IF:5.536]
• A Khot, M Dickinson, K Stokes, S Harrison, K Burbury, S Fleming, D Wall, P Gambell, HM Prince, JF Seymour, D Ritchie. Risk Adapted Protocol For Delayed Administration Of rhG-CSF Following High Dose Chemotherapy And Autologous Stem Cell Transplantation. Clin Lymph Myel Leuk 2013; 13: 42-47 [IF: IF:1.601]
• HM Prince, AG Martin, EA Olsen, DP Fivenson, M Duvic. Denileukin Diftitox for the Treatment of CD25 Low Expression Mycosis Fungoides and Sezary Syndrome. Leuk Lymphoma 2013; 54: 69-75 [IF:2.397]
• M Dickinson, C Cheah, HM Prince. Current Epigenetic Therapy for T Cell Lymphoma.   T-Cell Lymphomas    Chapter 16: pp 279 in Francine  Foss ed.   Humana Press 2013
• M Duvic, AG Martin, EA Olsen, DP Fivenson, HM Prince. The efficacy and safety of denileukin diftitox retreatment in patients with mycosis fungoides/Sezary syndrome. Leuk Lymphoma 2013;54; 514-519 [IF:2.397]
• H Quach, HM Prince. How To Treat – Multiple Myeloma. Australian Doctor 2012; May 11: 31-38
• Herbert KE, Gambell P, Link EK, Mouminoglou A, Stokes K, Wall DM, Harrison SJ, Ritchie DS, Seymour JF, Prince HM. Pegfilgrastim compared to filgrastim for cytokine-alone mobilization of autologous hematopoietic stem and progenitor cells. Bone Marr Transplant 2013; 48; 351-356 [IF:3.660]
• S Li, S Roberts, M Plebanski, P Latour, DC Jackson, L Brown, R Sparrow, HM Prince, D Hart, B Loveland, E Gowans. Induction of multi-functional T cells in a Phase I Clinical Trial of Dendritic Cell Immunotherapy in Hepatitis C Virus Infected Individuals. PloS ONE 2012; 7: e39368 [IF:4.351]
• M Duvic, L Geskin, HM Prince. Duration of Response in Cutaneous T-cell Lymphoma Patients Treated With Denileukin Diftitox: Results From Three Phase III Studies. Clin Lymph Myel Leuk 2013; 13: 377-384 [IF:1.537]
• Khot S, Dickinson M, Prince HM. Drug Evaluation: Panobinostat in lymphoid and myeloid malignancies. Expert Opinion on Investigational Drugs . 2013;;22:1211-23 [IF:4.744]
• CY Cheah, MS Hofman, M Dickinson, A Wirth, D Westerman, SJ Harrison, K Burbury, M Wolf, H Januszewicz, K Herbert, HM Prince, DA Carney, DS Ritchie, RJ Hicks, JF Seymour. Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Brit J Canc 2013; 109; 312-7 [IF:5.042]
• BW Teh, A Khot, SJ Harrison, HM Prince, MA Slavin. A messenger at the door: CMV retinitis in myeloma patients with relapsed disease. Transpl Inf Dis 2013: 15; E134-8 [IF:2.216]
• MJ Bishton, SJ Harrison, HM Prince, RW Johnstone. Histone Deacetylase Inhibitors reduce Glycoprotein VI expression and Platelet Responses to Collagen Related Peptide. Thrombosis Res 2013: 131:514-20 [IF:3.133]
• DJ DeAngelo, A Spencer, KN Bhalla, HM Prince, T Fischer, T Kindler, FJ Giles, JW Scott, K Parker, A Liu, M Woo, P Atadja, KK Mishra, OK Ottmann. Phase 1a/2, two-arm, multi-center, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematological malignancies Leukemia 2013: 27: 1628-36 [IF:6.612]
• S Sharma, J Beck, M Mita, S Paul, MM Woo, M Squier, B Gadbaw, HM Prince. A Phase I/IIa two-arm open-label dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. Investigational New Drugs 2013; 31: 974-85 [IF:3.498]
• Thompson P, Prince HM. Breast Implant-Associated Anaplastic Large Cell Lymphoma. A systematic review of the literature and mini-meta analysis. Current Hematologic Malignancy Reports. 2013: 8: 196-210. [IF:1.852]
• A Khot, M Dickinson, HM Prince. Romidepsin in Peripheral T-Cell Lymphoma. Expert Rev in Hematol 2013; 351-359 [IF:1.161]
• DS Ritchie, PJ Neeson, A Khot, S Peinert, T Tai, K Tainton, K Chen, M Shin, DM Wall, D Hönemann, P Gambell, DA Westerman, J Haurat, JA Westwood, AM Scott, L Kravets, M Dickinson, JA Trapani, MJ Smyth, PK Darcy, MH Kershaw, HM Prince. Persistence and efficacy of second generation CAR-T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 2013; 21: 2122-2129 [IF:6.873]
• HM Prince, A Khot, M Dickinson. Romidepsin for cutaneous T-cell lymphoma. Future Oncology 2013:9; 1819-1827 [IF: IF:3.202]

• SA Gangatharan, DA Carney, HM Prince, MM Wolf, EH Januszewicz, DS Ritchie, SJ Harrison. The emergence of CNS myeloma in the era of novel agents. Haematol Oncol 2012; 30: 170-4 [IF:2.258]
• S Shen, T O’Brien, LM Yap, HM Prince, C McCormack. The Use of Methotrexate in Dermatology: A Review. Aust J Dermatol 2012; 53; 1-18
• B Coiffier, B Pro, HM Prince, F Foss, L Sokol, M Greenwood, D Caballero, P Borchmann, F Morschhauser, M Wilhelm, L Pinter-Brown, S Padmanabhan, A Shustov, J Nichols, S Carroll, J Balser, S Horwitz. Results From a Pivotal, Open-Label, Phase 2 Study of Romidepsin in Progressive or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy. J Clin Oncol 2011; 30: 631-636 [IF: IF:18.970]
• HM Prince. Fludarabine and a histone deacetylase inhibitor – strange bedfellows (Editorial). Leuk Res 2012; 36: 385-386 [IF:2.555]
• Quach H, Prince HM on behalf of the Medical Scientific Advisory Board to the Myeloma Foundation of Australia. Clinical Practice Guidelines: Myeloma 2012 http://www.clinicalguidelines.gov.au/search.php?pageType=2&fldglrID=1917&

http://www.myeloma.org.au/LinkClick.aspx?fileticket=5TdcjoGc278%3d&tabid=150&mid=575

• KO Taylor, HR Webster, HM Prince. Anaplastic Large Cell Lymphoma and Breast Implants: Five Australian Cases. Plastic Reconstr Surg 2012; 129: 610e-617e [IF:2.647]
• A Younes, A Sureda, D Ben-Yehuda, M Baccarani, TC Ong, HM Prince, S Harrison, M Kirschbaum, P Johnston, J Gallagher, C Le Corre, A Shen, A Engert. Panobinostat in Relapsed/Refractory Hodgkin Lymphoma Patients Following Autologous Stem Cell Transplant: Results of a Phase II Study. J Clin Oncol 2012; 30:2197-2203 [IF: IF:18.970]
• Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; *MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012 May 10;366(19):1759-69. [IF: 53.1 ]
• P Gambell, K Herbert, M Dickinson, K Stokes, M Bressel, D Wall, S Harrison, HM Prince (MD).Peripheral Blood CD34+ cell enumeration as a predictor of apheresis yield – an analysis of over 1000 collections. Biol Blood Marrow Transpl 2012; 18: 763-772 [IF:3.275]
• P Mollee, C Tiley, I Cunningham, J Moore, HM Prince, P Cannell, S Gibbons, J Tate, S Paul, H Mar Fan, DS Gill. A Phase II Study of Risk-Adapted Intravenous Melphalan in Patients with AL Amyloidosis. Brit J Haematol; 2012; 157; 766-769[IF:4.942]
• HM Prince. Explainer: What is thalidomide? The Conversation. 2012 http://theconversation.edu.au/explainer-what-is-thalidomide-8327
• M Dickinson, HM Prince. Romidepsin for relapsed and refractory cutaneous T-cell lymphoma. Clinical Medicine Insights: Dermatology 2012: 5, 21-28
• HM Prince, M Dickinson. Romidepsin in cutaneous T cell lymphoma. Clin Canc Res 2012; 18, 3509-15[IF:7.742]
• HM Prince. Pioneering studies of histone deacetylase inhibitors in myeloma; signals of activity set the stage for combination therapy trials.(Editorial) Leukemia Lymphoma 2012, 53; 1658-9[IF:2.397]
• HM Prince, M Duvic, AG Martin, W Sterry, C Assaf, D Straus. Incidence of Spontaneous Remissions in Patients with CD25 Assay-Positive Mycosis Fungoides/Sezary Syndrome Receiving `Placebo. J Amer Acad Dermatol 2012, 67; 867-875 [IF:4.081]
• SJ Harrison, M Bishton, SE Bates, S Grant, RL Piekarz, RW Johnstone, YDai, B Lee, ME Araujo, HM Prince. A focus on the pre-clinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax®). Epigenomics 2012; 4: 571-589 [IF: IF:3.429]
• P Blombery, SQ Wong, HM Prince. Erdheim-Chester disease harbouring the BRAF V600E mutation. J Clin Oncol 2012; 30: e331-2 [IF: IF:18.970]

• KL Burbury, MJ Bishton, RW Johnstone, MJ Dickinson, J Szer, HM Prince. MLL-aberrant leukemia: Complete cytogenetic remission following treatment with a Histone Deacetylase inhibitor. Ann Hematol 2011; 90: 847-9 [IF: 2.919]
• PA Thompson, S Peinert, K Burbury, K Stokes, T Joyce, M Wolf, D Ritchie, HM Prince, JF Seymour, SJ Harrison. Bortezomib added to high dose melphalan conditioning in patients with heavily pretreated multiple myeloma. Bone Marrow Transpl 2011; 46: 764-765 [IF: 2.643]
• Lechner MG, Lade S, Liebertz Dj, Prince HM, Brody GS, Webster HR, Epstein AL. Breast implant-associated Alk-negative T cell anaplastic large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity. Cancer 2011; 117 (7): 1478-89 [IF: 5.418]
• Hsu A, Quach H, Tai T, Prince HM, Trapani JA, Smyth MJ, Neeson P, Ritchie DS. The immuno-stimulatory effect of lenalidomide on NK cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011, 117; 1605-1613 [IF:10.896]
• HJ Pegram, DS Ritchie, MJ Smyth, A Wiernik, HM Prince, PK Darcy, MH Kershaw. Alloreactive natural killer cells in hematopoietic stem cell transplantation. Leukemia Research. 2011 Jan;35(1):14-21 [IF: 2.358]
• S Lingaratnam, MA Slavin, B Koczwara, JF Seymour, J Szer, C Underhill, HM Prince, L Mileshkin, M O’Reilly, SW Kirsa, CA Bennett, ID Davis, O Morrissey, KA Thursky. Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Int Med J 2011, 41; 75-81[IF:1.786]
• S Lingaratnam, MA Slavin, L Mileshkin, B Solomon, K Burbury, JF Seymour, R Sharma, B Koczwara, SW Kirsa, ID Davis, HM Prince, J Szer, C Underhill, O Morrissey, KA Thursky. An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. Int Med J 2011, 41; 110-120 [IF:1.786]
• PA Blombery, A Wirth, HM Prince. How To Treat – Lymphoproliferative Disorders – Part 1. Aggressive non-Hodgkin Lymphoma and Hodgkin Lymphoma. Australian Doctor 2011; April 1: 27-31
• S Kamel, JF Seymour, HM Prince. How To Treat – Lymphoproliferative Disorders – Part 2. Chronic Lymphocytic Leukaemia and Follicular Lymphoma. Australian Doctor 2011; April 8: 29-36
• RA Howman, HM Prince. New Therapies in Peripheral T-cell Lymphoma. Expert Reviews of Anti-Cancer Therapies 2011, 11: 457-472) [IF:2.493]
• MJ Bishton, HM Prince, SJ Harrison, BP Martin, N McLaughlin, J Chloe, EC Josefsson, KJ Henley, BT Kile, RW Johnstone. Deciphering the molecular and biological processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 2011, 117: 3658-3668 [IF:10.896]
• EA Olsen, S Whittaker, YH Kim, M Duvic, HM Prince, SR Lessin, GS Wood,R Willemze, M-F Demierre, N Pimpinelli, MG Bernengo, PL Ortiz-Romero, M Bagot, T Estrach, J Guitart, R Knobler, JA Sanches, K Iwatsuki, M Sugaya, R Dummer, M Pittelkow, R Hoppe, S Parker, L Geskin, L Pinter-Brown, M Girardi, G Burg, A Ranki, M Vermeer, L Laroche, S Horwitz, S Rosen, L Cerroni, B Dreno, EC Vonderheid. Clinical Endpoints and Response Criteria in Mycosis Fungoides and Sézary Syndrome: a Consensus Statement of the International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC) and the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer (EORTC). J Clin Oncol 2011; 29: 2598-2607 [IF: IF:18.970]
• RL Piekarz, R Frye, HM Prince, MH Kirschbaum, J Zain, SL Allen, E Jaffe, A Ling, M Turner, C Peer, WD Figg, SM Steinberg, S Smith, D Joske, I Lewis, L Hutchins, Ml Craig, A Tito Fojo, JJ Wright, SE Bates. Phase II Trial of Romidepsin in Patients with Peripheral T-cell Lymphoma Blood 2011; 117: 5827-34 [IF:10.896]
• H Quach, HM Prince, Andrew Spencer. Managing Multiple Myeloma in the Elderly: Are We Making Progress? Expert Reviews in Hematol 2011; 4: 301-15 [IF:2.493]
• P Blombery, HM Prince, M Yang, E Wood, L Worth, J Main, D Westerman. Prophylactic Intravenous immunoglobulin prophylaxis during autologous hemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications. Ann Hematol 2011; 90: 1167-72 [IF: 2.919]
• SJ Harrison, H Quach, E Link, J Dean, S Ruell, JF Seymour, H Januszewicz, DS Ritchie, R Johnstone, P Neeson, M Dickinson, J Nichols, HM Prince. A High Rate Of Durable Responses with Romidepsin, Bortezomib And Dexamethasone In Relapsed or Refractory Multiple Myeloma Blood 2011; 118: 6274-83 [IF:10.896]
• Gangatharan S, Carney D, Campbell L, Prince HM, Kenealy M, Seymour J. Cytogenetic response is not a pre-requisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol. 2011; 87: 186-8 [IF:1.807]
• W Kempf, K Pfaltz, MH Vermeer, A Cozzio, P Ortiz, M Bagot, E Olsen, YH Kim, R Dummer, N Pimpinelli, S Whittaker, E Hodak, L Cerroni, E Berti, S Horwitz, HM Prince, J Guitart, T Estrach, JA Sanches, M Duvic, A Ranki, B Dreno, S Ostheeren-Michaelis, R Knobler, G Wood, R Willemze. European Organization for Research and Treatment of Cancer (EORTC), International Society of Cutaneous Lymphoma (ISCL) and United States Cutaneous Lymphoma Consortium (USCLC) consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118: 4024-35 [IF:10.896]
• Iland H, Bradstock K, Seymour J, Hertzberg M, Grigg A, Taylor K, Catalano J, Cannell P, Horvath N, Deveridge S, Browett P, Brighton T, Chong L, Springall F, Ayling J, Catalano A, Supple S, Collins M, Di Iulio J, Reynolds J; Australasian Leukaemia and Lymphoma Group* (Collaborators). Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. 2012 Feb;97(2):227-34. [IF:6.416]
• Sl Lingaratnam, LJ Worth, MA Slavin, CA Bennett, SW Kirsa, JF Seymour, A Dalton, B Koczwara, HM Prince, M O’Reilly, L Mileshkin, J Szer, KA Thursky. A Cost Analysis of Febrile Neutropenia Management in Australia: Ambulatory versus In-hospital Treatment. Australian Health Review 2011; 35: 491-500 [IF:0.803]
• A Hsu, H Quach, TY Tai, HM Prince, SJ Harrison, JA Trapani, MJ Smyth, PJ Neeson, DS Ritchie.Dexamethasone dose alters expression of NK activating receptors in vivo (Response to Letter). Blood 2011; 118: 6466-6468 [IF:10.896]

• PJ Shaughnessy, BJ Bolwell, K van Besien, M Mistrik, A Grigg, A Dodds, HM Prince, S Durrant, O Ilhan, D Parenti, J Rogers, J Gallo, F Foss, J Apperley, M-J Zhang, MM Horowitz, S Abhyankar. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl 2010: 45: 1068-76 [IF: 2.643]
• K Herbert, HM Prince, Ritchie D, JF Seymour. The role of ancestim (recombinant human stem cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution. Exp Opinion Biol Therap. 2010; 10 (1): pp 113-125
• S Nath, E Maxwell, M Peris, M Bishton, HM Prince. Light chain deposition disease presentinig as massive hepatomegaly. Pathology 2010; 42; 307-10 [IF:2.234]
• S Gill, D Carney, D Ritchie, M Wolf, D Westerman, HM Prince, H Januszewicz, JF Seymour. The frequency, manifestations and duration of prolonged cytopenias after first line fludarabine-combination chemotherapy. Ann Oncol 2010; 21: 331-4 [IF:4.875]
• H Quach, D Ritchie, AK Stewart, P Neesom, S Harrison, MJ Smyth, HM Prince. Mechanism of Action of Immunomodulatory Drugs in Multiple Myeloma. Leukemia 2010; 24: 22-32 [IF:6.612]
• Law A, Ryan G, Prince HM. Development of Kaposi’s Sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV negative patient.Int J Hematol 2010; 24: 347-8 [IF:1.283]
• HM Prince, M. Duvic, A Martin, W Sterry, C Assaf, A Negro-Vilar, Y Sun, D Straus, M Acosta. Phase 3 Placebo-Controlled Trial of Denileukin Diftitox for Patients With Primary Cutaneous T-Cell Lymphoma J Clin Oncol 2010; 28: 1870-1877[IF:18.970]
• A Grigg, A Schwarer, J Stone, M Wolf, HM Prince, J Seymour, D Gill, J Bashford, D Ellis, J Reynolds.^. Phase II study of autologous stem cell transplantation using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis low grade non-Hodgkin’s lymphoma. Leukemia Lymphoma 2010; 51: 641-9 [IF:2.397]
• S Peinert, HM Prince, PM Guru, MH Kershaw, MJ Smyth, JA Trapani, P Gambell, S Harrison, AM Scott, FE Smyth, PK Darcy, K Tainton, P Neeson, DS Ritchie, D Honemann. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Therapy 2010, 17: 347-348 [IF:4.4492]
• Chan AC, Neeson P, Leeansyah E, Tainton K, Quach H, Prince HM, Godfrey DI, Ritchie D, Berzins SP. Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients. Leukemia 2010, 24; 592-600.[IF:6.612]
• M Dickinson, R Hoyt, AW Roberts, A Grigg, JF Seymour, HM Prince, J Szer, David Ritchie. Improved Survival for Relapsed Diffuse Large B cell Lymphoma is Predicted by a Negative Pre-transplant FDG-PET Scan Following Salvage Chemotherapy. Brit J Haematol 2010; 150: 39-45 [IF:4.080]
• MS Liew, AM Chan, S Galloway, G Comin, B Flaim, HM Prince, H Quach. Extra-Nasal NK/T Cell Lymphoma Masquerading As Renal Infarction. Leukemia Lymphoma 2010; 51: 1139-41 [IF:2.397]
• EJ Gowans, S Roberts, K Jones, PA Latour, B Chua, EMY Eriksson, S Li, DM Wall, R Sparrow, HM Prince, D Hart, LE Brown, DC Jackson. A Phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol 2010; 53: 599-607 [IF:7.056]
• Neeson P, Shin A, Tainton K, Guru P, Prince HM, Harrison S, Peinert S, Smyth MJ, Trapani JA, Kershaw MH, Darcy PK, Ritchie DS. Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Therapy 2010; 17: 1105-1116 [IF:4.4492]
• PA Thompson, S Lade, H Webster, G Ryan, HM Prince. Effusion-associated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct clinico-pathological entity. Hematologica 2010;95:1977-9. [IF:6.416]
• S Peinert, CS Tam, HM Prince, J Scarlett, MM Wolf, EH Januszewicz, D Westerman, JF Seymour. Fludarabine Based Combinations Are Highly Effective as First-Line or Salvage Treatment in Patients with Waldenström Macroglobulinemia. Leukemia Lymphoma 2010; 51: 2188-2197[IF:2.397]
• HM Prince. The deacetylase inhibitors – here to stay! Investigational New Drugs. The Journal of New Anticancer Agents 2010;28 Suppl 1:S1-2. [IF:3.396]
• M Dickinson, R Johnstone, HM Prince. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Investigational New Drugs. The Journal of New Anticancer Agents 2010;28 Suppl 1:S3-20.[IF:3.396]
• DA Carney, DA Westerman, CS Tam, A Milner, HM Prince, M Kenealy, M Wolf, EH Januszewicz, D Ritchie, N Came, JF Seymour. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010;24(12):2056-62 [IF:6.612]
• M Bishton, R Johnstone, M Dickinson, S Harrison, HM Prince. Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. Pharmaceuticals 2010; 3: 2674-2688
• Blombery PA, Levinson MR, Pianko S, Prince HM, Bhathal PS. Rituximab-induced immune dysregulatory ileocolitis in a patient with follicular lymphoma. J Clin Oncol 2010; 29:e110-2 [IF: IF:18.970]

• PJ Kim, RJ Hicks, A Wirth, G Ryan, JF Seymour, HM Prince, MP Mac Manus. Impact of ¹⁸F-Fluorodeoxyglucose-Positron Emission Tomography before and after definitive radiation therapy in patients with apparently-solitary plasmacytoma. Int J Rad Oncol Biol Phys 2009, 74: 740-746 [IF:4.290]
• KE Herbert, S Morgan, HM Prince, DA Westerman, MM Wolf, DA Carney, K Yuen, JF Seymour. Stem Cell Factor and high-dose twice-daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with Fludarabine; results of a Phase II study with an historical comparator. Leukemia 2009 23; 305-12 [IF:612]
• JR Mikhael, AR Belch, HM Prince, MN Lucio, A Maiolino, A Corso, MT Petrucci, P Musto, M Komarnicki, AK Stewart. High response rate to bortezomib with or without dexamethasone in patients with relapsed and/or refractory multiple myeloma: results of a Global Phase 3b Velcade Expanded Access Program. Brit J Haematol 2009;144:169-75. [IF:4.490]
• MA Dawson, SS Opat, Y Taouk, M Donovan, M Zammit, K Monaghan, N Horvath, AW Roberts, HM Prince, M Hertzberg, CA McLean, A Spencer. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma. Clin Canc Res 2009 15:714-22 [IF:177]
• S Peinert, S Kamel, JF Seymour, HM Prince. Intralesional rituximab for localized palatal relapse of follicular lymphoma. Leukemia Lymphoma [IF:2.397] 2009; 50: 303-305
• H Quach, L Mileshkin, A Milner, JF Seymour, D Ritchie, S Harrison, D Westerman, S Peinert, HM Prince. Predicting durable remissions following thalidomide therapy for relapsed myeloma. Leukemia Lymphoma [IF:2.397] 2009; 50: 223-229
• HM Prince, M Bishton. Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma. Hematology Meeting Reports 2009;3 (1): 33-38
• A Spencer, HM Prince, AW Roberts, IW Prosser, KF Bradstock, L Coyle, DS Gill, N Horvath, J Reynolds, N Kennedy. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation (ASCT) procedure. J Clin Oncol 2009 27:1788-1793, 2009 [IF:17.157]
• HM Prince, D Honemann, A Spencer D Rizzieri, E Stadtmauer, A Roberts, N Bahlis, GTricot, S Kathman, KL Baker, L Pandite. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase II study of pazopanib (GW786034). Blood 2009 , 113; 4819-4820 [IF:10.896]
• M Rodrigues, C McCormack, L-M Yap, HM Prince, H Roberts, R Williams, P Foley. Successful treatment of Lymphomatoid Papulosis with Photodynamic Therapy. Aus J Dermatol 2009; 50: 129-132
• JA Westwood, WK Murray, M Trivett, NM Haynes, S Fox, B Solomon, L Mileshkin, D Ball, M Michael, L Devereux, A Burman, P Mayura-Guru, JA Trapani, S Peinert, D Honemann, HM Prince, AM Scott, FE Smyth, MJ Smyth, PK Darcy, MH Kershaw.The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. J Immunother 2009, 32:292-301 [IF: 4.837]
• HM Prince, M Bishton, RW Johnstone. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncology 2009, 5: 601-12
• HM Prince, M Bishton, S Harrison. Clinical Studies of Histone Deacetylase Inhibitors. Clin Canc Res 2009, 15: 3958-69 [IF:177]
• M Dickinson, HM Prince, S Kirsa, A Zannettino, SDJ Gibbs, L Mileshkin, J O’Grady, JF Seymour, J Szer, N Horvath, DE Joshua and others on behalf of the Medical and Scientific Advisory Group of the Myeloma Foundation of Australia. Osteonecrosis of the Jaw Complicating Bisphosphonate Treatment for Bone Disease in Multiple Myeloma: An Overview with Recommendations for Prevention and Treatment. Int Med J (In Press) 2009, 39: 304-316 [IF:1.402]
• V Kieu, T O’Brien, LM Yap, C Baker, P Foley, G Mason, HM Prince, C McCormack. Refractory Subacute Cutaneous Lupus Erythematosus Successfully Treated with Rituximab. Aust J Dermatol 2009, 202-206
• S Peinert, D Carney, HM Prince, EH Januszewicz, JF Seymour. Fludarabine combinations for patients with advanced marginal zone lymphomas – best treatment option or too toxic? Brit J Haematol 2009; 146, 685-686 [IF:4.080]
• S Gill, KE Herbert, HM Prince, MM Wolf, A Wirth, G Ryan, DA Carney, DS Ritchie, JM Davies, JF Seymour. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Brit J Haematol 2009;147(1):83-8 [IF:4.080]
• M Dickinson, D Ritchie, DJ DeAngelo, M Bishton, A Spencer, T Fischer, KN Bhalla, FJ Giles, A Liu, K Parker, G Laird, E Masson, JW Scott, OG Ottman, HM Prince. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Brit J Haematol 2009;147:97-101 [IF:4.080]
• RL Piekarz, R Frye, M Turner, JJ Wright, SL Allen, MH Kirschbaum, J Zain, HM Prince, JP Leonard, LJ Geskin, C Reeder, D Joske, WD Figg, ER Gardner, SM Steinberg, E Jaffe, M Stetler-Stevenson, A Tito Fojo, SE Bates. A Multi-Institutional Phase II Trial of the HDAC Inhibitor Romidepsin as Monotherapy for Patients with Cutaneous T-cell Lymphoma J Clin Oncol 2009: 27; 5410-7 [IF:17.157])
• D Ritchie, RL Piekarz, P Blombery, LJ Karai, S Pittaluga, ES Jaffe, M Raffeld, JE Janik, HM Prince, SE Bates. Reactivation of DNA viruses in association with histone deacetylase inhibitor (HDI) therapy: a case series report. Hematologica 2009;94: 1618-22 [IF:6.416]
• Bajel A, Hill P, Goodman D, McCormack C, Davison J, Honemann D, Kenealy M, Harrison S, Prince HM. IgA Nephropathy Associated with Cutaneous T Cell Lymphoma. Leukemia Lymphoma [IF:2.397] 2009; 50: 2083-5
• H Quach, N Horvath, P Cannell, JR Mikhael, BE Butcher, HM Prince. Safety and efficacy results from an international Expanded Access Program to Bortezomib for patients with relapsed and / or refractory multiple myeloma: a subset analysis of the Australian & New Zealand data of 111 patients. Int Med J 2009; 39: 290-295 [IF:1.402]
• A Spencer, HM Prince, AW Roberts. Response to M Cavo et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation (ASCT) procedure. J Clin Oncol 2009:27; 1788-93 [IF:17.157]
• EA Stadtmauer, DM Weber, R Niesvizky, A Belch, HM Prince, JF San Miguel, T Facon, M Olesnyckyj, Z Yu, JB Zeldis, R Knight, MA Dimopoulos. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Hematol 2009; 82: 426-32 [IF:1.807]
• Spencer A, Prince HM, Roberts AW. Response to Cavo M. Thalidomide maintenenence in multiple myeloma. Certainties and controversies. J Clin Oncol 2009; 27: 1788-93 [IF:17.157]
• S Peinert, MH Kershaw, HM Prince. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learnt to plan for the future. Immunotherapy 2009; 1: 905-12
• Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sezary Syndrome. Blood 2009; 114; 4337-4353 [IF:10.896]

• L Zhang, MC Cooper, D Lebwohl, E Masson, G Laird, HM Prince. Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (Panobinostat) J Clin Oncol 2008; 26: 332-333 [IF:15.484]
• J Green, E Upjohn, C McCormack, J Zeldis, HM Prince. Successful treatment of Behcet’s Disease with Lenalidomide. Brit J Dermatol 2008; 158: 197-198 [IF:3.334]
• N Bercovici, N Haicheur, S Massicard, F Vernel-Pauillac, O Adotevi0, D Landais, I.Gorin, C Robert, HM Prince, J-J Grob, M Leccia, T Lesimple, J Bartholeyns, WH Fridman, M Salcedo, E Ferries, E Tartour. Analysis and characterization of anti-tumor T cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunotherapy 2008, 31; 101-112 [IF:3.983]
• HM Prince, M Bishton, S Harrison. The Potential of Histone Deacetylase Inhibitors for the Treatment of Multiple Myeloma [Commentary] Leukemia Lymphoma 2008; 49(3): 385 – 387 [IF:1.939]
• JS Sutherland, LS Spyroglou, JL Muirhead, TS Heng, A Prieto-Hinojosa, HM Prince, AP Chidgey, AP Schwarer, Richard L. Boyd. Enhanced immune system regeneration in humans following allogeneic or autologous hemopoietic stem cell transplantation by temporary sex steroid blockade. Clin Canc Res 2008, 14: 1139-1148 [IF:177]
• Prince HM. Update of Histone Deacetylase Inhibitors for the Treatment of T-Cell Lymphoma and Multiple Myeloma. Oncology Briefings 2008; 6: 1-3
• HM Prince, DM Wall, D Ritchie, D Honemann, S Harrrison, H Quach, M Thompson, R Hicks, E Lau, J Davison, M Loudovaris, J Moloney, B Loveland, J Bartholeyns, A Katsifis, L Mileshkin. In vivo tracking of dendritic cells in patients with multiple myeloma. J Immunotherapy 2008; 31:166-179 [IF:3.983]
• Rasheed, M. Bishton, R Johnstone, H.M.Prince. Histone Deacetylase Inhibitors in Lymphoma and Solid Malignancies. Expert Rev Anti-Cancer Therapy 2008; 8 (3) 413-432 [IF:3.267]
• Prince HM. New Strategies in the treatment of T-cell lymphoma. Clin Adv Hematol Oncol 2008; 6 (1) Suppl 1. 1-16.
• Prince HM. Histone Deacetylase Inhibitors in the Treatment of Multiple Myeloma.Clinical Adv Hematol Oncol 2008; 6 (4) Suppl 8: 2-8
• S Peinert, HM Prince, SJ Harrison. The development of novel Immunotherapeutic approaches in Multiple Myeloma. Leukemia Lymphoma 2008;49:652-654 [IF:1.939]
• SI Gill, SW Lane, J Crawford, G Cull, P Marlton, PN Mollee, HM Prince, JF Seymour. Prolonged Haematologic Toxicity From The Hyper-CVAD Regimen: Manifestations, Frequency, and Natural History In A Cohort of 125 Consecutive Patients. Ann Hematol (2008) [Epub ahead of print] [IF:2.254]
• Herbert KH, Levasque JP, Haylock D, Prince HM. The use of experimental murine models to assess novel agents of hematopoietic stem and progenitor cell mobilization. Biol Blood Marrow Transpl Biol Blood Marrow Transpl 2008;14:603-621 [IF:3.278]
• L Ellis, Y Pan, GK Smyth, DJ George, LC McCormack, R Williams-Truax, P Atadja, C Zhao, M Dugan, K Culver, R Johnstone, HM Prince. The histone deacetylase inhibitor LBH589 induces responses with associated alterations in gene expression profiles in cutaneous T cell lymphoma. Clin Canc Res 2008; 14: 4500-4510 [IF:177]
• SI Gill, M Wolf, HM Prince, H Januszewicz, D Ritchie, RJ Hicks, JF Seymour. ¹⁸F-FDG-Positron Emission Tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma. 2008 Jun;8:159-65.
• JA Westwood, WK Murray, M Trivett, A Shin, P Neeson, DP MacGregor, NM Haynes1, JA Trapani, P Mayura-Guru1, S Fox, S Peinert, D Honemann, HM Prince, D Ritchie, AM Scott, FE Smyth, MJ Smyth, PK Darcy, MH Kershaw.Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice Gene Therapy 2008 Jul;15(14):1056-66 [IF:4.780]
• S Arulogun, HM Prince, S Lade, P Gambell, D Westerman, G Ryan, O Blewitt, E Eaton, C McCormack. Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol. J Am Assoc Dermatol 2008; 59: 589-95 [IF:2.421]
• MED Flowers, JF Apperley, K Van Besien, A Elmaagacli, A Grigg, VS Reddy, A Bacigalupo, H-J Kolb, L Bouzas, M Michallet, HM Prince, R Knobler, D Parenti, J Gallo, HT Greinix. A Multicenter Prospective Randomized Study of Extracorporeal Photopheresis Therapy for the Treatment of Chronic Graft-versus-Host Disease. Blood 2008; 112: 2667-2674 [IF:10.896]
• S Arulogun, HM Prince, J Ng, S Lade, G Ryan, O Blewitt, C McCormack.Long term outcomes of patients with advanced-stage cutaneous T cell lymphoma and large cell transformation. Blood 2008 15;112(8):3082-7. [IF:10.896]
• Bishton MJ, Hicks RJ, Westerman DA, Prince M, Wolf M, Seymour JF. A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin’s lymphoma following treatment with iodine-131-rituximab radio-immunotherapy. Haematologica. 2008;93:789-90. [IF:4.192]
• MJ Bishton, RJ Hicks, HM Prince, DS Ritchie, M Wolf, JF Seymour. Claimed association of the absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independent data set. Leukemia 2008 22: 2259-60 [IF:612]
• Prince HM. The potential of histone deacetylase inhibitors for the treatment of lymphoma and multiple
• Clin Adv Hematol Oncol 2008; 6 (12) supplt 20: 2-7
• Prince HM. Romidepsin in multiple myeloma. Clin Adv Hematol Oncol 2008; 6 (12) supplt 20: 8-11

• HM Prince, B Schenkel, L Mileshkin. An analysis of Clinical Trials Assessing the Efficacy and Safety of Single-agent Thalidomide in Patients With Relapsed or Refractory Multiple Myeloma. Leukemia Lymphoma 2007, 48: 46-55 [IF:1.939]
• H Dinh, C McCormack, S Hall, HM Prince. Rituximab for the treatment of the skin manifestations of dermatomyositis – a report of three cases. J Am Acad Dermatol 2007, 56; 148-153 [IF:2.421]
• DS Ritchie, JF Seymour, AP Grigg, AW Roberts, R Hoyt, S Thompson, J Szer, HM Prince. The Hyper-CVAD-Rituximab Chemotherapy Program Followed by High-Dose Busulfan, Melphalan and Autologous Stem Cell Transplantation Produces Excellent Event Free Survival in Patients with Previously Untreated Mantle Cell Lymphoma. Ann Hematol 2007, 86; 101-105 [IF:1.416]
• Ritchie D, Mileshkin L, Wall D, Auzelle F, Thompson M, Lau E, Wong J, Eu P, Hicks RJ, Prince HM. In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma. Cancer Immunol Immunother 2007, 56; 155-163 [IF:3.520]
• AP Ng, A Wirth, JF Seymour, M Lee, A Hogg, H Janusewicz, M Wolf, HM Prince, M MacManus, R Hicks. Early Therapeutic Response Assessment by ¹⁸FDG-Positron Emission Tomography During Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: Isolated Residual Positivity Involving Bone is Not Usually a Predictor Of Subsequent Treatment Failure. Leukemia Lymphoma 2007 48:596-600 [IF:1.939]
• WK Rasheed, RW. Johnstone, HM Prince. Histone Deacetylase Inhibitors in Cancer Therapy. Expert Opin Investig Drugs 2007, 16; 659 – 678 [IF:3.267]
• KE Herbert, CR Walkley, IG Winkler, J Hendy, G Haines, Y-D Yuan, R Chandraratna, HM Prince, J-P Lévesque, LE Purton. G-CSF and an RARa Specific Agonist, VTP195183, Synergize to Enhance the Mobilization of Hematopoietic Progenitor Cells. Transplantation 2007;83:375-84. [IF:3.608]
• JB Ruddle, HM Prince. Denileukin Diftitox and Vision Loss. Luekemia and Lymphoma (Editorial). Leukemia Lymphoma 2007, 48; 655-656 [IF:1.939]
• HM Prince, B Schenkel, L Mileshkin. Assessing Response Rates in Clinical Trials of Treatment for Relapsed or Refractory Multiple Myeloma: A Study of Bortezomib and Thalidomide. Leukemia 2007; 21: 818 – 820 [IF:6.612]
• MSY Goh, C McCormack, HV Dinh, B Welsh, P Foley, HM Prince. Rituximab in the adjuvant treatment of Pemphigus Vulgaris: A prospective open-label pilot study in five patients. Brit J Dermatol 2007, 156; 990 – 996 [IF:3.334]
• DM Wall, HM Prince. Cell Therapy in Australia. The International Society of Cellular Therapy Annual Meeting comes to Sydney in 2007 [Editorial].Cytotherapy 2007; 9:207 – 208 [IF:1.795]
• SK Nilsson, HM Prince, D Wall, DN Haylock. Recent Australian Experience with Haemopoietic Stem and Progenitor Cell Expansion. Cytotherapy 2007; 9: 231-235. [IF:1.795]
• HM Prince, M Adena, D Kingsford Smith, Judy Hertel. Efficacy of single-agent bortezomib versus single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison. Eur J Haematol 2007 79; 93-99 [IF: 1.807]
• L Mileshkin, P Gambell, D Ritchie, M Trivett, Y Hayakawa, D Honemann, M Smyth, V Beshay, P Simmons, AD Milner, JB Zeldis, HM Prince. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57⁺ cytotoxic T cells as predictors of outcome. Haematologica 2007 92; 1075 -1082 [IF:4.192].
• S Gill, J Shapiro, D Westerman, HM Prince. long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma. J Clin Oncol 2007 25: 4493-4494 [IF:15.484]
• H Quach, HM Prince, L Mileshkin. Treatment Strategies in Elderly Patients with Multiple Myeloma: Current Status. Drugs and Aging 2007; 24: 829-850 [IF:2.072]
• S Feyler, HM Prince, R Pearce, K Towlson, I Nivison-Smith, S Schey, J Gibson, N Patton, K Bradstock, D Marks, G Cook on behalf of the BSBMT & AMBTRR. The role of high dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transpl 2007;40:443-50 [IF:2.643]
• Herbert KE, True S, McArthur G, Prince HM. Safety and Efficacy of Combining ATRA with G-CSF in HSPC mobilization; a Pilot study in multiple myeloma and non-Hodgkin Lymphoma patients. Bone Marrow Transpl 2007;40:801-3 [IF:2.643]
• M Bishton, M Kenealy, R Johnstone, W Rasheed, HM Prince.Epigenetic Targets in Hematological Malignancies: A Focus on combination therapies with Histone Deacetylase Inhibitors and Demethylating Agents. Exp Rev Anticancer Ther 2007; 7: 1439-1449 [IF:3.267]
• M Dimopoulos, A Spencer, M Attal, HM Prince, J-L Harousseau, A Dmoszynska, J San Miguel,
  A Hellmann, T Facon, R Foà, M Lazzarino, Z Masliak, M Olesnyckyj, Z Yu, J Patin, JB. Zeldis, RD Knight. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Eng J Med. 2007; 357: 2123 – 2132 [IF: 53.1 ]
• MS Liew, MJ Bishton, H Januszewicz, S Alatakis, HM Prince. Spinal Epidural Lipomatosis in Myeloma Leukemia Lymphoma 2007;48:2068-70 [IF:1.939]

• AP Ng, S Lade, T Rutherford, HM Prince DA Westerman. Primary cutaneous CD4+/CD56+ hematodermic neoplasm (Blastic NK-cell lymphoma): a report of five cases. Haematologica/The Hematology Journal 2006, 91; 143-144 [IF:4.192]
• M Gandhi, E Lambley, J Burrows, U Dua, S Elliott, PJ Shaw HM Prince, M Wolf, A Grigg, K Clarke, C Underhill, T Mills, P Mollee, D Gill, P Marlton, JF Seymour, R Khanna. Plasma Epstein-Barr virus DNA is a Biomarker for EBV-associated Hodgkin Lymphoma. Clin Cancer Res 2006, 12; 460-464 [IF:5.625]
• H Robinson, Maxwell E, Prince HM, Jakobovits A. Cefotetan-induced life-threatening haemolysis. Med J Australia 2006, 184: 251 [IF:2.000]
• CS Tam, M Wolf, HM Prince, EH Januszewicz, D Westerman, KI Lin, D Carney, JF Seymour. Fludarabine, Cyclophosphamide And Rituximab For The Treatment Of Patients With Chronic Lymphocytic Leukaemia Or Indolent Non-Hodgkin Lymphoma. Cancer 2006, 106: 2412-2420 [IF:3.941]
• C Keane, S Gibbs, JF Seymour, AK Mills, K Grimmett, R Van Kuilenberg, R Saal, D Gill, HM Prince, P Marlton, P Mollee. The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilise peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilisation. Hematol Oncol 2006, 24: 159-163 [IF:1.650]
• L Mileshkin, R Stark, B Day, JF Seymour, M Faragher, JB Zeldis, HM Prince.The development of neuropathy in myeloma patients being treated with thalidomide: patterns of occurrence and the role of electrophysiological monitoring. J Clin Oncol 2006, 24:4507-14. [IF:15.484]
• F Cachin, HM Prince, A Hogg, RE Ware, RJ Hicks. Powerful prognostic stratification by ¹⁸F-FDG PET in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol 2006, 24:3026-3031 [IF:15.484]
• Schrover, M. A. Adena, R. De Abreu Lourenco, HM Prince, J. F. Seymour, M. J. Wonder. Development of a predictive population model for the prognosis of patients with chronic myeloid leukemia in chronic phase according to the cytogenetic response rate. Leukemia Lymphoma 2006, 47:1069-81. [IF:1.939]
• M Kenealy, HM Prince, D Hönemann. Tumour Lysis Syndrome in Relapsed Multiple Myeloma Patients Treated with Bortezomib. Pharmacotherapy 2006, 27; 1205-6 [IF:2.277]
• Polizzotto MN, Tam CS, Milner A, Januszewicz EH, Prince HM, Westerman D, Wolf MM, Seymour JF. The influence of increasing age on the deliverability and toxicity of fludarabine based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders. Cancer 2006; 107: 773-780 [IF:4.434].
• JB Ruddle, CA Harper, D Hönemann, JF Seymour, HM Prince. A Denileukin Diftitox (Ontak) Associated Retinopathy? Brit J Ophthalmol 2006, 90:1070-1 [IF:2.00].
• H Robinson, M Damasiewicz, D Honemann, A Boussioutas, HM Prince. Gastric Involvement Of Plasmacytoma Associated With t(4:14) and Chromosome 13 Deletion. Leukemia Lymphoma. Leukemia Lymphoma 2006, 47; 1973-1975 [IF:1.939]
• SW Lane, J Crawford, M Kenealy, G Cull, JF Seymour, M Prince, P Marlton, D Gill, PN Mollee. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leukemia Lymphoma 2006, 47; 1813-1817 [IF:1.939]
• M Rodrigues, D Westerman, S Lade, C McCormack, HM Prince. Methotrexate-Induced Lymphoproliferative Disorder in a patient with Sézary Syndrome. Leukemia Lymphoma 2006, 47; 2257-9 [IF:1.939]
• CS Tam, JF Seymour, HM Prince, M Kenealy, M Wolf, EH Januszewicz, D Westerman. Treatment Related Myelodysplasia Following Fludarabine combination chemotherapy. Haematologica 2006, 91; 1546-1550 [IF:4.192]
• D Honemann, HM Prince. Myeloma, Thalidomide and Thrombosis. (Review) Leukemia Lymphoma 2006, 47; 2273-2275 [IF:1.939]
• M Kenealy, HM Prince. The Current Status of New Drugs for the Treatment of Patients with Multiple Myeloma. (Review). Internal Medicine Journal 2006; 36; 781-789 [IF:1.518]
• L Mileshkin, HM Prince. The troublesome toxicity of peripheral neuropathy with thalidomide. Review. Leukemia Lymphoma 2006, 47; 2276-2279 [IF:1.939]
• SJ Harrison, G Cook, RJB Nibbs, HM Prince. Immunotherapy of Multiple Myeloma: The Start of a Long and Tortuous Journey. Expert Review of Anticancer Therapy 2006, 12; 1769-1785 [IF:3.267]
• H Robinson, HM Prince, S Ramdave, JF Seymour, P Elliott R Hicks,^. Preliminary experience with ¹⁸F-Fluorodeoxyglucose positron emission tomography in staging of Castleman’s Disease. Leukemia Lymphoma 2006, 14;2664-2666 [IF:1.939]
• E Upjohn, R Sinclair, P Foley, P Lane, J Magee, HM Prince, C McCormack. Clearance of patch stage mycosis fungoides with the 308 nm laser. Clin Exp Dermatol 2006, 32; 168-171 [IF:1.265]

• D Hönemann, HM Prince, RJ Hicks, JF Seymour. Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease – diagnostic dilemmas and management options Ann Hematol (2005) 84; 118-121 [IF:1.292]
• H Quach, G Ryan, V Ganju, HM Prince. Effective Treatment of Leptomeningeal Multiple Myeloma with Craniospinal Irradiation Supported by Second Donor Stem Cell Transplant Infusion. Bone Marrow Transpl (2005) 35; 423-4 [IF:2.643]
• A Wirth, HM Prince, M Wolf, J Stone, J Matthews, J Gibson, C MacCleod, J Szer, A Grigg, B To, D Roos, A Schwarer, S Davis. Optimal Scheduling to Reduce Morbidity of Involved Field Radiotherapy with Transplantation for Lymphomas; A Prospective Australasian Leukaemia and Lymphoma Group Study Bone Marrow Transpl (2005) 35; 291-298 [IF:2.643]
• JJ Biagi, KE Herbert, C Smith, E Abdi, M Leahy, C Falkson, M Wolf, H Januszewicz, JF Seymour, K Richards, JP Matthews, B Dale, HM Prince and on behalf of the ALLG. A Phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma Leuk Lymphoma (2005) 46; 197-206 [IF:1.939]
• Chionh F, Herbert KE, Seymour JF, Prince HM, Wolf M, Zimet A, Tam C, Kennedy GA. Ante-mortem diagnosis of localised invasive esophageal aspergillosis in a patient with acute myeloid leukaemia. Leuk Lymphoma (2005) 46:603-605 [IF:1.939]
• D Hönemann, HM Prince, JF Seymour, MM Wolf, D Westerman, E Henry Januszewicz. A phase II study of liposomal doxorubicin, vincristine and dexamethasone in multiple myeloma. Leuk Lymphoma (2005) 46; 945-948 [IF:1.939]
• Sarah Brennand, Vivian Sutton, James Biagi, David Westerman, Christopher J McCormack, John F Seymour, H Miles Prince. Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy. Brit J Dermatol (2005) 152; 1199-1205 [IF:3.334]
• C Tam, JF Seymour, HM Prince. Recent advances in the treatment of chronic lymphocytic leukaemia. Hospital Pharmacy Europe 2005; May/June 86-87
• A Spencer, N Horvath, J Gibson, HM Prince, R Hermann, J Bashford, D Joske, A Grigg, J Mckendrick, I Prosser, R Lowenthal, S Deveridge, K Taylor. Prospective randomized trial of amifostine cryoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transpl (2005) 35 :971-977. [IF:2.643]
• Bell, HM. PRINCE and R. Chin on behalf of the Australian Cancer Anaemia Association. Anaemia in Cancer Patients: Assessment, Management and the Use of Erythropoietic Agents. Clinical Reviews in Oncology (2005) 3 Suppl; 1-16  
• Mileshkin L, Prince HM. The adverse prognostic impact of advanced age in multiple myeloma Leuk Lymphoma (2005) 46; 951-966 [IF:1.939]
• T Seshadri, HM Prince, D Bell, P Coughlin, P James, G Richardson, B Chern, P Briggs, J Norman, I Olver, C Karapetis, J Stewart for the Australia Cancer Anaemia Study (ACAS) Group. The Australian Cancer Anaemia Survey: A Snapshot Of Anaemia In Adult Cancer Patients In Australia Med J Aust (2005) 182: 453-457 [IF:2.000]
• F Chionh, KE Herbert, JF Seymour, HM Prince, M Wolf, A Zimet, C Tam, GA Kennedy. Ante-mortem diagnosis of localised invasive oesophageal aspergillosis in a patient with acute myeloid leukemia. Leuk Lymphoma (2005); 46: 603-605 [IF:1.939]
• CS Tam, MM Wolf, D Westerman, EH Januszewicz, HM Prince, JF Seymour. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstrőm’s macroglobulinemia. Clin Lymphoma and Myeloma (2005) 6: 136-139 [IF:1.758]
• SDJ Gibbs, C McCormack, S Lade, D Westerman, G Ryan, JF Seymour, HM Prince. Early B-cell chronic lymphocytic leukemia presenting as cutaneous lesions with a normal blood lymphocyte count. J Am Academy Dermatol (2005) 53: 534-535 [IF:2.358]
• SDJ Gibbs, DA Westerman, JF Seymour and HM Prince. Severe and prolonged myeloid hematopoietic toxicity following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Brit J Haematol (2005); 130: 87-91 [IF:4.080]
• L Mileshkin, D Rischin, J Zalcberg, HM Prince. The contribution of cytotoxic chemotherapy to the management of cancer. Clinical Oncology (R Coll Radiol) (2005) 17: 294
• LR Mileshkin, JF Seymour, M Wolf, P Gates, EH Januszewicz, T Joyce, HM Prince. Increased, but manageable, Cardiovascular Toxicity during High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for patients aged 60 years and older. Leuk Lymphoma (2005) 46; 1575-1579 [IF:1.939]
• HM Prince, L Mileshkin, A Roberts, V Ganju, C Underhill, J Catalano, R Bell, JF Seymour, D Westerman, PJ Simmons, K Lillie, AD Milner, JB Zeldis, R Ramsay. A multi-centre phase-II trial of thalidomide and celecoxib for relapsed and refractory multiple myeloma. Clin Canc Res (2005) 11; 5504-5514 [IF:5.625]
• Prince HM, Regester G, Gates P, Jablonkis L, Seymour JF, Lillie K, West R, Wolf M, Januszewicz H, Belford D. A Phase I study of PV01, a milk protein extract for the prevention of mucositis in patients undergoing high-dose BEAM chemotherapy. Biol Blood Marrow Transpl (2005) 11: 512-520 [IF:3.278]
• GA Kennedy, S Lade, J Scarlett, HM Prince. Primary cutaneous mantle cell lymphoma: a case report of this very rare condition. Dermatology On-line (2005) (In Press)
• SV Nath, HM Prince, PFM Choong, GC Toner. Durable remissions are rare following high dose therapy with autologous stem cell transplantation for adults with bone and soft tissue sarcoma. Int Semin Surg Oncol (2005) 2:12 pp1-7 [IF:3.052]
• KA Thursky, LJ Worth, JF Seymour, HM Prince, MA Slavin. A Review of Spectrum of Infection, Risk and Recommendations for Prophylaxis and Screening among Patients with Lymphoproliferative Disorders Treated with Alemtuzumab. Brit J Haematol (2005) 132: 3-12 [IF:4.080]
• AP Ng, L Worth, L Chen, JF Seymour, HM Prince, M Slavin, K Thursky. Cytomegalovirus DNAemia and Disease: Incidence, Natural History and Management in settings other than allogeneic transplantation. Hematologica (2005) 90: 1672-9 [IF:4.192]
• Thompson M, Wall D, Hicks RJ, Prince HM. In vivo tracking for cell therapies. Q J Nucl Med Mol Imaging (2005) 49:339-48.
• SDJ Gibbs, J O’Grady, JF Seymour, HM Prince. Bisphosphonate-induced osteonecrosis of the jaw is an underdiagnosed and preventable condition requiring early detection and intervention. Med J Aust (2005) 183: 549-550. [IF:2.000]
• Anderson KC, Prince HM. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma. Semin Hematol. 2005 Oct;42(4 Suppl 4):S1-2 [IF:3.835]
• Prince HM. Evidence mounts on using pegfilgrastim for peripheral blood stem cell mobilisation. Amgenda [non peer-reviewed] (2005) 29: 4-5
• JA Westwood, MJ Smyth, MWL Teng, M Moeller, JA Trapani, AM Scott, FE Smyth, GA Cartwright, BE Power, D Honemann, HM Prince, PK Darcy, MH Kershaw. Adoptive Transfer of T cells modified with humanized chimeric receptor gene inhibits growth of Lewis-Y expressing tumors in mice. Proceedings of the National Academy of Science. 2005, 102: 19051-19056. [IF:10.452]
• MW Chao, P Gibbs, P Norris, HM Prince, J Kiffer, M Feigen, G Quong, A Wirth, KH Liew. Role of radiotherapy in solitary bone plasmacytomas. Asia Pacific Journal of Clinical Oncology 2005:1; 35-40
• Australian Cancer Network Diagnosis and Management of Lymphoma Guidelines Working Party. Guidelines for the Diagnosis and Management of Lymphoma. The Cancer Council Australia and Australian Cancer Network, Sydeny 2005.[Chapter 18: Primary Cutaneous Lymphomas]

• Tam, HM PRINCE, D Westerman, JF Seymour and S Juneja. Leukaemic Subtype Of Marginal Zone Lymphoma : A Presentation Of Three Cases And Literature Review. Leukemia and Lymphoma (2004) v45; 705-710 [IF:1.939]
• GA Kennedy, R Blum, C McCormack, HM Prince. Treatment of primary cutaneous follicular center lymphoma with rituximab: a report of 2 cases. Austral J Dermatol (2004) 45: 34-7
• M Moloney, HM Prince, JF Seymour, M Slavin, M Dooley. Dosing Schedule of Oral Valacyclovir for Prevention of Herpes Simplex Virus. Bone Marrow Transpl (2003) 32; 1035 [IF:2.643]
• AK Stewart, J Berenson, I Borello, M Hussein, J Mehta, M Prince, D Seigel, S Singhal, R Vescio. Maximizing Response to Thalidomide Therapy in Multiple Myeloma: Panel Discussion Proceedings. Celgene Corporation, Warren, New Jersey 2003 [non-peer reviewed]
• L Mileshkin, HM Prince, JF Seymour, JJ Biagi. Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide Br J Haematol (2003) 123: 747-748 [IF:3.052]
• Mileshkin L, Blum R, Seymour JF, Patrikeos A, Hicks RJ and Prince HM. A Comparison of Fluorine-18 Fluoro-deoxyglucose PET and Technetium-99m Sestamibi in Assessing Patients with Multiple Myeloma. Submitted to Eur J Haematol (2004) 72: 32-37 [IF:1.807]
• SJ Morgan, JF Seymour, A Grigg, JP Matthews, HM Prince, MM Wolf, EH Januszewicz Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine Leukemia (2004) 18: 1034-1038 [IF:6.612]
• Morgan, JF Seymour, HM Prince, DA Westerman, MM. Wolf. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukaemia including patients with chromosome 17p deletions and without detectable CD25 expression. Clin Cancer Res (2004) 10: 3572-5 [IF:5.991]
• HM Prince, C McCormack,G Ryan,R O’Keefe,JF Seymour,C Baker. Management of the Primary Cutaneous Lymphomas. 2004 Australian Cancer Network Lymphoma Guidelines
• PRINCE HM, Stokes K, Wall D, Wood R. From the Field: Australian Centre Conducts Cell Processing for Clinical Trials and Commercial Manufacture (2004) ISCT Telegraft 11 (1) 6-7 [non-peer reviewed]
• HM Prince, DP Wall, KH Stokes, Ray Wood, SR Burger, P Coghlan, N Boyce. Centre for Blood Cell Therapies and Cell Therapies Pty Ltd: Cell Processing for Clinical Trials and Commercial Manufacture Cell and Gene Therapy (2004)1; 16-22
• Tam CS, Wolf MM, Januszewicz EH, Prince HM, Westerman D, Seymour JF.Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies. Cancer (2004); 100: 2181-9 [IF:3.941]
• Tam CS, Galanos J, Seymour JF, Pitman AG, Stark R, Prince HM. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for haematologic malignancies Am J Hematol 2004:77; 72-76 [IF:1.793]
• MA Slavin, J Szer, AP Grigg, AW Roberts, JF Seymour, HM Prince, J Sasadeusz, K Thursky, SC Chen, CO Morrissey, CH Heath, T Sorrell. Guidelines for the use of antifungal agents in the treatment of invasive candida and mould infections. Int J Med; (2004) 34: 192-200 [IF:0.062]
• HM Prince, PJ Simmons, G Whitty, DP Wall, L Barber, GC Toner, JF Seymour, G Richardson, R Mrongovius, DN Haylock. Improved hemopoietic recovery following transplantation with ex vivo expanded mobilized blood cells (2004) Brit J Haematol 126; 536-545 [I IF:4.080]
• Herbert KE, Spencer A^, Grigg A, Ryan G, McCormack C, Prince HM. Graft-Versus-Lymphoma effect in refractory cutaneous T cell Lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transpl (2004) 34: 521-5 [IF:2.643]
• DN Haylock, PJ Simmons, HM Prince. Transplantation with Ex vivo Expanded CD34⁺ cells: The Melbourne Experience. Exp Hematol (In Press)
• PRINCE HM, Stokes K, Wall D, Wood R. From the Field: Australian Centre Conducts Cell Processing for Clinical Trials and Commercial Manufacture (2004) ISCT Telegraft [non-peer reviewed]
• S Aranda, J Bartlett, K Botting, N Boyce, R Condon, C French, C Hogan, M Kennedy, G Magrin, L Martin, L McNicol, T Nallanthamby, HM Prince, H Savoia, D Skewes, T Sutherland, G Whyte. Blood Matters Breakthrough Collaborative – Service Improvement Guide (2004) Victorian Department of Human Services
• DJ Gibbs, KE Herbert, C McCormack, JF Seymour, HM Prince. Alemtuzumab; effective monotherapy for simultaneous B-cell Chronic Lymphocytic Leukemia and Sézary Syndrome. Eur J Hematol (2004) 73; 447-449 [IF:1.807]
• C Tam, MM Wolf, EH Januszewicz, AP Grigg, HM Prince, D Westerman, JF Seymour. A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies Cancer (2004) 101; 2042-2049 [IF:3.941]

• PRINCE HM, Yap LM. Blum R, McCormack C. Primary Cutaneous B–cell lymphomas. Clin Exp Dermatol (2003) 28; 8-12 [IF:1.265]
• KE Herbert, HM PRINCE, DA Westerman. Pure red cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab. Blood (2003) 15; 1654 [IF: 9.631]
• To LB, Bashford J, Durrant S, MacMillan J, Schwarer AP, PRINCE HM, Gibson J, Lewis I, Swart B, Marty J, Rawling T, Ashman L, Charles S, Cohen B. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. Bone Marrow Transplant (2003);31:371-378 [IF:2.643]
• Yap LM, Blum R, Foley P, McCormack C, Turner H, Seymour JF, PRINCE HM. A clinical study of primary cutaneous B-cell lymphoma using both the European Organization for Research and Treatment of Cancer (EORTC) and World Health Organization (WHO) classifications. Australas J Dermatol (2003) 44; 110-115
• L Mileshkin, JJ Biagi, P Mitchell, Craig Underhill, A Grigg, R Bell, J McKendrick, P Briggs, JF Seymour, K Lillie, JG Smith, JB Zeldis, HM PRINCE. A multi-centre phase-II trial of thalidomide in relapsed/refractory multiple myeloma reveals a dominant adverse prognostic impact of advanced age. Blood (2003) 102; 69-77 [IF: 9.631]
• SJ Morgan, HM PRINCE, DA Westerman, R O’Hehir. Clonal T helper lymphocytes and elevated IL-5 levels in episodic angioedema and eosinophilia (Gleich’s syndrome). Leuk Lymph 2003: 44; 1623-25
• JN Macatschek, D Westerman, HM PRINCE, JF Seymour. A Case Of Clinical Indolent Natural Killer Cell Lineage Large Granular Lymphocytic Leukemia In A Patient with Rheumatoid Arthritis Leuk Lymph (2003)44; 1223-1227 [IF:1.335]
• DMP Wall, HM Prince. Regulation of Cellular Therapies: The Australian Perspective. Cytotherapy (2003) 5; 284-288 [IF:1.795]
• MW Saville, MC Benyunes, PS Multani, HM Prince, K Herbert, D Westerman. No clinical evidence for CD4+ cell depletion caused by rituximab. Blood (2003)102; 408-409 [IF: 9.631]
• Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD for the members* of the Worldwide Bexarotene study group. *HM Prince (member). Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: Results of the phase III clinical trial. J Am Acad Dermatol. 2003; 49:801-15. [IF:2.421]
• Westerman DA, Mills AK, Juneja SK, Ding JC, Taylor KM, PRINCE HM. B Cell Lymphoblastic Lymphoma Presenting with Hypercalcaemia and Lytic Bone Lesions in Adults: Case Reports and Review of the Literature. J Hematol (In Press)
• HM PRINCE, C McCormack,G Ryan, R O’Keefe, JF Seymour, C Baker. Management of the primary cutaneous lymphomas. Aust J Dermatol 2003; 44: 227-240
• Kennedy GA, Seymour JF, Wolf M, Januszewicz H, Davison J, McCormack C, Ryan G and Prince HM. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. Eur J Hematol (2003) 71: 250-256 [IF: 1.807]

• R Blum, HM PRINCE, RJ Hicks, A Patrikeos, J Seymour. Discordant response to chemotherapy detected by PET scanning: unveiling of a second primary cancer. Am J Clin Oncol (2002) 25; pp 368-370 [IF:1.136]
• PRINCE HM, O’Keefe R, Ryan G, McCormack C, Turner H, P Waring, Baker C. Cutaneous Lymphomas: Which Pathological Classification. Pathology (2002) 34: 36-45 [IF:0.880]
• HM PRINCE, D Wall, D Rischin, GC Toner, JF Seymour, D Blakey, D Haylock, P Simmons, M Wolf, EH Januszewicz, D Westerman, G Richardson, J Scarlett, P Briggs. CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy Cytotherapy (2002) 4: 147-155 [IF:1.795]
• HM PRINCE, J Bashford, D Wall, N Parker, D Rischin, GC Toner, JF Seymour, D Blakey, D Haylock, P Simmons, P Francis, M Wolf, EH Januszewicz, G Richardson, J Scarlett, P Briggs. Isolex 300I CD-34-selected cells to support multiple cycles of high-dose therapy Cytotherapy (2002) 4: 137-145 [IF:1.795]
• Wirth A, Seymour JF, Hicks RJ, Ware R, Fisher R, PRINCE HM, MacManus MP, Ryan G, Januszewicz H, Wolf M. Fluorine-18 Fluorodeoxyglucose Positron Emmision Tomography, Gallium-67 Scintigraphy, and Conventional Staging for Hodgkin’s Disease and Non-Hodgkin’s Lymphoma. Am J Med (2002) 112; 262-268 [IF:4.904]
• SL Chua, JF. Seymour, J Streater, MM Wolf, EH. Januszewicz, HM PRINCE. Intrathecal Chemotherapy is Inadequate Central Nervous System Prophylaxis in Patients with Intermediate-grade Non-Hodgkin’s Lymphoma Leukemia and Lymphoma (2002) 43; 1783-1788 [IF:1.939]

• Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley CA, Yokum R for the *Worldwide Bexarotene Study Group *HM Prince (member). Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-Cell lymphoma: Multinational phase II-III trial results. J Clin Oncol (2001) 19: 2456-2471. [IF:9.868]
• Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC for the *Worldwide Bexarotene Study Group *HM Prince (member). Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol (2001) 137: 581-93 [IF:2.761]
• Chapple P, PRINCE HM, Wall D, Filshie R, Haylock D, Quinn M, Bretell M, Venter D. Comparison of Three Methods of CD34+ Cell Enumeration in Peripheral Blood: Dual-Platform ISHAGE Protocol Versus Single-Platform Versus Microvolume Fluorimetry. Cytotherapy (2001) 2; 371-376 [IF:1.795]
• PRINCE HM, Ryan G, Seymour JF, McCormack C. Pegylated liposomal doxorubicin for cutaneous T cell Lymphomas. J Am Acad Dermatol (2001) 44; 149 [IF:2.421]
• Campbell JK, PRINCE HM, Juneja SK, Slavin M. Diffuse Large Cell Lymphoma and t(8;22) (q24;q11) in a Patient with Idiopathic CD4+ T-Lymphocytopenia. Leukemia Lymphoma (2001) 41: 421-423 [IF:1.939]
• PRINCE HM, Ryan G, McCormack C, Baker C, Rotstein H, Davison J, Yocum R. Bexarotene Capsules and Gel for Previously Treated Patients with Cutaneous T-cell Lymphoma: The Australian Experience. Aust J Dermatol (2001) 42: 91-97
• L Mileshkin, HM PRINCE, D Rischin. Severe interstital pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature. Bone Marrow Transplant (2001) 27: 559-563 [IF:1.939]
• PRINCE HM, Rischin D, Quinn M, Allen D, Planner R, Neesham D, Gates P, Davison J. Repetitive High-Dose Topotecan, Carboplatin and Paclitaxel with Peripheral Blood Progenitor Cell Support in Previously Untreated Ovarian Cancer: Results of a Phase I Study Gynecol Oncol (2001) 81: 216-224
• Clark L, Eerhard S, PRINCE M, Gale J, Spencer D. Trends in Cancer Nursing: the Haematology Nurse Practitioner Experience. Cancer Forum (2001) 25: 22-24
• Dowling AJ, PRINCE HM, Wirth A, Wolf M, Januscewicz EH, Juneja S, Seymour JF, Gates P, Smith JG. High-Dose Therapy and Autologous Transplantation for Lymphoma: The Peter MacCallum Cancer Institute Experience. Internal Medicine Journal (2001) 31: 279-289 [IF: 1.00]
• PRINCE HM, Wall D, Chapple P, Quinn M, Brettell M, Haylock D, Seymour JF, Wolf M, Januscewicz H, Richardson G, Joyce T, Maisano R, Rischin D. CliniMACS CD34-selected cells to support high-dose therapy. Transfusion and Apheresis Science (2001) 24: 183 [IF: 0.182]
• BJP Huntly, AG Reid, AJ Bench, LJ Campbell, N Telford, P Shepherd, J Szer, HM PRINCE, P Turner, C Grace, EP Nacheva, AR Green. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood (2001) 98: 1732-1738 [IF: 9.631]
• J Biagi, L Mileshkin, A Grigg, D Westerman, HM PRINCE. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplantation (2001) 28: 1145-1150 [IF:2.643]
• J Biagi, HM PRINCE. Thalidomide is effective for extramedullary relapse of multiple myeloma post-allogeneic bone marrow transplantation B J Haematol (2001) 115; 484 [IF:3.052]
• Al-Homaidhi A, PRINCE HM, Al-Zahrani H, Doucette D, Keating A. Granulocyte-Macrophage Colony Stimulating Factor-Associated Histiocytosis and Capillary-Leak Syndrome Following Autologous Bone Marrow Transplantation: Two Case Reports and a Review of the Literature. Review Series Oncology (2001) 1: 16-17 [non-peer reviewed]
• F. Seymour, B. Solomon, M.M. Wolf, E.H. Janusczewicz, A. Wirth, H.M. PRINCE. Primary Large-cell Non-Hodgkin’s Lymphoma of the Testis: A Retrospective Analysis of Patterns of Failure and Prognostic Factors. Clinical Lymphoma (2001) 2: 109-115 [IF:2.184]
• PRINCE HM. Recommendation for a ban of reproductive cloning and a green light for stem cell research in Australia. (2001) Telegraft [non-peer reviewed]
• Solomon B, Moore J, Arthur C, PRINCE HM. Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters: a multicentre randomized comparison of urokinase versus heparin. Eur J Cancer (2001) 37; 2379-2384 [IF:3.562]

• Juneja S, Trute L, Westerman D, Venter D, Seymour JF, PRINCE HM. Paraffin Section Immunotyping of Leukaemias. Brit J Haematol (2000) 109: 267-271 [IF:4.080]
• PRINCE HM, Toner GC, Seymour JF, Blakey D, Gates P, Eerhard S, Chapple P, Wall D, Quinn M, Juneja S, Wolf M, Januszewicz EH, Richardson G, Scarlett J, Briggs P, Brettell M, Rischin D. Docetaxel Effectively Mobilises Peripheral Blood CD34+ Cells. Bone Marrow Transplantation (2000) 26: 483-488 [IF:2.643]
• Hill PA, PRINCE HM, Power DA. Tubointerstitial Nephritis Following High Dose Ifosfamide: Three Breast Cancer Patients. Pathology (2000) 32;116-170 [IF:0.880]
• PRINCE HM, Rischin D, Toner GC, Seymour JF, Blakey D, Gates P, Eerhard S, Chapple P, Quinn M, Brettell M, Juneja S, Wolf M, Januszewicz EH, Richardson G, Scarlett J, Briggs P. Repetitive High-Dose Therapy with Cyclophosphamide, Thiotepa and Docetaxel with Peripheral Blood Progenitor Cell and Filgrastim Support for Metastatic and Locally advanced Breast Cancer: Results of a Phase I Study. Bone Marrow Transplantation (2000) 26: 955-961 [IF:2.643]
• PRINCE HM. Regulation of Blood Products in Australia: A New Approach in the Making. (2000) ISHAGE Telegraft 7: 8-9 [non-peer reviewed]

• PRINCE HM, Millward MJ, Rischin D, Gates P. Repetitive High-Dose Therapy with PBPC Support for Patients with Metastatic and Locally Advanced Breast Cancer. Autologous Marrow and Blood Transplantation. Eds. KA Dicke and A Keating. The Cancer Treatment Research and Educational Institute. pp 303-331(1999)
• PRINCE HM, Gardyn J, Millward MJ, Rischin D, Francis P, Gates P, Chapple P, Quinn M, Juneja S, Wolf M, Januszewicz EH, Richardson G, Scarlett J, Briggs P, Brettell M, Toner GC. Ifosfamide in Combination with Paclitaxel or Doxorubicin: Regimens which Effectively Mobilize Peripheral Blood Progenitor Cells while Demonstrating Anti-Tumour Activity in Patients with Metastatic Breast Cancer. Bone Marrow Transplantation (1999) 23: 427-436 [IF:2.643]
• Barber L, PRINCE HM, Rossi R, Bertoncello I. Fluoro-Gold: An Alternative and Versatile Viability Stain for Multi-Colour Flow Cytometric Analysis. Cytometry (1999) 36: 394-354 [IF:1.933]
• Wirth A, Wolf M, PRINCE HM. Current Trends in the Management of Early Stage Hodgkin’s Disease. Aust NZ J Med (1999) 29: 535-544 [IF: 0.620]
• PRINCE HM, Millward MJ, Rischin D, Blakey D, Francis P, Gates P, Chapple P, Quinn M, Juneja S, Wolf M, Januszewicz EH, Seymour JF, Brettell M, Strickland A, Zalcberg J, Richardson G, Scarlett J, Briggs P, Toner GC. Repetitive High-Dose Therapy with Ifosfamide, Thiotepa and Paclitaxel with Peripheral Blood Progenitor Cell and Filgrastim Support for Metastatic and Locally Advanced Breast Cancer: Results of a Phase I Study. Annals of Oncology (1999) 10: 479-481[IF:3.114]
• Juneja S, Carney D, Ellis D, Januszewicz EH, Wolf M, PRINCE HM. Hodgkin’s Disease Type Richter’s Syndrome in Chronic Lymphocytic Leukemia. Leukemia (1999) 13: 826-827 [IF:4.693]
• Wilke R, Brettell M, PRINCE HM, Wolf M, McKenna R, Serpell E, Molloy M, Stevens H, Quinn M, Gates P, Chapple P. Comparison of Cobe Spectra Software Version 4.7 PBSC and Version 6.0 Auto PBSC Programs. J Clin Apheresis (1999) 14: 26-30 [IF:1.220]
• Seymour JF, Juneja SK, Campbell LJ, Ellims PH, Estey EH, PRINCE HM. Secondary Acute Myeloid Leukemia with inv(16): Report of Two Cases Following Paclitaxel and Review of the Role of Intensified AraC Therapy. Leukemia (1999) 13: 1735-1740 [IF:4.693]
• Westerman DA, PRINCE HM, Speed BR. Fatal Disseminated Infection by Scedosporium Prolificans During Induction Therapy for Acute Leukaemia: A Case Report and Literature Review. Pathology (1999) 31: 393-394 [IF:0.880]
• Srickland AH, Seymour C, PRINCE HM, Wolf M, Juneja S, Januszewicz EH. Fludarabine and High Dose Cytarabine (FLA): A Well Tolerated Salvage Regimen in Acute Myeloid Leukemia. Aust NZ J Med (1999) 29: 556-558 [IF: 0.620]
• Chua SL, Seymour JF, PRINCE HM. Deafness From Eighth Cranial Nerve Involvement in a Patient with Large-Cell Tansformation of Mycosis Fungoides. Eur J Haematol (1999) 63: 340-343 [IF: 1.807]

• PRINCE HM, Dessureault S, Gallinger S, Graham FL, Sutherland DR, Stewart AK. Efficient Adenoviral-Mediated Gene Expression in Malignant Human Plasma Cells: Relative Lymphoid Resistance Experimental Hematology (1998) 26: 27-36 [IF:3.366]
• Martinow AJ, Yuen K, Cooper IA, Mathews JP, Juneja S, Wolf M, Januszewicz H, PRINCE HM. Prognostic Markers of Disease Activity in Hodgkin’s Disease. Leukemia and Lymphoma (1998) 29: 383-389 [IF:1.939]
• Al-Homaidhi A, PRINCE HM, Al-Zahrani H, Doucette D, Keating A. Granulocyte-Macrophage Colony Stimulating Factor-Associated Histiocytosis and Capillary-Leak Syndrome Following Autologous Bone Marrow Transplatation: Two Case Reports and a Review of the Literature. Bone Marrow Transplantation (1998) 21: 209-214 [IF:2.643]
• Chapple P, PRINCE HM, Quinn M, Bertoncello I, Juneja S, Wolf M, Januszewicz H, Bretell M, Gardyn J, Seymour C, Venter D. Peripheral Blood CD34-Positive Cell Count Reliably Predicts Autograft Yield. Bone Marrow Transplantation (1998) 22: 125-130 [IF:2.643]
• Imrie K, Dube I, PRINCE HM, Girourd C, Crump M, Keating A. New Clonal Karyotypic Abnormalities Acquired Following Autologous Bone Marrow Transplantation for Acute Myeloid Leukemia do not Appear to Confer an Adverse Prognosis. Bone Marrow Transplantation (1998) 21: 395-400 [IF:2.643]
• PRINCE HM. Guest Commentary; High Dose Chemotherapy with Hematopoietic Rescue as Primary Treatment for Metastatic Breast Cancer: A Randomized Study. (1998) Amgenda 8; 11-14 [non-peer reviewed]
• PRINCE HM. Gene Transfer: A Review of Methods and Applications. Pathology (1998) 30: 335-347 [IF:0.88]
• Wirth A, PRINCE HM, Wolf M. Treatment of Intermediate-Grade and High-Grade Non-Hodgkin’s Lymphoma (letter) New England Journal of Medicine (1998) 339:1475-1477 [IF:31.736]

• PRINCE HM, Keating A. Theoretical Basis of Autografting. In. Autologous Stem Cell Transplantation: Biological and Clinical Results in Malignancies. pp 47-63Ed. AM Carella. Churchill Livingstone (1997)
• Girouard C, Dufresne J, Imrie K, Stewart AK, Brandwein J, PRINCE HM, Pantolony D, Keating A, Crump M. Salvage Chemotherapy with Mini-BEAM for Relapsed or Refractory Non-Hodgkin’s Lymphoma Prior to Autologous Bone Marrow Transplant. Annals Oncol (1997) 8: 675-680 [IF:3.114]
• Al-Fiar F, PRINCE HM, Imrie K, Keating A. Bone Marrow Mononuclear Cell Count does not Predict Neutrophil and Platelet Recovery Following Autologous Bone Marrow Transplantation; Value of Colony Forming Unit-Granulocyte Macrophage (CFU-GM) Assay. Cell Transplantation (1997) 5: 491-495
• HM PRINCE, A Wirth, M Wolf. Hodgkin’s Disease Failures: Incorporating Radiotherapy and High-Dose Treatment J Clin Oncol (1997) 15: 3021-3033 [IF:9.868]

.

• Crump M, Goss PE, PRINCE HM, Girouard C. Outcome of Extensive Evaluation Prior to Adjuvant Therapy in Women with Breast Cancer and 10 Positive Axillary Lymph Nodes. Journal Clinical Oncology (1996) 14: 66-69 [IF:9.868]
• Hsu J, PRINCE HM, Imrie K. Prolonged Ciprofloxacin Administration does not Accelerate Neutrophil Recovery Following Autologous Bone Marrow Transplantation. Pharmacotherapy (1996) 16: 652-655 [IF:1.924]
• Imrie K, Stewart AK, Crump RM, PRINCE HM, Trip K. Blood Stem Cell Collections: Factors Influencing the Recovery of Granulocyte-Macrophage Colony Forming Cells. Cell Transplantation (1996) 5: 379-383 [IF:2.420]
• PRINCE HM, Imrie K, Sutherland DR, Girouard C, Keating A,Crump M, Trip K, Stewart AK. Peripheral Blood Progenitor Cell Collection in Multiple Myeloma: Predictors and Management of Inadequate Collections. British Journal of Haematology (1996) 93: 142-145 [IF:4.080]
• PRINCE HM, Imrie K, Colwill R, Crump M, Stewart AK, Sutton DMC, Scott JG, Pantolony D, Carstairs K, Sutcliffe S, Keating A. The Role of Intensive Therapy and ABMT for Chemotherapy-Sensitive Relapsed and Primary Refractory NHL: Identification of Major Prognostic Groups. Br J Haematol (1996) 92: 880-889 [IF:3.052]
• Stewart AK, PRINCE HM, Cappe D, Nanji S, Rudie C, Wild A, Chu P, Sutherland DR, Dube¢ In Vitro Maintenance and Transduction of Human Myeloma Cells in Long-Term Marrow Cultures Cancer Gene Therapy (1997) 4:148-156 [IF:2.929]
• PRINCE HM, Crump RM, Imrie K, Stewart AK, Sutcliffe S, Tsang R, Pantolony D, Carstairs K, Keating A. Intensive Therapy and Autotransplant for Patients with an Incomplete Response to Front-Line Therapy for Lymphoma. Annals of Oncology (1996) 7: 1043-1049 [IF:3.114]

• PRINCE HM, Szer J, Van Der Weyden MB, Pederson JS, Holdsworth RF, Whyte G. Transfusion Associated Graft-versus-Host Disease After Cardiac Surgery: Response to Antithymocyte-Globulin and Corticosteriod Therapy. Aust NZ J Med (1991) 21:43-46 [IF: 0.620]
• PRINCE HM, Van Der Weyden MB, Bashford J. CD11c, CD5 Positive CLL/PLL with TRAP Positivity. Blood (1992) 80:1095-1096 [IF: 9.631]
• Szer J, Holdsworth RF, PRINCE HM. Fatal Transfusion Associated Graft-vs-Host Disease. Aust N Z J Med. (1993) 23:308-309 [IF: 0.620]
• PRINCE HM, Keating A, Cheng M, Cameron R. Severe Hepatotoxicity Following Granulocyte-Macrophage Colony-Stimulating Factor After Autologous Bone Marrow Transplantation. Bone Marrow Transplantation (1995) 16: 195-197 [IF:2.643]
• PRINCE HM, Page SR, Keating A, Saragosa RF, Vukovic NM, Imrie KR, Crump M, Stewart AK. Microbial Contamination of Harvested Bone Marrow and Peripheral Blood. Bone Marrow Transplantation (1995)15: 87-91 [IF:2.643]
• Imrie KR, PRINCE HM, Couture F, Brandwein J, Keating A. Effect of Antimicrobial Prophylaxis Following Autologous Bone Marrow Transplantation: Ciprofloxacin Versus Co-Trimoxazole. Bone Marrow Transplantation (1995) 15: 267-270 [IF:2.643]
• PRINCE HM, Imrie K, Keating A. Autologous Bone Marrow Transplantation with Etoposide and Melphalan for Poor Prognosis Non Hodgkin’s Lymphoma: The Importance of Disease Status at Transplant. In: Autologous Marrow and Blood Transplantation. Proceedings of the Seventh International Symposium. Eds. KA Dicke and A Keating. The Cancer Treatment Research and Educational Institute. (1995) pp 339-356
• PRINCE HM, Thurlow PJ, Buchanan RC, Ibrahim KMA, Neeson PJ Acquired Protein S Deficiency Causing Central Retinal Vein Thrombosis in a Patient with Systemic Lupus Erythematosus J Clin Pathol (1995)48: 387-389 [IF:2.549]
• Stewart AK, PRINCE HM, Dube ID. Background and Update to a Phase I Trial of Stem Cell Gene Marking in Multiple Myeloma. Transfusion Science (1995) 17:175-184

• P Varma, J Falconer, A Aga, HM Prince, S Pianko. Rituximab-Induced Crohn’s Disease. Scand J Gastroenterol 2017; 52: 606-608 [IF:2.199]
• D Talaulikar, CS Tam, D Joshua, J Ho, J Szer, H Quach, A Spencer, S Harrison, P Mollee, AW Roberts, N Horvath, C Lee, A Zannettino, R Brown, B Augustson, W Jaksic, J Gibson, A Kalff, A Johnston, J Trotman, A Kalro, G Grigoriadis, C Ward, HM Prince. Treatment of Patients with Waldenström Macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Int Med J 2017; 47: 35-49 [IF:1.526]
• Chan, KL; Van Der Weyden, C; Koo, C; Lade, S; Blombery, P; Westerman, D; Khot, A; Melo, B; Johnstone, R; Prince, HM; Dickinson, M. Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement. Leuk Lymphoma 2017; 58: 996-998 [IF:2.755]
• Chan KL, Lokan J, Tam CS, Lew TE, Prince HM. Central nervous system immune reconstitution inflammatory syndrome after ibrutinib therapy for Richter transformation. Leuk Lymphoma 2017; 58:207-210 [IF:2.755]
• CY Slaney, B von Scheidt, AJ Davenport, PA Beavis, JA Westwood, S Mardiana, DC Tscharke, HM Prince, JA Trapani, RW Johnstone, MJ Smyth, MW Teng, SA Rosenberg, NP Restifo, P Neeson, PK Darcy, MH Kershaw. Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting. Clin Canc Res (In Press) [IF:8.738]
• D Oberoi, V White, J Seymour, HM Prince, S Harrison, M Jefford, I Winship, D Hill, D Bolton, A Kay, J Millar, N Wong Doo, G Giles.  The course of anxiety, depression and unmet needs in survivors of Diffuse Large B Cell Lymphoma and Multiple Myeloma in the early survivorship period. J Canc Survivorship 2017 (In Press) [IF:3.478]
• Shustov A, Coiffier B, Horwitz S, Sokol L, Pro B, Wolfson J,Balser B,Frye Eisch R,Popplewell L,Prince HM,Allen SL, Piekarz R,Bates S. Romidepsin Is Effective and Well Tolerated in Older Patients With Peripheral T-Cell Lymphoma: Analysis of 2 Phase II Trials Leuk Lymphoma 2016; 58: 2335-2341 [IF:2.755]
• White V, Marco DJT, Bolton D, Davis ID, Jefford M^, Hill D, Prince HM, Millar J, Winship M, Coory M, Giles GG. Trends in the surgical management of Stage 1 Renal Cell Carcinoma: findings from a population-based study Brit J Urol Int 2017 (Epub ahead of Print) [IF:4.387]
• Newland K, Prince HM. Denileukin Diftitox for the treatment of cutaneous T cell lymphoma. Expert Opinion on Orphan Drugs. 2016 (In Press) [IF: 3.525]
• Van der Weyden C, Bates S, Dickinson M, Prince HM. Romidepsin for treating cutaneous T-cell lymphoma. Expert Opinion on Orphan Drugs. 2016 (In Press) [IF: 3.525]
• F Foss, B Pro, HM Prince, L Sokol,M Greenwood,D Caballero, S Horwitz, B Coiffier. Responses to Romidepsin by Line of Therapy in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. (PTCL) Cancer Med 2016 (In Press) [IF:3.420]
• H Quach, L Fernyhough, R Henderson, G Corbett, B Baker, P Browett, H Blacklock, C Forsyth, C Underhill, P Cannell, J Trotman, A Neylon, S Harrison, E Link, A Swern, L Cowan, MA Dimopoulos, HM Prince.^.Lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: Final analysis of the phase II RevLite study. B J Hematol 2016 (In Press) [IF:5.812]
• HM Prince, YH Kim, SM Horwitz, R Dummer, J Scarisbrick, P Quaglino, PL Zinzani, P Wolter, JA Sanches, PL Ortiz-Romero, OE Akilov, L Geskin, J Trotman, K Taylor, S Dalle, M Weichenthal, J Walewski, D Fisher, B Dréno, R Stadler, T Feldman, TM Kuzel, Y Wang, MC Palanca-Wessels, E Zagadailov, WL Trepicchio,W Zhang, H-M Lin,Y Liu, D Huebner,M Little, S Whittaker, M Duvic on behalf of the ALCANZA study group^. Brentuximab vedotin or Physician’s Choice in CD30-positive Cutaneous T-Cell Lymphoma. Lancet (On line http://dx.doi.org/10.1016/S0140-6736(17)31266-7 [IF:45.217]
• Seymour JF, Blombery P, Prince HM. Primary Breast Lymphoma – population level insights into an infrequent, but increasingly recognized, subtype of lymphoma. (Editorial) J Nat Canc Inst 2017 (In Press) [IF:11.370]
• TA Rasmussen, J McMahon, JJ Chang, F Wightman, J Symons, M Roche, A Solomon, A Dantanarayana, A Okoye, B Hirner, S Palmer, WS Lee, S Kent, C Van Der Weyden, HM Prince, PU Cameron, SR Lewin. Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary’s syndrome AIDS 2017 (In Press) [IF:4.407]
• A Loch-Wilkinson, KJ Beath, RJW Knight, WLF Wessels, M Magnusson, T Papadopoulos, T Connell, J Lofts, M Locke, I Hopper, R Cooter, K Vickery, PA Joshi, HM Prince, AK Deva. Breast implant associated Anaplastic Large Cell Lymphoma in Australia and New Zealand – higher surface area textured implants are associated with increased risk Plas Rec Surg 2017 (In Press) [IF:3.087]
• Mota TM, Rasmussen TA, Rhodes A, Tennakoon S, Dantanarayana A, Wightman F, Hagenauer M, Roney J, Spelman T, Purcell DF, McMahon J, Hoy JF, Prince HM, Elliott JH, Lewin SR. No adverse safety or virological changes two years following vorinostat in HIV-infected individuals on antiretroviral therapy. AIDS 2017 (In Press) [IF:4.407]
• OL Lee, N Horvath, C Lee, D Joshua, J Ho, J Szer, H Quach, A Spencer, S Harrison, P Mollee, AW Roberts, D Talaulikar, R Brown, B Augustson, S Ling, W Jaksic, J Gibson, A Kalff, A Johnston, A Kalro, C Ward, HM Prince, Andrew Zannettino. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Int Med J 2017 (In Press) [IF:1.526]

• N Wong Doo, E Makalic, E Joo, CM Vajdic, DF Schmidt, M Wong, C-H Jung, G Severi, DJ Park, J Chung, L Baglietto, HM Prince, JF Seymour, C Tam, JL Hopper, DR English, RL Milne, SJ Harrison, MC Southey, GG Giles. Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B cell neoplasms. Epigenomics 2016; 8: 55-66 [IF: IF:4.649]
• F Foss, S Horwitz, B Pro, HM Prince, L Sokol, B Balser, J Wolfson, B Coiffier. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol 2016: 9 (1) 22. doi: 10.1186/s13045-016-0243-8. [IF: IF:4.81]
• DV Oberoi; V White; M Jefford; D Bolton; I Davis; D Hill; I Winship; M Prince; J Millar; S Harrison; A Kay; G Giles. Caregivers’ information needs and their ‘experiences of care’ during treatment are associated with elevated anxiety and depression: A cross sectional study of the caregivers of renal cancer survivors. Support Care Canc 2016; 24: 4177-86 [IF:2.364]
• Van der Weyden C, Prince HM. High-dose thiotepa-based conditioning regimens for relapsed lymphoma involving the central nervous system: from ‘orphan drug’ to a standard-of-care? Leuk Lymphoma 2016; 57: 1-3 [IF:2.397]
• Whittaker S, Hoppe R, Prince HM. How I treat Mycosis Fungoides and Sezary Syndrome. Blood 2016; 127: 3142-3153 [IF: IF:10.452]
• CF Hughes, K Newland, C McCormack, HM Prince. Mycosis Fungoides and Sézary Syndrome: Current challenges in assessment, management and prognostic markers. Australas J Dermatol 2016; 57: 182-191 [IF:0.982]
• KL Chan, S Lade, HM Prince, SJ Harrison. Update and new approaches in the treatment of Castleman disease. J Blood Med 2016; 7:145-15
• Prince HM, Johnstone RJ. Commentary on: Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Aesth Surg J 2016; 36: 782-783 [IF: IF:1.841]
• H Hu, K Aljohani, A Almatroudi, K Vickery, B Van Natta, ME Kadin, G Brody, M Clemens, CY Cheah, S Lade, P Joshi, HM Prince, A Deva. Bacterial biofilm infection detected in breast implant associated anaplastic large cell lymphoma. Plastic and Reconstructive Surgery 2016; 137: 1659-1669 [IF: IF:2.993]
• TE Lew, C Cheah, DA Carney, HM Prince, M Wolf, A Bazargan, EH Januszewicz, R Filshie, D Westerman, JF Seymour, CS Tam. Dose reduced fludarabine, cyclophosphamide and rituximab (FCR) is well tolerated in older patients with chronic lymphocytic leukaemia (CLL) and has preserved therapeutic efficacy. Leuk Lymphoma 2016; 57: 1044-1053 [IF:2.397]
• Cooke RE, Gherardin NA, Harrison SJ, Quach H, Godfrey DI, Prince HM, Neeson P, Koldej R, Ritchie DS. Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human myeloma J Transl Med 14:259: DOI 10.1186/s12967-016-0994-6 [IF:3.694]
• Newland K, Prince HM. Denileukin Diftitox for the treatment of cutaneous T cell lymphoma. Expert Opinion on Orphan Drugs. 2016 (In Press) [IF: 3.525]
• Van der Weyden C, Bates S, Dickinson M, Prince HM. Romidepsin for treating cutaneous T-cell lymphoma. Expert Opinion on Orphan Drugs. 2016 (In Press) [IF: 3.525]
• Chan KL, Lokan J, Tam CS, Lew TE, Prince HM. Central nervous system immune reconstitution inflammatory syndrome after ibrutinib therapy for Richter transformation. Leuk Lymphoma 2016 (Epub ahead of Print) [IF:2.397]
• CSM Yong, LB John, C Devaud, HM Prince, RW Johnstone, JA Trapani, PK Darcy, M Kershaw. A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer. Oncotarget 2016 (In Press) [IF: IF:6.359]
• A Newbold, KJ Falkenberg, HM Prince, RW Johnstone. How do tumor cells respond to HDAC inhibition? FEBS J 2016 (In Press) [IF:4.001]
• Blombery P, Thompson E, Jones K, Mir Arnau G, Lade S, Markham JF, Li J, Deva A, Johnstone RW, Khot A, Prince HM, Westerman D. Whole exome sequencing reveals activating JAK1 and STAT3mutations in breast-implant associated anaplastic large cell lymphoma. Haematologica 2016; 101(9): e387-90 [IF:5.814]
• B Pro, SM Horwitz, HM Prince, FM Foss, L Sokol, M Greenwood, D Caballero, F Morschhauser, M Wilhelm, L Pinter-Brown, S Iyer, AR Shustov, J Wolfson, BE Balser, B Coiffier. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematological Oncology 2016 (Epub ahead of Print) [IF:3.084]
• Chan, KL; Van Der Weyden, C; Koo, C; Lade, S; Blombery, P; Westerman, D; Khot, A; Melo, B; Johnstone, R; Prince, HM; Dickinson, M. Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement. Leuk Lymphoma 2016 (Epub ahead of Print) [IF:2.397]
• F Foss, B Pro, HM Prince, L Sokol,M Greenwood,D Caballero, S Horwitz, B Coiffier. Responses to Romidepsin by Line of Therapy in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. (PTCL) Cancer Med 2016 (In Press) [IF:3.420]
• CS Tam, D Talaulikar, D Joshua, J Ho, J Szer, H Quach, A Spencer, S Harrison, P Mollee, AW Roberts, N Horvath, C Lee, A Zannettino, R Brown, B Augustson, W Jaksic, J Gibson, A Kalff, A Johnston, J Trotman, A Kalro, G Grigoriadis, C Ward, HM Prince. Treatment of Patients with Waldenström Macroglobulinaemia: Position Statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Int Med J 2016 (In Press) [IF:1.526]

• CF Hughes, A Khot, C McCormack, S Lade, DA Westerman, R Twigger, O Buelens, K Newland, C Tam, M Dickinson, G Ryan, D Ritchie, C Wood, HM Prince. The lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 2015; 125:71-81 [IF:9.775]
• H Quach, D Joshua, J Ho, J Szer, A Spencer, SJ Harrison, P Mollee, AW Roberts, N Horvath, D Talulikar, B To, A Zannettino, R Brown, L Catley, B Augustson, W Jaksic, J Gibson, HM Prince. Treatment of Patients with Multiple Myeloma who are Eligible for Stem Cell Transplantation: Position statement of the Myeloma Foundation Australia Medical and Scientific Advisory Group. Int Med J 2015; 45; 94-105 [IF:1.699]
• Newland K, Prince HM. Denileukin Diftitox for the treatment of cutaneous T cell lymphoma. Expert Opinion on Orphan Drugs. 2014 (In Press) [IF: 3.525]
• Trubiano JA, George A, Teh BW, Barnett J, Siwan M, Prince HM, Slavin MA.A Different Kind of ‘allogeneic transplant’: Successful Faecal Microbiota Transplantation for Recurrent and Refractory Clostridium difficile Infection in a Patient with Recurrent Aggressive B-cell Lymphoma. Leuk Lymphoma 2014 (In Press) [IF:2.397]
• Newland, CJ McCormack, HM Prince, S Lade. Cutaneous CD30 positive lymphoproliferative disorders with coexistent epithelial neoplasms: Report of two cases. Aust J Dermatol 2014 (In Press) [IF:0.965]
• Cheah CY, Hofman MS, Seymour JF, Ritchie DS, Dickinson M, Wirth A, Prince HM, Wolf M, Januszcewicz EH, Carney DA, Herbert KE, Harrison SJ, Burbury K, Tam CS. The utility and limitations of PET-CT in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. Leuk Lymphoma 2014 (In Press) [IF:2.397]
• N Weber, P Mollee, B Augustson, R Brown, L Catley, J Gibson, S Harrison, J Ho, N Horvath, W Jaksic, D Joshua, H Quach, A Roberts, A Spencer, J Szer, D Talaulikar, B To, A Zannettino, HM Prince. Management of Systemic Light Chain (AL) Amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Int Med Journal 2014 (In Press) [IF:1.699]
• H Quach, D Joshua, J Ho, J Szer, A Spencer, SJ Harrison, P Mollee, AW Roberts, N Horvath, D Talulikar, B To, A Zannettino, R Brown, L Catley, B Augustson, W Jaksic, J Gibson, HM Prince. Treatment of Patients with Multiple Myeloma who are Not Eligible for Stem Cell Transplantation: Position statement of the Myeloma Foundation Australian Medical and Scientific Advisory Group (MSAG). Int Med J. 2014 (In Press) [IF:1.699]
• Horwitz, B. Coiffier, F. Foss, HM. Prince, L Sokol, M Greenwood, D Caballero, F Morschhauser, L Pinter-Brown, SP Iyer, A Shustov, J Nichols, J. Balser, B Balser, B Pro. Utility of ¹⁸Fluoro-Deoxyglucose Positron Emission Tomography for Prognosis and Response Assessments in a Phase 2 Study of Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. Ann Oncol(In Press) [IF:6.578]
• J. Harrison, H. Quach, E. Link, H. Feng, J. Dean, M. Copeman, H. Van De Velde, A. Schwarer, B. Baker, A. Spencer, J. Catalano, P. Campbell, B. Augustson, K. Romeril, HM Prince. Bortezomib and dexamethasone from cycle 1 improves response and time to progression for patients with relapsed Myeloma. Am J Hematol (In Press) [IF:3.477]
• Bates S et al. Romidepsin in Peripheral and Cutaneous T-Cell Lymphoma: Mechanistic Implications from Clinical and Correlative Data Brit J Haematol (In Press) [IF:xxxxx]

• N Wong Doo, T Joyce, PA Thompson, HM Prince, JF Seymour, D Ritchie, K Stokes, K Burbury, M Wolf, S Peinert, SJ Harrison. Bortezomib with high dose melphalan conditioning for autologous transplantation is safe and effective in patients with heavily pre-treated and high risk multiple myeloma. Leuk Lymphoma 2013: 54;: 1465-72 [IF:2.397]
• M Duvic, R Dummer, JC Becker, N Poulalhon, PO Romero, MG Bernengo, C Lebbé, C Assaf, M Squier, D Williams, M Marshood, F Tai, HM Prince. Panobinostat Activity in Both Bexarotene-Exposed and -Naïve Patients With Refractory Cutaneous T-Cell Lymphoma: Results of a Phase II Trial. Eur J Cancer 2013; 48: 386-394 [IF: IF:5.536]
• A Khot, M Dickinson, K Stokes, S Harrison, K Burbury, S Fleming, D Wall, P Gambell, HM Prince, JF Seymour, D Ritchie. Risk Adapted Protocol For Delayed Administration Of rhG-CSF Following High Dose Chemotherapy And Autologous Stem Cell Transplantation. Clin Lymph Myel Leuk 2013; 13: 42-47 [IF: IF:1.601]
• HM Prince, AG Martin, EA Olsen, DP Fivenson, M Duvic. Denileukin Diftitox for the Treatment of CD25 Low Expression Mycosis Fungoides and Sezary Syndrome. Leuk Lymphoma 2013; 54: 69-75 [IF:2.397]
• M Dickinson, C Cheah, HM Prince. Current Epigenetic Therapy for T Cell Lymphoma.   T-Cell Lymphomas    Chapter 16: pp 279 in Francine  Foss ed.   Humana Press 2013
• M Duvic, AG Martin, EA Olsen, DP Fivenson, HM Prince. The efficacy and safety of denileukin diftitox retreatment in patients with mycosis fungoides/Sezary syndrome. Leuk Lymphoma 2013;54; 514-519 [IF:2.397]
• H Quach, HM Prince. How To Treat – Multiple Myeloma. Australian Doctor 2012; May 11: 31-38
• Herbert KE, Gambell P, Link EK, Mouminoglou A, Stokes K, Wall DM, Harrison SJ, Ritchie DS, Seymour JF, Prince HM. Pegfilgrastim compared to filgrastim for cytokine-alone mobilization of autologous hematopoietic stem and progenitor cells. Bone Marr Transplant 2013; 48; 351-356 [IF:3.660]
• S Li, S Roberts, M Plebanski, P Latour, DC Jackson, L Brown, R Sparrow, HM Prince, D Hart, B Loveland, E Gowans. Induction of multi-functional T cells in a Phase I Clinical Trial of Dendritic Cell Immunotherapy in Hepatitis C Virus Infected Individuals. PloS ONE 2012; 7: e39368 [IF:4.351]
• M Duvic, L Geskin, HM Prince. Duration of Response in Cutaneous T-cell Lymphoma Patients Treated With Denileukin Diftitox: Results From Three Phase III Studies. Clin Lymph Myel Leuk 2013; 13: 377-384 [IF:1.537]
• Khot S, Dickinson M, Prince HM. Drug Evaluation: Panobinostat in lymphoid and myeloid malignancies. Expert Opinion on Investigational Drugs . 2013;;22:1211-23 [IF:4.744]
• CY Cheah, MS Hofman, M Dickinson, A Wirth, D Westerman, SJ Harrison, K Burbury, M Wolf, H Januszewicz, K Herbert, HM Prince, DA Carney, DS Ritchie, RJ Hicks, JF Seymour. Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Brit J Canc 2013; 109; 312-7 [IF:5.042]
• BW Teh, A Khot, SJ Harrison, HM Prince, MA Slavin. A messenger at the door: CMV retinitis in myeloma patients with relapsed disease. Transpl Inf Dis 2013: 15; E134-8 [IF:2.216]
• MJ Bishton, SJ Harrison, HM Prince, RW Johnstone. Histone Deacetylase Inhibitors reduce Glycoprotein VI expression and Platelet Responses to Collagen Related Peptide. Thrombosis Res 2013: 131:514-20 [IF:3.133]
• DJ DeAngelo, A Spencer, KN Bhalla, HM Prince, T Fischer, T Kindler, FJ Giles, JW Scott, K Parker, A Liu, M Woo, P Atadja, KK Mishra, OK Ottmann. Phase 1a/2, two-arm, multi-center, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematological malignancies Leukemia 2013: 27: 1628-36 [IF:6.612]
• S Sharma, J Beck, M Mita, S Paul, MM Woo, M Squier, B Gadbaw, HM Prince. A Phase I/IIa two-arm open-label dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. Investigational New Drugs 2013; 31: 974-85 [IF:3.498]
• Thompson P, Prince HM. Breast Implant-Associated Anaplastic Large Cell Lymphoma. A systematic review of the literature and mini-meta analysis. Current Hematologic Malignancy Reports. 2013: 8: 196-210. [IF:1.852]
• A Khot, M Dickinson, HM Prince. Romidepsin in Peripheral T-Cell Lymphoma. Expert Rev in Hematol 2013; 351-359 [IF:1.161]
• DS Ritchie, PJ Neeson, A Khot, S Peinert, T Tai, K Tainton, K Chen, M Shin, DM Wall, D Hönemann, P Gambell, DA Westerman, J Haurat, JA Westwood, AM Scott, L Kravets, M Dickinson, JA Trapani, MJ Smyth, PK Darcy, MH Kershaw, HM Prince. Persistence and efficacy of second generation CAR-T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 2013; 21: 2122-2129 [IF:6.873]
• HM Prince, A Khot, M Dickinson. Romidepsin for cutaneous T-cell lymphoma. Future Oncology 2013:9; 1819-1827 [IF: IF:3.202]

• SA Gangatharan, DA Carney, HM Prince, MM Wolf, EH Januszewicz, DS Ritchie, SJ Harrison. The emergence of CNS myeloma in the era of novel agents. Haematol Oncol 2012; 30: 170-4 [IF:2.258]
• S Shen, T O’Brien, LM Yap, HM Prince, C McCormack. The Use of Methotrexate in Dermatology: A Review. Aust J Dermatol 2012; 53; 1-18
• B Coiffier, B Pro, HM Prince, F Foss, L Sokol, M Greenwood, D Caballero, P Borchmann, F Morschhauser, M Wilhelm, L Pinter-Brown, S Padmanabhan, A Shustov, J Nichols, S Carroll, J Balser, S Horwitz. Results From a Pivotal, Open-Label, Phase 2 Study of Romidepsin in Progressive or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy. J Clin Oncol 2011; 30: 631-636 [IF: IF:18.970]
• HM Prince. Fludarabine and a histone deacetylase inhibitor – strange bedfellows (Editorial). Leuk Res 2012; 36: 385-386 [IF:2.555]
• Quach H, Prince HM on behalf of the Medical Scientific Advisory Board to the Myeloma Foundation of Australia. Clinical Practice Guidelines: Myeloma 2012 http://www.clinicalguidelines.gov.au/search.php?pageType=2&fldglrID=1917&

http://www.myeloma.org.au/LinkClick.aspx?fileticket=5TdcjoGc278%3d&tabid=150&mid=575

• KO Taylor, HR Webster, HM Prince. Anaplastic Large Cell Lymphoma and Breast Implants: Five Australian Cases. Plastic Reconstr Surg 2012; 129: 610e-617e [IF:2.647]
• A Younes, A Sureda, D Ben-Yehuda, M Baccarani, TC Ong, HM Prince, S Harrison, M Kirschbaum, P Johnston, J Gallagher, C Le Corre, A Shen, A Engert. Panobinostat in Relapsed/Refractory Hodgkin Lymphoma Patients Following Autologous Stem Cell Transplant: Results of a Phase II Study. J Clin Oncol 2012; 30:2197-2203 [IF: IF:18.970]
• Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; *MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012 May 10;366(19):1759-69. [IF: 53.1 ]
• P Gambell, K Herbert, M Dickinson, K Stokes, M Bressel, D Wall, S Harrison, HM Prince (MD).Peripheral Blood CD34+ cell enumeration as a predictor of apheresis yield – an analysis of over 1000 collections. Biol Blood Marrow Transpl 2012; 18: 763-772 [IF:3.275]
• P Mollee, C Tiley, I Cunningham, J Moore, HM Prince, P Cannell, S Gibbons, J Tate, S Paul, H Mar Fan, DS Gill. A Phase II Study of Risk-Adapted Intravenous Melphalan in Patients with AL Amyloidosis. Brit J Haematol; 2012; 157; 766-769[IF:4.942]
• HM Prince. Explainer: What is thalidomide? The Conversation. 2012 http://theconversation.edu.au/explainer-what-is-thalidomide-8327
• M Dickinson, HM Prince. Romidepsin for relapsed and refractory cutaneous T-cell lymphoma. Clinical Medicine Insights: Dermatology 2012: 5, 21-28
• HM Prince, M Dickinson. Romidepsin in cutaneous T cell lymphoma. Clin Canc Res 2012; 18, 3509-15[IF:7.742]
• HM Prince. Pioneering studies of histone deacetylase inhibitors in myeloma; signals of activity set the stage for combination therapy trials.(Editorial) Leukemia Lymphoma 2012, 53; 1658-9[IF:2.397]
• HM Prince, M Duvic, AG Martin, W Sterry, C Assaf, D Straus. Incidence of Spontaneous Remissions in Patients with CD25 Assay-Positive Mycosis Fungoides/Sezary Syndrome Receiving `Placebo. J Amer Acad Dermatol 2012, 67; 867-875 [IF:4.081]
• SJ Harrison, M Bishton, SE Bates, S Grant, RL Piekarz, RW Johnstone, YDai, B Lee, ME Araujo, HM Prince. A focus on the pre-clinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax®). Epigenomics 2012; 4: 571-589 [IF: IF:3.429]
• P Blombery, SQ Wong, HM Prince. Erdheim-Chester disease harbouring the BRAF V600E mutation. J Clin Oncol 2012; 30: e331-2 [IF: IF:18.970]

• KL Burbury, MJ Bishton, RW Johnstone, MJ Dickinson, J Szer, HM Prince. MLL-aberrant leukemia: Complete cytogenetic remission following treatment with a Histone Deacetylase inhibitor. Ann Hematol 2011; 90: 847-9 [IF: 2.919]
• PA Thompson, S Peinert, K Burbury, K Stokes, T Joyce, M Wolf, D Ritchie, HM Prince, JF Seymour, SJ Harrison. Bortezomib added to high dose melphalan conditioning in patients with heavily pretreated multiple myeloma. Bone Marrow Transpl 2011; 46: 764-765 [IF: 2.643]
• Lechner MG, Lade S, Liebertz Dj, Prince HM, Brody GS, Webster HR, Epstein AL. Breast implant-associated Alk-negative T cell anaplastic large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity. Cancer 2011; 117 (7): 1478-89 [IF: 5.418]
• Hsu A, Quach H, Tai T, Prince HM, Trapani JA, Smyth MJ, Neeson P, Ritchie DS. The immuno-stimulatory effect of lenalidomide on NK cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011, 117; 1605-1613 [IF:10.896]
• HJ Pegram, DS Ritchie, MJ Smyth, A Wiernik, HM Prince, PK Darcy, MH Kershaw. Alloreactive natural killer cells in hematopoietic stem cell transplantation. Leukemia Research. 2011 Jan;35(1):14-21 [IF: 2.358]
• S Lingaratnam, MA Slavin, B Koczwara, JF Seymour, J Szer, C Underhill, HM Prince, L Mileshkin, M O’Reilly, SW Kirsa, CA Bennett, ID Davis, O Morrissey, KA Thursky. Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Int Med J 2011, 41; 75-81[IF:1.786]
• S Lingaratnam, MA Slavin, L Mileshkin, B Solomon, K Burbury, JF Seymour, R Sharma, B Koczwara, SW Kirsa, ID Davis, HM Prince, J Szer, C Underhill, O Morrissey, KA Thursky. An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. Int Med J 2011, 41; 110-120 [IF:1.786]
• PA Blombery, A Wirth, HM Prince. How To Treat – Lymphoproliferative Disorders – Part 1. Aggressive non-Hodgkin Lymphoma and Hodgkin Lymphoma. Australian Doctor 2011; April 1: 27-31
• S Kamel, JF Seymour, HM Prince. How To Treat – Lymphoproliferative Disorders – Part 2. Chronic Lymphocytic Leukaemia and Follicular Lymphoma. Australian Doctor 2011; April 8: 29-36
• RA Howman, HM Prince. New Therapies in Peripheral T-cell Lymphoma. Expert Reviews of Anti-Cancer Therapies 2011, 11: 457-472) [IF:2.493]
• MJ Bishton, HM Prince, SJ Harrison, BP Martin, N McLaughlin, J Chloe, EC Josefsson, KJ Henley, BT Kile, RW Johnstone. Deciphering the molecular and biological processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 2011, 117: 3658-3668 [IF:10.896]
• EA Olsen, S Whittaker, YH Kim, M Duvic, HM Prince, SR Lessin, GS Wood,R Willemze, M-F Demierre, N Pimpinelli, MG Bernengo, PL Ortiz-Romero, M Bagot, T Estrach, J Guitart, R Knobler, JA Sanches, K Iwatsuki, M Sugaya, R Dummer, M Pittelkow, R Hoppe, S Parker, L Geskin, L Pinter-Brown, M Girardi, G Burg, A Ranki, M Vermeer, L Laroche, S Horwitz, S Rosen, L Cerroni, B Dreno, EC Vonderheid. Clinical Endpoints and Response Criteria in Mycosis Fungoides and Sézary Syndrome: a Consensus Statement of the International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC) and the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer (EORTC). J Clin Oncol 2011; 29: 2598-2607 [IF: IF:18.970]
• RL Piekarz, R Frye, HM Prince, MH Kirschbaum, J Zain, SL Allen, E Jaffe, A Ling, M Turner, C Peer, WD Figg, SM Steinberg, S Smith, D Joske, I Lewis, L Hutchins, Ml Craig, A Tito Fojo, JJ Wright, SE Bates. Phase II Trial of Romidepsin in Patients with Peripheral T-cell Lymphoma Blood 2011; 117: 5827-34 [IF:10.896]
• H Quach, HM Prince, Andrew Spencer. Managing Multiple Myeloma in the Elderly: Are We Making Progress? Expert Reviews in Hematol 2011; 4: 301-15 [IF:2.493]
• P Blombery, HM Prince, M Yang, E Wood, L Worth, J Main, D Westerman. Prophylactic Intravenous immunoglobulin prophylaxis during autologous hemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications. Ann Hematol 2011; 90: 1167-72 [IF: 2.919]
• SJ Harrison, H Quach, E Link, J Dean, S Ruell, JF Seymour, H Januszewicz, DS Ritchie, R Johnstone, P Neeson, M Dickinson, J Nichols, HM Prince. A High Rate Of Durable Responses with Romidepsin, Bortezomib And Dexamethasone In Relapsed or Refractory Multiple Myeloma Blood 2011; 118: 6274-83 [IF:10.896]
• Gangatharan S, Carney D, Campbell L, Prince HM, Kenealy M, Seymour J. Cytogenetic response is not a pre-requisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol. 2011; 87: 186-8 [IF:1.807]
• W Kempf, K Pfaltz, MH Vermeer, A Cozzio, P Ortiz, M Bagot, E Olsen, YH Kim, R Dummer, N Pimpinelli, S Whittaker, E Hodak, L Cerroni, E Berti, S Horwitz, HM Prince, J Guitart, T Estrach, JA Sanches, M Duvic, A Ranki, B Dreno, S Ostheeren-Michaelis, R Knobler, G Wood, R Willemze. European Organization for Research and Treatment of Cancer (EORTC), International Society of Cutaneous Lymphoma (ISCL) and United States Cutaneous Lymphoma Consortium (USCLC) consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118: 4024-35 [IF:10.896]
• Iland H, Bradstock K, Seymour J, Hertzberg M, Grigg A, Taylor K, Catalano J, Cannell P, Horvath N, Deveridge S, Browett P, Brighton T, Chong L, Springall F, Ayling J, Catalano A, Supple S, Collins M, Di Iulio J, Reynolds J; Australasian Leukaemia and Lymphoma Group* (Collaborators). Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. 2012 Feb;97(2):227-34. [IF:6.416]
• Sl Lingaratnam, LJ Worth, MA Slavin, CA Bennett, SW Kirsa, JF Seymour, A Dalton, B Koczwara, HM Prince, M O’Reilly, L Mileshkin, J Szer, KA Thursky. A Cost Analysis of Febrile Neutropenia Management in Australia: Ambulatory versus In-hospital Treatment. Australian Health Review 2011; 35: 491-500 [IF:0.803]
• A Hsu, H Quach, TY Tai, HM Prince, SJ Harrison, JA Trapani, MJ Smyth, PJ Neeson, DS Ritchie.Dexamethasone dose alters expression of NK activating receptors in vivo (Response to Letter). Blood 2011; 118: 6466-6468 [IF:10.896]

• PJ Shaughnessy, BJ Bolwell, K van Besien, M Mistrik, A Grigg, A Dodds, HM Prince, S Durrant, O Ilhan, D Parenti, J Rogers, J Gallo, F Foss, J Apperley, M-J Zhang, MM Horowitz, S Abhyankar. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl 2010: 45: 1068-76 [IF: 2.643]
• K Herbert, HM Prince, Ritchie D, JF Seymour. The role of ancestim (recombinant human stem cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution. Exp Opinion Biol Therap. 2010; 10 (1): pp 113-125
• S Nath, E Maxwell, M Peris, M Bishton, HM Prince. Light chain deposition disease presentinig as massive hepatomegaly. Pathology 2010; 42; 307-10 [IF:2.234]
• S Gill, D Carney, D Ritchie, M Wolf, D Westerman, HM Prince, H Januszewicz, JF Seymour. The frequency, manifestations and duration of prolonged cytopenias after first line fludarabine-combination chemotherapy. Ann Oncol 2010; 21: 331-4 [IF:4.875]
• H Quach, D Ritchie, AK Stewart, P Neesom, S Harrison, MJ Smyth, HM Prince. Mechanism of Action of Immunomodulatory Drugs in Multiple Myeloma. Leukemia 2010; 24: 22-32 [IF:6.612]
• Law A, Ryan G, Prince HM. Development of Kaposi’s Sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV negative patient.Int J Hematol 2010; 24: 347-8 [IF:1.283]
• HM Prince, M. Duvic, A Martin, W Sterry, C Assaf, A Negro-Vilar, Y Sun, D Straus, M Acosta. Phase 3 Placebo-Controlled Trial of Denileukin Diftitox for Patients With Primary Cutaneous T-Cell Lymphoma J Clin Oncol 2010; 28: 1870-1877[IF:18.970]
• A Grigg, A Schwarer, J Stone, M Wolf, HM Prince, J Seymour, D Gill, J Bashford, D Ellis, J Reynolds.^. Phase II study of autologous stem cell transplantation using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis low grade non-Hodgkin’s lymphoma. Leukemia Lymphoma 2010; 51: 641-9 [IF:2.397]
• S Peinert, HM Prince, PM Guru, MH Kershaw, MJ Smyth, JA Trapani, P Gambell, S Harrison, AM Scott, FE Smyth, PK Darcy, K Tainton, P Neeson, DS Ritchie, D Honemann. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Therapy 2010, 17: 347-348 [IF:4.4492]
• Chan AC, Neeson P, Leeansyah E, Tainton K, Quach H, Prince HM, Godfrey DI, Ritchie D, Berzins SP. Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients. Leukemia 2010, 24; 592-600.[IF:6.612]
• M Dickinson, R Hoyt, AW Roberts, A Grigg, JF Seymour, HM Prince, J Szer, David Ritchie. Improved Survival for Relapsed Diffuse Large B cell Lymphoma is Predicted by a Negative Pre-transplant FDG-PET Scan Following Salvage Chemotherapy. Brit J Haematol 2010; 150: 39-45 [IF:4.080]
• MS Liew, AM Chan, S Galloway, G Comin, B Flaim, HM Prince, H Quach. Extra-Nasal NK/T Cell Lymphoma Masquerading As Renal Infarction. Leukemia Lymphoma 2010; 51: 1139-41 [IF:2.397]
• EJ Gowans, S Roberts, K Jones, PA Latour, B Chua, EMY Eriksson, S Li, DM Wall, R Sparrow, HM Prince, D Hart, LE Brown, DC Jackson. A Phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol 2010; 53: 599-607 [IF:7.056]
• Neeson P, Shin A, Tainton K, Guru P, Prince HM, Harrison S, Peinert S, Smyth MJ, Trapani JA, Kershaw MH, Darcy PK, Ritchie DS. Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Therapy 2010; 17: 1105-1116 [IF:4.4492]
• PA Thompson, S Lade, H Webster, G Ryan, HM Prince. Effusion-associated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct clinico-pathological entity. Hematologica 2010;95:1977-9. [IF:6.416]
• S Peinert, CS Tam, HM Prince, J Scarlett, MM Wolf, EH Januszewicz, D Westerman, JF Seymour. Fludarabine Based Combinations Are Highly Effective as First-Line or Salvage Treatment in Patients with Waldenström Macroglobulinemia. Leukemia Lymphoma 2010; 51: 2188-2197[IF:2.397]
• HM Prince. The deacetylase inhibitors – here to stay! Investigational New Drugs. The Journal of New Anticancer Agents 2010;28 Suppl 1:S1-2. [IF:3.396]
• M Dickinson, R Johnstone, HM Prince. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Investigational New Drugs. The Journal of New Anticancer Agents 2010;28 Suppl 1:S3-20.[IF:3.396]
• DA Carney, DA Westerman, CS Tam, A Milner, HM Prince, M Kenealy, M Wolf, EH Januszewicz, D Ritchie, N Came, JF Seymour. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010;24(12):2056-62 [IF:6.612]
• M Bishton, R Johnstone, M Dickinson, S Harrison, HM Prince. Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. Pharmaceuticals 2010; 3: 2674-2688
• Blombery PA, Levinson MR, Pianko S, Prince HM, Bhathal PS. Rituximab-induced immune dysregulatory ileocolitis in a patient with follicular lymphoma. J Clin Oncol 2010; 29:e110-2 [IF: IF:18.970]

• PJ Kim, RJ Hicks, A Wirth, G Ryan, JF Seymour, HM Prince, MP Mac Manus. Impact of ¹⁸F-Fluorodeoxyglucose-Positron Emission Tomography before and after definitive radiation therapy in patients with apparently-solitary plasmacytoma. Int J Rad Oncol Biol Phys 2009, 74: 740-746 [IF:4.290]
• KE Herbert, S Morgan, HM Prince, DA Westerman, MM Wolf, DA Carney, K Yuen, JF Seymour. Stem Cell Factor and high-dose twice-daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with Fludarabine; results of a Phase II study with an historical comparator. Leukemia 2009 23; 305-12 [IF:612]
• JR Mikhael, AR Belch, HM Prince, MN Lucio, A Maiolino, A Corso, MT Petrucci, P Musto, M Komarnicki, AK Stewart. High response rate to bortezomib with or without dexamethasone in patients with relapsed and/or refractory multiple myeloma: results of a Global Phase 3b Velcade Expanded Access Program. Brit J Haematol 2009;144:169-75. [IF:4.490]
• MA Dawson, SS Opat, Y Taouk, M Donovan, M Zammit, K Monaghan, N Horvath, AW Roberts, HM Prince, M Hertzberg, CA McLean, A Spencer. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma. Clin Canc Res 2009 15:714-22 [IF:177]
• S Peinert, S Kamel, JF Seymour, HM Prince. Intralesional rituximab for localized palatal relapse of follicular lymphoma. Leukemia Lymphoma [IF:2.397] 2009; 50: 303-305
• H Quach, L Mileshkin, A Milner, JF Seymour, D Ritchie, S Harrison, D Westerman, S Peinert, HM Prince. Predicting durable remissions following thalidomide therapy for relapsed myeloma. Leukemia Lymphoma [IF:2.397] 2009; 50: 223-229
• HM Prince, M Bishton. Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma. Hematology Meeting Reports 2009;3 (1): 33-38
• A Spencer, HM Prince, AW Roberts, IW Prosser, KF Bradstock, L Coyle, DS Gill, N Horvath, J Reynolds, N Kennedy. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation (ASCT) procedure. J Clin Oncol 2009 27:1788-1793, 2009 [IF:17.157]
• HM Prince, D Honemann, A Spencer D Rizzieri, E Stadtmauer, A Roberts, N Bahlis, GTricot, S Kathman, KL Baker, L Pandite. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase II study of pazopanib (GW786034). Blood 2009 , 113; 4819-4820 [IF:10.896]
• M Rodrigues, C McCormack, L-M Yap, HM Prince, H Roberts, R Williams, P Foley. Successful treatment of Lymphomatoid Papulosis with Photodynamic Therapy. Aus J Dermatol 2009; 50: 129-132
• JA Westwood, WK Murray, M Trivett, NM Haynes, S Fox, B Solomon, L Mileshkin, D Ball, M Michael, L Devereux, A Burman, P Mayura-Guru, JA Trapani, S Peinert, D Honemann, HM Prince, AM Scott, FE Smyth, MJ Smyth, PK Darcy, MH Kershaw.The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. J Immunother 2009, 32:292-301 [IF: 4.837]
• HM Prince, M Bishton, RW Johnstone. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncology 2009, 5: 601-12
• HM Prince, M Bishton, S Harrison. Clinical Studies of Histone Deacetylase Inhibitors. Clin Canc Res 2009, 15: 3958-69 [IF:177]
• M Dickinson, HM Prince, S Kirsa, A Zannettino, SDJ Gibbs, L Mileshkin, J O’Grady, JF Seymour, J Szer, N Horvath, DE Joshua and others on behalf of the Medical and Scientific Advisory Group of the Myeloma Foundation of Australia. Osteonecrosis of the Jaw Complicating Bisphosphonate Treatment for Bone Disease in Multiple Myeloma: An Overview with Recommendations for Prevention and Treatment. Int Med J (In Press) 2009, 39: 304-316 [IF:1.402]
• V Kieu, T O’Brien, LM Yap, C Baker, P Foley, G Mason, HM Prince, C McCormack. Refractory Subacute Cutaneous Lupus Erythematosus Successfully Treated with Rituximab. Aust J Dermatol 2009, 202-206
• S Peinert, D Carney, HM Prince, EH Januszewicz, JF Seymour. Fludarabine combinations for patients with advanced marginal zone lymphomas – best treatment option or too toxic? Brit J Haematol 2009; 146, 685-686 [IF:4.080]
• S Gill, KE Herbert, HM Prince, MM Wolf, A Wirth, G Ryan, DA Carney, DS Ritchie, JM Davies, JF Seymour. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Brit J Haematol 2009;147(1):83-8 [IF:4.080]
• M Dickinson, D Ritchie, DJ DeAngelo, M Bishton, A Spencer, T Fischer, KN Bhalla, FJ Giles, A Liu, K Parker, G Laird, E Masson, JW Scott, OG Ottman, HM Prince. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Brit J Haematol 2009;147:97-101 [IF:4.080]
• RL Piekarz, R Frye, M Turner, JJ Wright, SL Allen, MH Kirschbaum, J Zain, HM Prince, JP Leonard, LJ Geskin, C Reeder, D Joske, WD Figg, ER Gardner, SM Steinberg, E Jaffe, M Stetler-Stevenson, A Tito Fojo, SE Bates. A Multi-Institutional Phase II Trial of the HDAC Inhibitor Romidepsin as Monotherapy for Patients with Cutaneous T-cell Lymphoma J Clin Oncol 2009: 27; 5410-7 [IF:17.157])
• D Ritchie, RL Piekarz, P Blombery, LJ Karai, S Pittaluga, ES Jaffe, M Raffeld, JE Janik, HM Prince, SE Bates. Reactivation of DNA viruses in association with histone deacetylase inhibitor (HDI) therapy: a case series report. Hematologica 2009;94: 1618-22 [IF:6.416]
• Bajel A, Hill P, Goodman D, McCormack C, Davison J, Honemann D, Kenealy M, Harrison S, Prince HM. IgA Nephropathy Associated with Cutaneous T Cell Lymphoma. Leukemia Lymphoma [IF:2.397] 2009; 50: 2083-5
• H Quach, N Horvath, P Cannell, JR Mikhael, BE Butcher, HM Prince. Safety and efficacy results from an international Expanded Access Program to Bortezomib for patients with relapsed and / or refractory multiple myeloma: a subset analysis of the Australian & New Zealand data of 111 patients. Int Med J 2009; 39: 290-295 [IF:1.402]
• A Spencer, HM Prince, AW Roberts. Response to M Cavo et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation (ASCT) procedure. J Clin Oncol 2009:27; 1788-93 [IF:17.157]
• EA Stadtmauer, DM Weber, R Niesvizky, A Belch, HM Prince, JF San Miguel, T Facon, M Olesnyckyj, Z Yu, JB Zeldis, R Knight, MA Dimopoulos. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Hematol 2009; 82: 426-32 [IF:1.807]
• Spencer A, Prince HM, Roberts AW. Response to Cavo M. Thalidomide maintenenence in multiple myeloma. Certainties and controversies. J Clin Oncol 2009; 27: 1788-93 [IF:17.157]
• S Peinert, MH Kershaw, HM Prince. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learnt to plan for the future. Immunotherapy 2009; 1: 905-12
• Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sezary Syndrome. Blood 2009; 114; 4337-4353 [IF:10.896]

• L Zhang, MC Cooper, D Lebwohl, E Masson, G Laird, HM Prince. Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (Panobinostat) J Clin Oncol 2008; 26: 332-333 [IF:15.484]
• J Green, E Upjohn, C McCormack, J Zeldis, HM Prince. Successful treatment of Behcet’s Disease with Lenalidomide. Brit J Dermatol 2008; 158: 197-198 [IF:3.334]
• N Bercovici, N Haicheur, S Massicard, F Vernel-Pauillac, O Adotevi0, D Landais, I.Gorin, C Robert, HM Prince, J-J Grob, M Leccia, T Lesimple, J Bartholeyns, WH Fridman, M Salcedo, E Ferries, E Tartour. Analysis and characterization of anti-tumor T cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunotherapy 2008, 31; 101-112 [IF:3.983]
• HM Prince, M Bishton, S Harrison. The Potential of Histone Deacetylase Inhibitors for the Treatment of Multiple Myeloma [Commentary] Leukemia Lymphoma 2008; 49(3): 385 – 387 [IF:1.939]
• JS Sutherland, LS Spyroglou, JL Muirhead, TS Heng, A Prieto-Hinojosa, HM Prince, AP Chidgey, AP Schwarer, Richard L. Boyd. Enhanced immune system regeneration in humans following allogeneic or autologous hemopoietic stem cell transplantation by temporary sex steroid blockade. Clin Canc Res 2008, 14: 1139-1148 [IF:177]
• Prince HM. Update of Histone Deacetylase Inhibitors for the Treatment of T-Cell Lymphoma and Multiple Myeloma. Oncology Briefings 2008; 6: 1-3
• HM Prince, DM Wall, D Ritchie, D Honemann, S Harrrison, H Quach, M Thompson, R Hicks, E Lau, J Davison, M Loudovaris, J Moloney, B Loveland, J Bartholeyns, A Katsifis, L Mileshkin. In vivo tracking of dendritic cells in patients with multiple myeloma. J Immunotherapy 2008; 31:166-179 [IF:3.983]
• Rasheed, M. Bishton, R Johnstone, H.M.Prince. Histone Deacetylase Inhibitors in Lymphoma and Solid Malignancies. Expert Rev Anti-Cancer Therapy 2008; 8 (3) 413-432 [IF:3.267]
• Prince HM. New Strategies in the treatment of T-cell lymphoma. Clin Adv Hematol Oncol 2008; 6 (1) Suppl 1. 1-16.
• Prince HM. Histone Deacetylase Inhibitors in the Treatment of Multiple Myeloma.Clinical Adv Hematol Oncol 2008; 6 (4) Suppl 8: 2-8
• S Peinert, HM Prince, SJ Harrison. The development of novel Immunotherapeutic approaches in Multiple Myeloma. Leukemia Lymphoma 2008;49:652-654 [IF:1.939]
• SI Gill, SW Lane, J Crawford, G Cull, P Marlton, PN Mollee, HM Prince, JF Seymour. Prolonged Haematologic Toxicity From The Hyper-CVAD Regimen: Manifestations, Frequency, and Natural History In A Cohort of 125 Consecutive Patients. Ann Hematol (2008) [Epub ahead of print] [IF:2.254]
• Herbert KH, Levasque JP, Haylock D, Prince HM. The use of experimental murine models to assess novel agents of hematopoietic stem and progenitor cell mobilization. Biol Blood Marrow Transpl Biol Blood Marrow Transpl 2008;14:603-621 [IF:3.278]
• L Ellis, Y Pan, GK Smyth, DJ George, LC McCormack, R Williams-Truax, P Atadja, C Zhao, M Dugan, K Culver, R Johnstone, HM Prince. The histone deacetylase inhibitor LBH589 induces responses with associated alterations in gene expression profiles in cutaneous T cell lymphoma. Clin Canc Res 2008; 14: 4500-4510 [IF:177]
• SI Gill, M Wolf, HM Prince, H Januszewicz, D Ritchie, RJ Hicks, JF Seymour. ¹⁸F-FDG-Positron Emission Tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma. 2008 Jun;8:159-65.
• JA Westwood, WK Murray, M Trivett, A Shin, P Neeson, DP MacGregor, NM Haynes1, JA Trapani, P Mayura-Guru1, S Fox, S Peinert, D Honemann, HM Prince, D Ritchie, AM Scott, FE Smyth, MJ Smyth, PK Darcy, MH Kershaw.Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice Gene Therapy 2008 Jul;15(14):1056-66 [IF:4.780]
• S Arulogun, HM Prince, S Lade, P Gambell, D Westerman, G Ryan, O Blewitt, E Eaton, C McCormack. Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol. J Am Assoc Dermatol 2008; 59: 589-95 [IF:2.421]
• MED Flowers, JF Apperley, K Van Besien, A Elmaagacli, A Grigg, VS Reddy, A Bacigalupo, H-J Kolb, L Bouzas, M Michallet, HM Prince, R Knobler, D Parenti, J Gallo, HT Greinix. A Multicenter Prospective Randomized Study of Extracorporeal Photopheresis Therapy for the Treatment of Chronic Graft-versus-Host Disease. Blood 2008; 112: 2667-2674 [IF:10.896]
• S Arulogun, HM Prince, J Ng, S Lade, G Ryan, O Blewitt, C McCormack.Long term outcomes of patients with advanced-stage cutaneous T cell lymphoma and large cell transformation. Blood 2008 15;112(8):3082-7. [IF:10.896]
• Bishton MJ, Hicks RJ, Westerman DA, Prince M, Wolf M, Seymour JF. A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin’s lymphoma following treatment with iodine-131-rituximab radio-immunotherapy. Haematologica. 2008;93:789-90. [IF:4.192]
• MJ Bishton, RJ Hicks, HM Prince, DS Ritchie, M Wolf, JF Seymour. Claimed association of the absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independent data set. Leukemia 2008 22: 2259-60 [IF:612]
• Prince HM. The potential of histone deacetylase inhibitors for the treatment of lymphoma and multiple
• Clin Adv Hematol Oncol 2008; 6 (12) supplt 20: 2-7
• Prince HM. Romidepsin in multiple myeloma. Clin Adv Hematol Oncol 2008; 6 (12) supplt 20: 8-11

• HM Prince, B Schenkel, L Mileshkin. An analysis of Clinical Trials Assessing the Efficacy and Safety of Single-agent Thalidomide in Patients With Relapsed or Refractory Multiple Myeloma. Leukemia Lymphoma 2007, 48: 46-55 [IF:1.939]
• H Dinh, C McCormack, S Hall, HM Prince. Rituximab for the treatment of the skin manifestations of dermatomyositis – a report of three cases. J Am Acad Dermatol 2007, 56; 148-153 [IF:2.421]
• DS Ritchie, JF Seymour, AP Grigg, AW Roberts, R Hoyt, S Thompson, J Szer, HM Prince. The Hyper-CVAD-Rituximab Chemotherapy Program Followed by High-Dose Busulfan, Melphalan and Autologous Stem Cell Transplantation Produces Excellent Event Free Survival in Patients with Previously Untreated Mantle Cell Lymphoma. Ann Hematol 2007, 86; 101-105 [IF:1.416]
• Ritchie D, Mileshkin L, Wall D, Auzelle F, Thompson M, Lau E, Wong J, Eu P, Hicks RJ, Prince HM. In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma. Cancer Immunol Immunother 2007, 56; 155-163 [IF:3.520]
• AP Ng, A Wirth, JF Seymour, M Lee, A Hogg, H Janusewicz, M Wolf, HM Prince, M MacManus, R Hicks. Early Therapeutic Response Assessment by ¹⁸FDG-Positron Emission Tomography During Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: Isolated Residual Positivity Involving Bone is Not Usually a Predictor Of Subsequent Treatment Failure. Leukemia Lymphoma 2007 48:596-600 [IF:1.939]
• WK Rasheed, RW. Johnstone, HM Prince. Histone Deacetylase Inhibitors in Cancer Therapy. Expert Opin Investig Drugs 2007, 16; 659 – 678 [IF:3.267]
• KE Herbert, CR Walkley, IG Winkler, J Hendy, G Haines, Y-D Yuan, R Chandraratna, HM Prince, J-P Lévesque, LE Purton. G-CSF and an RARa Specific Agonist, VTP195183, Synergize to Enhance the Mobilization of Hematopoietic Progenitor Cells. Transplantation 2007;83:375-84. [IF:3.608]
• JB Ruddle, HM Prince. Denileukin Diftitox and Vision Loss. Luekemia and Lymphoma (Editorial). Leukemia Lymphoma 2007, 48; 655-656 [IF:1.939]
• HM Prince, B Schenkel, L Mileshkin. Assessing Response Rates in Clinical Trials of Treatment for Relapsed or Refractory Multiple Myeloma: A Study of Bortezomib and Thalidomide. Leukemia 2007; 21: 818 – 820 [IF:6.612]
• MSY Goh, C McCormack, HV Dinh, B Welsh, P Foley, HM Prince. Rituximab in the adjuvant treatment of Pemphigus Vulgaris: A prospective open-label pilot study in five patients. Brit J Dermatol 2007, 156; 990 – 996 [IF:3.334]
• DM Wall, HM Prince. Cell Therapy in Australia. The International Society of Cellular Therapy Annual Meeting comes to Sydney in 2007 [Editorial].Cytotherapy 2007; 9:207 – 208 [IF:1.795]
• SK Nilsson, HM Prince, D Wall, DN Haylock. Recent Australian Experience with Haemopoietic Stem and Progenitor Cell Expansion. Cytotherapy 2007; 9: 231-235. [IF:1.795]
• HM Prince, M Adena, D Kingsford Smith, Judy Hertel. Efficacy of single-agent bortezomib versus single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison. Eur J Haematol 2007 79; 93-99 [IF: 1.807]
• L Mileshkin, P Gambell, D Ritchie, M Trivett, Y Hayakawa, D Honemann, M Smyth, V Beshay, P Simmons, AD Milner, JB Zeldis, HM Prince. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57⁺ cytotoxic T cells as predictors of outcome. Haematologica 2007 92; 1075 -1082 [IF:4.192].
• S Gill, J Shapiro, D Westerman, HM Prince. long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma. J Clin Oncol 2007 25: 4493-4494 [IF:15.484]
• H Quach, HM Prince, L Mileshkin. Treatment Strategies in Elderly Patients with Multiple Myeloma: Current Status. Drugs and Aging 2007; 24: 829-850 [IF:2.072]
• S Feyler, HM Prince, R Pearce, K Towlson, I Nivison-Smith, S Schey, J Gibson, N Patton, K Bradstock, D Marks, G Cook on behalf of the BSBMT & AMBTRR. The role of high dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transpl 2007;40:443-50 [IF:2.643]
• Herbert KE, True S, McArthur G, Prince HM. Safety and Efficacy of Combining ATRA with G-CSF in HSPC mobilization; a Pilot study in multiple myeloma and non-Hodgkin Lymphoma patients. Bone Marrow Transpl 2007;40:801-3 [IF:2.643]
• M Bishton, M Kenealy, R Johnstone, W Rasheed, HM Prince.Epigenetic Targets in Hematological Malignancies: A Focus on combination therapies with Histone Deacetylase Inhibitors and Demethylating Agents. Exp Rev Anticancer Ther 2007; 7: 1439-1449 [IF:3.267]
• M Dimopoulos, A Spencer, M Attal, HM Prince, J-L Harousseau, A Dmoszynska, J San Miguel,
  A Hellmann, T Facon, R Foà, M Lazzarino, Z Masliak, M Olesnyckyj, Z Yu, J Patin, JB. Zeldis, RD Knight. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Eng J Med. 2007; 357: 2123 – 2132 [IF: 53.1 ]
• MS Liew, MJ Bishton, H Januszewicz, S Alatakis, HM Prince. Spinal Epidural Lipomatosis in Myeloma Leukemia Lymphoma 2007;48:2068-70 [IF:1.939]

• AP Ng, S Lade, T Rutherford, HM Prince DA Westerman. Primary cutaneous CD4+/CD56+ hematodermic neoplasm (Blastic NK-cell lymphoma): a report of five cases. Haematologica/The Hematology Journal 2006, 91; 143-144 [IF:4.192]
• M Gandhi, E Lambley, J Burrows, U Dua, S Elliott, PJ Shaw HM Prince, M Wolf, A Grigg, K Clarke, C Underhill, T Mills, P Mollee, D Gill, P Marlton, JF Seymour, R Khanna. Plasma Epstein-Barr virus DNA is a Biomarker for EBV-associated Hodgkin Lymphoma. Clin Cancer Res 2006, 12; 460-464 [IF:5.625]
• H Robinson, Maxwell E, Prince HM, Jakobovits A. Cefotetan-induced life-threatening haemolysis. Med J Australia 2006, 184: 251 [IF:2.000]
• CS Tam, M Wolf, HM Prince, EH Januszewicz, D Westerman, KI Lin, D Carney, JF Seymour. Fludarabine, Cyclophosphamide And Rituximab For The Treatment Of Patients With Chronic Lymphocytic Leukaemia Or Indolent Non-Hodgkin Lymphoma. Cancer 2006, 106: 2412-2420 [IF:3.941]
• C Keane, S Gibbs, JF Seymour, AK Mills, K Grimmett, R Van Kuilenberg, R Saal, D Gill, HM Prince, P Marlton, P Mollee. The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilise peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilisation. Hematol Oncol 2006, 24: 159-163 [IF:1.650]
• L Mileshkin, R Stark, B Day, JF Seymour, M Faragher, JB Zeldis, HM Prince.The development of neuropathy in myeloma patients being treated with thalidomide: patterns of occurrence and the role of electrophysiological monitoring. J Clin Oncol 2006, 24:4507-14. [IF:15.484]
• F Cachin, HM Prince, A Hogg, RE Ware, RJ Hicks. Powerful prognostic stratification by ¹⁸F-FDG PET in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol 2006, 24:3026-3031 [IF:15.484]
• Schrover, M. A. Adena, R. De Abreu Lourenco, HM Prince, J. F. Seymour, M. J. Wonder. Development of a predictive population model for the prognosis of patients with chronic myeloid leukemia in chronic phase according to the cytogenetic response rate. Leukemia Lymphoma 2006, 47:1069-81. [IF:1.939]
• M Kenealy, HM Prince, D Hönemann. Tumour Lysis Syndrome in Relapsed Multiple Myeloma Patients Treated with Bortezomib. Pharmacotherapy 2006, 27; 1205-6 [IF:2.277]
• Polizzotto MN, Tam CS, Milner A, Januszewicz EH, Prince HM, Westerman D, Wolf MM, Seymour JF. The influence of increasing age on the deliverability and toxicity of fludarabine based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders. Cancer 2006; 107: 773-780 [IF:4.434].
• JB Ruddle, CA Harper, D Hönemann, JF Seymour, HM Prince. A Denileukin Diftitox (Ontak) Associated Retinopathy? Brit J Ophthalmol 2006, 90:1070-1 [IF:2.00].
• H Robinson, M Damasiewicz, D Honemann, A Boussioutas, HM Prince. Gastric Involvement Of Plasmacytoma Associated With t(4:14) and Chromosome 13 Deletion. Leukemia Lymphoma. Leukemia Lymphoma 2006, 47; 1973-1975 [IF:1.939]
• SW Lane, J Crawford, M Kenealy, G Cull, JF Seymour, M Prince, P Marlton, D Gill, PN Mollee. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leukemia Lymphoma 2006, 47; 1813-1817 [IF:1.939]
• M Rodrigues, D Westerman, S Lade, C McCormack, HM Prince. Methotrexate-Induced Lymphoproliferative Disorder in a patient with Sézary Syndrome. Leukemia Lymphoma 2006, 47; 2257-9 [IF:1.939]
• CS Tam, JF Seymour, HM Prince, M Kenealy, M Wolf, EH Januszewicz, D Westerman. Treatment Related Myelodysplasia Following Fludarabine combination chemotherapy. Haematologica 2006, 91; 1546-1550 [IF:4.192]
• D Honemann, HM Prince. Myeloma, Thalidomide and Thrombosis. (Review) Leukemia Lymphoma 2006, 47; 2273-2275 [IF:1.939]
• M Kenealy, HM Prince. The Current Status of New Drugs for the Treatment of Patients with Multiple Myeloma. (Review). Internal Medicine Journal 2006; 36; 781-789 [IF:1.518]
• L Mileshkin, HM Prince. The troublesome toxicity of peripheral neuropathy with thalidomide. Review. Leukemia Lymphoma 2006, 47; 2276-2279 [IF:1.939]
• SJ Harrison, G Cook, RJB Nibbs, HM Prince. Immunotherapy of Multiple Myeloma: The Start of a Long and Tortuous Journey. Expert Review of Anticancer Therapy 2006, 12; 1769-1785 [IF:3.267]
• H Robinson, HM Prince, S Ramdave, JF Seymour, P Elliott R Hicks,^. Preliminary experience with ¹⁸F-Fluorodeoxyglucose positron emission tomography in staging of Castleman’s Disease. Leukemia Lymphoma 2006, 14;2664-2666 [IF:1.939]
• E Upjohn, R Sinclair, P Foley, P Lane, J Magee, HM Prince, C McCormack. Clearance of patch stage mycosis fungoides with the 308 nm laser. Clin Exp Dermatol 2006, 32; 168-171 [IF:1.265]

• D Hönemann, HM Prince, RJ Hicks, JF Seymour. Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease – diagnostic dilemmas and management options Ann Hematol (2005) 84; 118-121 [IF:1.292]
• H Quach, G Ryan, V Ganju, HM Prince. Effective Treatment of Leptomeningeal Multiple Myeloma with Craniospinal Irradiation Supported by Second Donor Stem Cell Transplant Infusion. Bone Marrow Transpl (2005) 35; 423-4 [IF:2.643]
• A Wirth, HM Prince, M Wolf, J Stone, J Matthews, J Gibson, C MacCleod, J Szer, A Grigg, B To, D Roos, A Schwarer, S Davis. Optimal Scheduling to Reduce Morbidity of Involved Field Radiotherapy with Transplantation for Lymphomas; A Prospective Australasian Leukaemia and Lymphoma Group Study Bone Marrow Transpl (2005) 35; 291-298 [IF:2.643]
• JJ Biagi, KE Herbert, C Smith, E Abdi, M Leahy, C Falkson, M Wolf, H Januszewicz, JF Seymour, K Richards, JP Matthews, B Dale, HM Prince and on behalf of the ALLG. A Phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma Leuk Lymphoma (2005) 46; 197-206 [IF:1.939]
• Chionh F, Herbert KE, Seymour JF, Prince HM, Wolf M, Zimet A, Tam C, Kennedy GA. Ante-mortem diagnosis of localised invasive esophageal aspergillosis in a patient with acute myeloid leukaemia. Leuk Lymphoma (2005) 46:603-605 [IF:1.939]
• D Hönemann, HM Prince, JF Seymour, MM Wolf, D Westerman, E Henry Januszewicz. A phase II study of liposomal doxorubicin, vincristine and dexamethasone in multiple myeloma. Leuk Lymphoma (2005) 46; 945-948 [IF:1.939]
• Sarah Brennand, Vivian Sutton, James Biagi, David Westerman, Christopher J McCormack, John F Seymour, H Miles Prince. Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy. Brit J Dermatol (2005) 152; 1199-1205 [IF:3.334]
• C Tam, JF Seymour, HM Prince. Recent advances in the treatment of chronic lymphocytic leukaemia. Hospital Pharmacy Europe 2005; May/June 86-87
• A Spencer, N Horvath, J Gibson, HM Prince, R Hermann, J Bashford, D Joske, A Grigg, J Mckendrick, I Prosser, R Lowenthal, S Deveridge, K Taylor. Prospective randomized trial of amifostine cryoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transpl (2005) 35 :971-977. [IF:2.643]
• Bell, HM. PRINCE and R. Chin on behalf of the Australian Cancer Anaemia Association. Anaemia in Cancer Patients: Assessment, Management and the Use of Erythropoietic Agents. Clinical Reviews in Oncology (2005) 3 Suppl; 1-16  
• Mileshkin L, Prince HM. The adverse prognostic impact of advanced age in multiple myeloma Leuk Lymphoma (2005) 46; 951-966 [IF:1.939]
• T Seshadri, HM Prince, D Bell, P Coughlin, P James, G Richardson, B Chern, P Briggs, J Norman, I Olver, C Karapetis, J Stewart for the Australia Cancer Anaemia Study (ACAS) Group. The Australian Cancer Anaemia Survey: A Snapshot Of Anaemia In Adult Cancer Patients In Australia Med J Aust (2005) 182: 453-457 [IF:2.000]
• F Chionh, KE Herbert, JF Seymour, HM Prince, M Wolf, A Zimet, C Tam, GA Kennedy. Ante-mortem diagnosis of localised invasive oesophageal aspergillosis in a patient with acute myeloid leukemia. Leuk Lymphoma (2005); 46: 603-605 [IF:1.939]
• CS Tam, MM Wolf, D Westerman, EH Januszewicz, HM Prince, JF Seymour. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstrőm’s macroglobulinemia. Clin Lymphoma and Myeloma (2005) 6: 136-139 [IF:1.758]
• SDJ Gibbs, C McCormack, S Lade, D Westerman, G Ryan, JF Seymour, HM Prince. Early B-cell chronic lymphocytic leukemia presenting as cutaneous lesions with a normal blood lymphocyte count. J Am Academy Dermatol (2005) 53: 534-535 [IF:2.358]
• SDJ Gibbs, DA Westerman, JF Seymour and HM Prince. Severe and prolonged myeloid hematopoietic toxicity following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Brit J Haematol (2005); 130: 87-91 [IF:4.080]
• L Mileshkin, D Rischin, J Zalcberg, HM Prince. The contribution of cytotoxic chemotherapy to the management of cancer. Clinical Oncology (R Coll Radiol) (2005) 17: 294
• LR Mileshkin, JF Seymour, M Wolf, P Gates, EH Januszewicz, T Joyce, HM Prince. Increased, but manageable, Cardiovascular Toxicity during High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for patients aged 60 years and older. Leuk Lymphoma (2005) 46; 1575-1579 [IF:1.939]
• HM Prince, L Mileshkin, A Roberts, V Ganju, C Underhill, J Catalano, R Bell, JF Seymour, D Westerman, PJ Simmons, K Lillie, AD Milner, JB Zeldis, R Ramsay. A multi-centre phase-II trial of thalidomide and celecoxib for relapsed and refractory multiple myeloma. Clin Canc Res (2005) 11; 5504-5514 [IF:5.625]
• Prince HM, Regester G, Gates P, Jablonkis L, Seymour JF, Lillie K, West R, Wolf M, Januszewicz H, Belford D. A Phase I study of PV01, a milk protein extract for the prevention of mucositis in patients undergoing high-dose BEAM chemotherapy. Biol Blood Marrow Transpl (2005) 11: 512-520 [IF:3.278]
• GA Kennedy, S Lade, J Scarlett, HM Prince. Primary cutaneous mantle cell lymphoma: a case report of this very rare condition. Dermatology On-line (2005) (In Press)
• SV Nath, HM Prince, PFM Choong, GC Toner. Durable remissions are rare following high dose therapy with autologous stem cell transplantation for adults with bone and soft tissue sarcoma. Int Semin Surg Oncol (2005) 2:12 pp1-7 [IF:3.052]
• KA Thursky, LJ Worth, JF Seymour, HM Prince, MA Slavin. A Review of Spectrum of Infection, Risk and Recommendations for Prophylaxis and Screening among Patients with Lymphoproliferative Disorders Treated with Alemtuzumab. Brit J Haematol (2005) 132: 3-12 [IF:4.080]
• AP Ng, L Worth, L Chen, JF Seymour, HM Prince, M Slavin, K Thursky. Cytomegalovirus DNAemia and Disease: Incidence, Natural History and Management in settings other than allogeneic transplantation. Hematologica (2005) 90: 1672-9 [IF:4.192]
• Thompson M, Wall D, Hicks RJ, Prince HM. In vivo tracking for cell therapies. Q J Nucl Med Mol Imaging (2005) 49:339-48.
• SDJ Gibbs, J O’Grady, JF Seymour, HM Prince. Bisphosphonate-induced osteonecrosis of the jaw is an underdiagnosed and preventable condition requiring early detection and intervention. Med J Aust (2005) 183: 549-550. [IF:2.000]
• Anderson KC, Prince HM. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma. Semin Hematol. 2005 Oct;42(4 Suppl 4):S1-2 [IF:3.835]
• Prince HM. Evidence mounts on using pegfilgrastim for peripheral blood stem cell mobilisation. Amgenda [non peer-reviewed] (2005) 29: 4-5
• JA Westwood, MJ Smyth, MWL Teng, M Moeller, JA Trapani, AM Scott, FE Smyth, GA Cartwright, BE Power, D Honemann, HM Prince, PK Darcy, MH Kershaw. Adoptive Transfer of T cells modified with humanized chimeric receptor gene inhibits growth of Lewis-Y expressing tumors in mice. Proceedings of the National Academy of Science. 2005, 102: 19051-19056. [IF:10.452]
• MW Chao, P Gibbs, P Norris, HM Prince, J Kiffer, M Feigen, G Quong, A Wirth, KH Liew. Role of radiotherapy in solitary bone plasmacytomas. Asia Pacific Journal of Clinical Oncology 2005:1; 35-40
• Australian Cancer Network Diagnosis and Management of Lymphoma Guidelines Working Party. Guidelines for the Diagnosis and Management of Lymphoma. The Cancer Council Australia and Australian Cancer Network, Sydeny 2005.[Chapter 18: Primary Cutaneous Lymphomas]

• Tam, HM PRINCE, D Westerman, JF Seymour and S Juneja. Leukaemic Subtype Of Marginal Zone Lymphoma : A Presentation Of Three Cases And Literature Review. Leukemia and Lymphoma (2004) v45; 705-710 [IF:1.939]
• GA Kennedy, R Blum, C McCormack, HM Prince. Treatment of primary cutaneous follicular center lymphoma with rituximab: a report of 2 cases. Austral J Dermatol (2004) 45: 34-7
• M Moloney, HM Prince, JF Seymour, M Slavin, M Dooley. Dosing Schedule of Oral Valacyclovir for Prevention of Herpes Simplex Virus. Bone Marrow Transpl (2003) 32; 1035 [IF:2.643]
• AK Stewart, J Berenson, I Borello, M Hussein, J Mehta, M Prince, D Seigel, S Singhal, R Vescio. Maximizing Response to Thalidomide Therapy in Multiple Myeloma: Panel Discussion Proceedings. Celgene Corporation, Warren, New Jersey 2003 [non-peer reviewed]
• L Mileshkin, HM Prince, JF Seymour, JJ Biagi. Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide Br J Haematol (2003) 123: 747-748 [IF:3.052]
• Mileshkin L, Blum R, Seymour JF, Patrikeos A, Hicks RJ and Prince HM. A Comparison of Fluorine-18 Fluoro-deoxyglucose PET and Technetium-99m Sestamibi in Assessing Patients with Multiple Myeloma. Submitted to Eur J Haematol (2004) 72: 32-37 [IF:1.807]
• SJ Morgan, JF Seymour, A Grigg, JP Matthews, HM Prince, MM Wolf, EH Januszewicz Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine Leukemia (2004) 18: 1034-1038 [IF:6.612]
• Morgan, JF Seymour, HM Prince, DA Westerman, MM. Wolf. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukaemia including patients with chromosome 17p deletions and without detectable CD25 expression. Clin Cancer Res (2004) 10: 3572-5 [IF:5.991]
• HM Prince, C McCormack,G Ryan,R O’Keefe,JF Seymour,C Baker. Management of the Primary Cutaneous Lymphomas. 2004 Australian Cancer Network Lymphoma Guidelines
• PRINCE HM, Stokes K, Wall D, Wood R. From the Field: Australian Centre Conducts Cell Processing for Clinical Trials and Commercial Manufacture (2004) ISCT Telegraft 11 (1) 6-7 [non-peer reviewed]
• HM Prince, DP Wall, KH Stokes, Ray Wood, SR Burger, P Coghlan, N Boyce. Centre for Blood Cell Therapies and Cell Therapies Pty Ltd: Cell Processing for Clinical Trials and Commercial Manufacture Cell and Gene Therapy (2004)1; 16-22
• Tam CS, Wolf MM, Januszewicz EH, Prince HM, Westerman D, Seymour JF.Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies. Cancer (2004); 100: 2181-9 [IF:3.941]
• Tam CS, Galanos J, Seymour JF, Pitman AG, Stark R, Prince HM. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for haematologic malignancies Am J Hematol 2004:77; 72-76 [IF:1.793]
• MA Slavin, J Szer, AP Grigg, AW Roberts, JF Seymour, HM Prince, J Sasadeusz, K Thursky, SC Chen, CO Morrissey, CH Heath, T Sorrell. Guidelines for the use of antifungal agents in the treatment of invasive candida and mould infections. Int J Med; (2004) 34: 192-200 [IF:0.062]
• HM Prince, PJ Simmons, G Whitty, DP Wall, L Barber, GC Toner, JF Seymour, G Richardson, R Mrongovius, DN Haylock. Improved hemopoietic recovery following transplantation with ex vivo expanded mobilized blood cells (2004) Brit J Haematol 126; 536-545 [I IF:4.080]
• Herbert KE, Spencer A^, Grigg A, Ryan G, McCormack C, Prince HM. Graft-Versus-Lymphoma effect in refractory cutaneous T cell Lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transpl (2004) 34: 521-5 [IF:2.643]
• DN Haylock, PJ Simmons, HM Prince. Transplantation with Ex vivo Expanded CD34⁺ cells: The Melbourne Experience. Exp Hematol (In Press)
• PRINCE HM, Stokes K, Wall D, Wood R. From the Field: Australian Centre Conducts Cell Processing for Clinical Trials and Commercial Manufacture (2004) ISCT Telegraft [non-peer reviewed]
• S Aranda, J Bartlett, K Botting, N Boyce, R Condon, C French, C Hogan, M Kennedy, G Magrin, L Martin, L McNicol, T Nallanthamby, HM Prince, H Savoia, D Skewes, T Sutherland, G Whyte. Blood Matters Breakthrough Collaborative – Service Improvement Guide (2004) Victorian Department of Human Services
• DJ Gibbs, KE Herbert, C McCormack, JF Seymour, HM Prince. Alemtuzumab; effective monotherapy for simultaneous B-cell Chronic Lymphocytic Leukemia and Sézary Syndrome. Eur J Hematol (2004) 73; 447-449 [IF:1.807]
• C Tam, MM Wolf, EH Januszewicz, AP Grigg, HM Prince, D Westerman, JF Seymour. A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies Cancer (2004) 101; 2042-2049 [IF:3.941]

• PRINCE HM, Yap LM. Blum R, McCormack C. Primary Cutaneous B–cell lymphomas. Clin Exp Dermatol (2003) 28; 8-12 [IF:1.265]
• KE Herbert, HM PRINCE, DA Westerman. Pure red cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab. Blood (2003) 15; 1654 [IF: 9.631]
• To LB, Bashford J, Durrant S, MacMillan J, Schwarer AP, PRINCE HM, Gibson J, Lewis I, Swart B, Marty J, Rawling T, Ashman L, Charles S, Cohen B. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. Bone Marrow Transplant (2003);31:371-378 [IF:2.643]
• Yap LM, Blum R, Foley P, McCormack C, Turner H, Seymour JF, PRINCE HM. A clinical study of primary cutaneous B-cell lymphoma using both the European Organization for Research and Treatment of Cancer (EORTC) and World Health Organization (WHO) classifications. Australas J Dermatol (2003) 44; 110-115
• L Mileshkin, JJ Biagi, P Mitchell, Craig Underhill, A Grigg, R Bell, J McKendrick, P Briggs, JF Seymour, K Lillie, JG Smith, JB Zeldis, HM PRINCE. A multi-centre phase-II trial of thalidomide in relapsed/refractory multiple myeloma reveals a dominant adverse prognostic impact of advanced age. Blood (2003) 102; 69-77 [IF: 9.631]
• SJ Morgan, HM PRINCE, DA Westerman, R O’Hehir. Clonal T helper lymphocytes and elevated IL-5 levels in episodic angioedema and eosinophilia (Gleich’s syndrome). Leuk Lymph 2003: 44; 1623-25
• JN Macatschek, D Westerman, HM PRINCE, JF Seymour. A Case Of Clinical Indolent Natural Killer Cell Lineage Large Granular Lymphocytic Leukemia In A Patient with Rheumatoid Arthritis Leuk Lymph (2003)44; 1223-1227 [IF:1.335]
• DMP Wall, HM Prince. Regulation of Cellular Therapies: The Australian Perspective. Cytotherapy (2003) 5; 284-288 [IF:1.795]
• MW Saville, MC Benyunes, PS Multani, HM Prince, K Herbert, D Westerman. No clinical evidence for CD4+ cell depletion caused by rituximab. Blood (2003)102; 408-409 [IF: 9.631]
• Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD for the members* of the Worldwide Bexarotene study group. *HM Prince (member). Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: Results of the phase III clinical trial. J Am Acad Dermatol. 2003; 49:801-15. [IF:2.421]
• Westerman DA, Mills AK, Juneja SK, Ding JC, Taylor KM, PRINCE HM. B Cell Lymphoblastic Lymphoma Presenting with Hypercalcaemia and Lytic Bone Lesions in Adults: Case Reports and Review of the Literature. J Hematol (In Press)
• HM PRINCE, C McCormack,G Ryan, R O’Keefe, JF Seymour, C Baker. Management of the primary cutaneous lymphomas. Aust J Dermatol 2003; 44: 227-240
• Kennedy GA, Seymour JF, Wolf M, Januszewicz H, Davison J, McCormack C, Ryan G and Prince HM. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. Eur J Hematol (2003) 71: 250-256 [IF: 1.807]

• R Blum, HM PRINCE, RJ Hicks, A Patrikeos, J Seymour. Discordant response to chemotherapy detected by PET scanning: unveiling of a second primary cancer. Am J Clin Oncol (2002) 25; pp 368-370 [IF:1.136]
• PRINCE HM, O’Keefe R, Ryan G, McCormack C, Turner H, P Waring, Baker C. Cutaneous Lymphomas: Which Pathological Classification. Pathology (2002) 34: 36-45 [IF:0.880]
• HM PRINCE, D Wall, D Rischin, GC Toner, JF Seymour, D Blakey, D Haylock, P Simmons, M Wolf, EH Januszewicz, D Westerman, G Richardson, J Scarlett, P Briggs. CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy Cytotherapy (2002) 4: 147-155 [IF:1.795]
• HM PRINCE, J Bashford, D Wall, N Parker, D Rischin, GC Toner, JF Seymour, D Blakey, D Haylock, P Simmons, P Francis, M Wolf, EH Januszewicz, G Richardson, J Scarlett, P Briggs. Isolex 300I CD-34-selected cells to support multiple cycles of high-dose therapy Cytotherapy (2002) 4: 137-145 [IF:1.795]
• Wirth A, Seymour JF, Hicks RJ, Ware R, Fisher R, PRINCE HM, MacManus MP, Ryan G, Januszewicz H, Wolf M. Fluorine-18 Fluorodeoxyglucose Positron Emmision Tomography, Gallium-67 Scintigraphy, and Conventional Staging for Hodgkin’s Disease and Non-Hodgkin’s Lymphoma. Am J Med (2002) 112; 262-268 [IF:4.904]
• SL Chua, JF. Seymour, J Streater, MM Wolf, EH. Januszewicz, HM PRINCE. Intrathecal Chemotherapy is Inadequate Central Nervous System Prophylaxis in Patients with Intermediate-grade Non-Hodgkin’s Lymphoma Leukemia and Lymphoma (2002) 43; 1783-1788 [IF:1.939]

• Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley CA, Yokum R for the *Worldwide Bexarotene Study Group *HM Prince (member). Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-Cell lymphoma: Multinational phase II-III trial results. J Clin Oncol (2001) 19: 2456-2471. [IF:9.868]
• Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC for the *Worldwide Bexarotene Study Group *HM Prince (member). Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol (2001) 137: 581-93 [IF:2.761]
• Chapple P, PRINCE HM, Wall D, Filshie R, Haylock D, Quinn M, Bretell M, Venter D. Comparison of Three Methods of CD34+ Cell Enumeration in Peripheral Blood: Dual-Platform ISHAGE Protocol Versus Single-Platform Versus Microvolume Fluorimetry. Cytotherapy (2001) 2; 371-376 [IF:1.795]
• PRINCE HM, Ryan G, Seymour JF, McCormack C. Pegylated liposomal doxorubicin for cutaneous T cell Lymphomas. J Am Acad Dermatol (2001) 44; 149 [IF:2.421]
• Campbell JK, PRINCE HM, Juneja SK, Slavin M. Diffuse Large Cell Lymphoma and t(8;22) (q24;q11) in a Patient with Idiopathic CD4+ T-Lymphocytopenia. Leukemia Lymphoma (2001) 41: 421-423 [IF:1.939]
• PRINCE HM, Ryan G, McCormack C, Baker C, Rotstein H, Davison J, Yocum R. Bexarotene Capsules and Gel for Previously Treated Patients with Cutaneous T-cell Lymphoma: The Australian Experience. Aust J Dermatol (2001) 42: 91-97
• L Mileshkin, HM PRINCE, D Rischin. Severe interstital pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature. Bone Marrow Transplant (2001) 27: 559-563 [IF:1.939]
• PRINCE HM, Rischin D, Quinn M, Allen D, Planner R, Neesham D, Gates P, Davison J. Repetitive High-Dose Topotecan, Carboplatin and Paclitaxel with Peripheral Blood Progenitor Cell Support in Previously Untreated Ovarian Cancer: Results of a Phase I Study Gynecol Oncol (2001) 81: 216-224
• Clark L, Eerhard S, PRINCE M, Gale J, Spencer D. Trends in Cancer Nursing: the Haematology Nurse Practitioner Experience. Cancer Forum (2001) 25: 22-24
• Dowling AJ, PRINCE HM, Wirth A, Wolf M, Januscewicz EH, Juneja S, Seymour JF, Gates P, Smith JG. High-Dose Therapy and Autologous Transplantation for Lymphoma: The Peter MacCallum Cancer Institute Experience. Internal Medicine Journal (2001) 31: 279-289 [IF: 1.00]
• PRINCE HM, Wall D, Chapple P, Quinn M, Brettell M, Haylock D, Seymour JF, Wolf M, Januscewicz H, Richardson G, Joyce T, Maisano R, Rischin D. CliniMACS CD34-selected cells to support high-dose therapy. Transfusion and Apheresis Science (2001) 24: 183 [IF: 0.182]
• BJP Huntly, AG Reid, AJ Bench, LJ Campbell, N Telford, P Shepherd, J Szer, HM PRINCE, P Turner, C Grace, EP Nacheva, AR Green. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood (2001) 98: 1732-1738 [IF: 9.631]
• J Biagi, L Mileshkin, A Grigg, D Westerman, HM PRINCE. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplantation (2001) 28: 1145-1150 [IF:2.643]
• J Biagi, HM PRINCE. Thalidomide is effective for extramedullary relapse of multiple myeloma post-allogeneic bone marrow transplantation B J Haematol (2001) 115; 484 [IF:3.052]
• Al-Homaidhi A, PRINCE HM, Al-Zahrani H, Doucette D, Keating A. Granulocyte-Macrophage Colony Stimulating Factor-Associated Histiocytosis and Capillary-Leak Syndrome Following Autologous Bone Marrow Transplantation: Two Case Reports and a Review of the Literature. Review Series Oncology (2001) 1: 16-17 [non-peer reviewed]
• F. Seymour, B. Solomon, M.M. Wolf, E.H. Janusczewicz, A. Wirth, H.M. PRINCE. Primary Large-cell Non-Hodgkin’s Lymphoma of the Testis: A Retrospective Analysis of Patterns of Failure and Prognostic Factors. Clinical Lymphoma (2001) 2: 109-115 [IF:2.184]
• PRINCE HM. Recommendation for a ban of reproductive cloning and a green light for stem cell research in Australia. (2001) Telegraft [non-peer reviewed]
• Solomon B, Moore J, Arthur C, PRINCE HM. Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters: a multicentre randomized comparison of urokinase versus heparin. Eur J Cancer (2001) 37; 2379-2384 [IF:3.562]

• Juneja S, Trute L, Westerman D, Venter D, Seymour JF, PRINCE HM. Paraffin Section Immunotyping of Leukaemias. Brit J Haematol (2000) 109: 267-271 [IF:4.080]
• PRINCE HM, Toner GC, Seymour JF, Blakey D, Gates P, Eerhard S, Chapple P, Wall D, Quinn M, Juneja S, Wolf M, Januszewicz EH, Richardson G, Scarlett J, Briggs P, Brettell M, Rischin D. Docetaxel Effectively Mobilises Peripheral Blood CD34+ Cells. Bone Marrow Transplantation (2000) 26: 483-488 [IF:2.643]
• Hill PA, PRINCE HM, Power DA. Tubointerstitial Nephritis Following High Dose Ifosfamide: Three Breast Cancer Patients. Pathology (2000) 32;116-170 [IF:0.880]
• PRINCE HM, Rischin D, Toner GC, Seymour JF, Blakey D, Gates P, Eerhard S, Chapple P, Quinn M, Brettell M, Juneja S, Wolf M, Januszewicz EH, Richardson G, Scarlett J, Briggs P. Repetitive High-Dose Therapy with Cyclophosphamide, Thiotepa and Docetaxel with Peripheral Blood Progenitor Cell and Filgrastim Support for Metastatic and Locally advanced Breast Cancer: Results of a Phase I Study. Bone Marrow Transplantation (2000) 26: 955-961 [IF:2.643]
• PRINCE HM. Regulation of Blood Products in Australia: A New Approach in the Making. (2000) ISHAGE Telegraft 7: 8-9 [non-peer reviewed]

• PRINCE HM, Millward MJ, Rischin D, Gates P. Repetitive High-Dose Therapy with PBPC Support for Patients with Metastatic and Locally Advanced Breast Cancer. Autologous Marrow and Blood Transplantation. Eds. KA Dicke and A Keating. The Cancer Treatment Research and Educational Institute. pp 303-331(1999)
• PRINCE HM, Gardyn J, Millward MJ, Rischin D, Francis P, Gates P, Chapple P, Quinn M, Juneja S, Wolf M, Januszewicz EH, Richardson G, Scarlett J, Briggs P, Brettell M, Toner GC. Ifosfamide in Combination with Paclitaxel or Doxorubicin: Regimens which Effectively Mobilize Peripheral Blood Progenitor Cells while Demonstrating Anti-Tumour Activity in Patients with Metastatic Breast Cancer. Bone Marrow Transplantation (1999) 23: 427-436 [IF:2.643]
• Barber L, PRINCE HM, Rossi R, Bertoncello I. Fluoro-Gold: An Alternative and Versatile Viability Stain for Multi-Colour Flow Cytometric Analysis. Cytometry (1999) 36: 394-354 [IF:1.933]
• Wirth A, Wolf M, PRINCE HM. Current Trends in the Management of Early Stage Hodgkin’s Disease. Aust NZ J Med (1999) 29: 535-544 [IF: 0.620]
• PRINCE HM, Millward MJ, Rischin D, Blakey D, Francis P, Gates P, Chapple P, Quinn M, Juneja S, Wolf M, Januszewicz EH, Seymour JF, Brettell M, Strickland A, Zalcberg J, Richardson G, Scarlett J, Briggs P, Toner GC. Repetitive High-Dose Therapy with Ifosfamide, Thiotepa and Paclitaxel with Peripheral Blood Progenitor Cell and Filgrastim Support for Metastatic and Locally Advanced Breast Cancer: Results of a Phase I Study. Annals of Oncology (1999) 10: 479-481[IF:3.114]
• Juneja S, Carney D, Ellis D, Januszewicz EH, Wolf M, PRINCE HM. Hodgkin’s Disease Type Richter’s Syndrome in Chronic Lymphocytic Leukemia. Leukemia (1999) 13: 826-827 [IF:4.693]
• Wilke R, Brettell M, PRINCE HM, Wolf M, McKenna R, Serpell E, Molloy M, Stevens H, Quinn M, Gates P, Chapple P. Comparison of Cobe Spectra Software Version 4.7 PBSC and Version 6.0 Auto PBSC Programs. J Clin Apheresis (1999) 14: 26-30 [IF:1.220]
• Seymour JF, Juneja SK, Campbell LJ, Ellims PH, Estey EH, PRINCE HM. Secondary Acute Myeloid Leukemia with inv(16): Report of Two Cases Following Paclitaxel and Review of the Role of Intensified AraC Therapy. Leukemia (1999) 13: 1735-1740 [IF:4.693]
• Westerman DA, PRINCE HM, Speed BR. Fatal Disseminated Infection by Scedosporium Prolificans During Induction Therapy for Acute Leukaemia: A Case Report and Literature Review. Pathology (1999) 31: 393-394 [IF:0.880]
• Srickland AH, Seymour C, PRINCE HM, Wolf M, Juneja S, Januszewicz EH. Fludarabine and High Dose Cytarabine (FLA): A Well Tolerated Salvage Regimen in Acute Myeloid Leukemia. Aust NZ J Med (1999) 29: 556-558 [IF: 0.620]
• Chua SL, Seymour JF, PRINCE HM. Deafness From Eighth Cranial Nerve Involvement in a Patient with Large-Cell Tansformation of Mycosis Fungoides. Eur J Haematol (1999) 63: 340-343 [IF: 1.807]

• PRINCE HM, Dessureault S, Gallinger S, Graham FL, Sutherland DR, Stewart AK. Efficient Adenoviral-Mediated Gene Expression in Malignant Human Plasma Cells: Relative Lymphoid Resistance Experimental Hematology (1998) 26: 27-36 [IF:3.366]
• Martinow AJ, Yuen K, Cooper IA, Mathews JP, Juneja S, Wolf M, Januszewicz H, PRINCE HM. Prognostic Markers of Disease Activity in Hodgkin’s Disease. Leukemia and Lymphoma (1998) 29: 383-389 [IF:1.939]
• Al-Homaidhi A, PRINCE HM, Al-Zahrani H, Doucette D, Keating A. Granulocyte-Macrophage Colony Stimulating Factor-Associated Histiocytosis and Capillary-Leak Syndrome Following Autologous Bone Marrow Transplatation: Two Case Reports and a Review of the Literature. Bone Marrow Transplantation (1998) 21: 209-214 [IF:2.643]
• Chapple P, PRINCE HM, Quinn M, Bertoncello I, Juneja S, Wolf M, Januszewicz H, Bretell M, Gardyn J, Seymour C, Venter D. Peripheral Blood CD34-Positive Cell Count Reliably Predicts Autograft Yield. Bone Marrow Transplantation (1998) 22: 125-130 [IF:2.643]
• Imrie K, Dube I, PRINCE HM, Girourd C, Crump M, Keating A. New Clonal Karyotypic Abnormalities Acquired Following Autologous Bone Marrow Transplantation for Acute Myeloid Leukemia do not Appear to Confer an Adverse Prognosis. Bone Marrow Transplantation (1998) 21: 395-400 [IF:2.643]
• PRINCE HM. Guest Commentary; High Dose Chemotherapy with Hematopoietic Rescue as Primary Treatment for Metastatic Breast Cancer: A Randomized Study. (1998) Amgenda 8; 11-14 [non-peer reviewed]
• PRINCE HM. Gene Transfer: A Review of Methods and Applications. Pathology (1998) 30: 335-347 [IF:0.88]
• Wirth A, PRINCE HM, Wolf M. Treatment of Intermediate-Grade and High-Grade Non-Hodgkin’s Lymphoma (letter) New England Journal of Medicine (1998) 339:1475-1477 [IF:31.736]

• PRINCE HM, Keating A. Theoretical Basis of Autografting. In. Autologous Stem Cell Transplantation: Biological and Clinical Results in Malignancies. pp 47-63Ed. AM Carella. Churchill Livingstone (1997)
• Girouard C, Dufresne J, Imrie K, Stewart AK, Brandwein J, PRINCE HM, Pantolony D, Keating A, Crump M. Salvage Chemotherapy with Mini-BEAM for Relapsed or Refractory Non-Hodgkin’s Lymphoma Prior to Autologous Bone Marrow Transplant. Annals Oncol (1997) 8: 675-680 [IF:3.114]
• Al-Fiar F, PRINCE HM, Imrie K, Keating A. Bone Marrow Mononuclear Cell Count does not Predict Neutrophil and Platelet Recovery Following Autologous Bone Marrow Transplantation; Value of Colony Forming Unit-Granulocyte Macrophage (CFU-GM) Assay. Cell Transplantation (1997) 5: 491-495
• HM PRINCE, A Wirth, M Wolf. Hodgkin’s Disease Failures: Incorporating Radiotherapy and High-Dose Treatment J Clin Oncol (1997) 15: 3021-3033 [IF:9.868]

.

• Crump M, Goss PE, PRINCE HM, Girouard C. Outcome of Extensive Evaluation Prior to Adjuvant Therapy in Women with Breast Cancer and 10 Positive Axillary Lymph Nodes. Journal Clinical Oncology (1996) 14: 66-69 [IF:9.868]
• Hsu J, PRINCE HM, Imrie K. Prolonged Ciprofloxacin Administration does not Accelerate Neutrophil Recovery Following Autologous Bone Marrow Transplantation. Pharmacotherapy (1996) 16: 652-655 [IF:1.924]
• Imrie K, Stewart AK, Crump RM, PRINCE HM, Trip K. Blood Stem Cell Collections: Factors Influencing the Recovery of Granulocyte-Macrophage Colony Forming Cells. Cell Transplantation (1996) 5: 379-383 [IF:2.420]
• PRINCE HM, Imrie K, Sutherland DR, Girouard C, Keating A,Crump M, Trip K, Stewart AK. Peripheral Blood Progenitor Cell Collection in Multiple Myeloma: Predictors and Management of Inadequate Collections. British Journal of Haematology (1996) 93: 142-145 [IF:4.080]
• PRINCE HM, Imrie K, Colwill R, Crump M, Stewart AK, Sutton DMC, Scott JG, Pantolony D, Carstairs K, Sutcliffe S, Keating A. The Role of Intensive Therapy and ABMT for Chemotherapy-Sensitive Relapsed and Primary Refractory NHL: Identification of Major Prognostic Groups. Br J Haematol (1996) 92: 880-889 [IF:3.052]
• Stewart AK, PRINCE HM, Cappe D, Nanji S, Rudie C, Wild A, Chu P, Sutherland DR, Dube¢ In Vitro Maintenance and Transduction of Human Myeloma Cells in Long-Term Marrow Cultures Cancer Gene Therapy (1997) 4:148-156 [IF:2.929]
• PRINCE HM, Crump RM, Imrie K, Stewart AK, Sutcliffe S, Tsang R, Pantolony D, Carstairs K, Keating A. Intensive Therapy and Autotransplant for Patients with an Incomplete Response to Front-Line Therapy for Lymphoma. Annals of Oncology (1996) 7: 1043-1049 [IF:3.114]

• PRINCE HM, Szer J, Van Der Weyden MB, Pederson JS, Holdsworth RF, Whyte G. Transfusion Associated Graft-versus-Host Disease After Cardiac Surgery: Response to Antithymocyte-Globulin and Corticosteriod Therapy. Aust NZ J Med (1991) 21:43-46 [IF: 0.620]
• PRINCE HM, Van Der Weyden MB, Bashford J. CD11c, CD5 Positive CLL/PLL with TRAP Positivity. Blood (1992) 80:1095-1096 [IF: 9.631]
• Szer J, Holdsworth RF, PRINCE HM. Fatal Transfusion Associated Graft-vs-Host Disease. Aust N Z J Med. (1993) 23:308-309 [IF: 0.620]
• PRINCE HM, Keating A, Cheng M, Cameron R. Severe Hepatotoxicity Following Granulocyte-Macrophage Colony-Stimulating Factor After Autologous Bone Marrow Transplantation. Bone Marrow Transplantation (1995) 16: 195-197 [IF:2.643]
• PRINCE HM, Page SR, Keating A, Saragosa RF, Vukovic NM, Imrie KR, Crump M, Stewart AK. Microbial Contamination of Harvested Bone Marrow and Peripheral Blood. Bone Marrow Transplantation (1995)15: 87-91 [IF:2.643]
• Imrie KR, PRINCE HM, Couture F, Brandwein J, Keating A. Effect of Antimicrobial Prophylaxis Following Autologous Bone Marrow Transplantation: Ciprofloxacin Versus Co-Trimoxazole. Bone Marrow Transplantation (1995) 15: 267-270 [IF:2.643]
• PRINCE HM, Imrie K, Keating A. Autologous Bone Marrow Transplantation with Etoposide and Melphalan for Poor Prognosis Non Hodgkin’s Lymphoma: The Importance of Disease Status at Transplant. In: Autologous Marrow and Blood Transplantation. Proceedings of the Seventh International Symposium. Eds. KA Dicke and A Keating. The Cancer Treatment Research and Educational Institute. (1995) pp 339-356
• PRINCE HM, Thurlow PJ, Buchanan RC, Ibrahim KMA, Neeson PJ Acquired Protein S Deficiency Causing Central Retinal Vein Thrombosis in a Patient with Systemic Lupus Erythematosus J Clin Pathol (1995)48: 387-389 [IF:2.549]
• Stewart AK, PRINCE HM, Dube ID. Background and Update to a Phase I Trial of Stem Cell Gene Marking in Multiple Myeloma. Transfusion Science (1995) 17:175-184